









































TOXICOLOGICAL PROFILE FOR  
VANADIUM  
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  




















Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic






























UPDATE STATEMENT  
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    vVANADIUM
FOREWORD
This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the toxic substances each profile describes.  Each peer-reviewed profile identifies and
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is
also presented but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with 
a public health statement that describes, in nontechnical language, a substance's relevant toxicological
properties.  Following the public health statement is information concerning levels of significant human 
exposure and, where known, significant health effects. A health effects summary describes the adequacy
of information to determine a substance's health effects. ATSDR identifies data needs that are significant
to protection of public health. 
Each profile:
(A) Examines, summarizes, and interprets available toxicologic information and
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) Determines whether adequate information on the health effects of each substance is
available or being developed to determine levels of exposure that present a significant risk to
human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of
exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are federal, state, and local health professionals;
interested private sector organizations and groups; and members of the public.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been
peer-reviewed.  Staff of the Centers for Disease Control and Prevention and other federal scientists also 
have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel
and was made available for public review.  Final responsibility for the contents and views expressed in
this toxicological profile resides with ATSDR. 
Christopher J. Portier, Ph.D. 
Assistant Administrator















    






   
 
  
     
       
 
   vi VANADIUM
*Legislative Background
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise













   








     
  
     
  
 
    
  
 
   
  
  
   
     




   
     
   
   
 
 
   




           




    
  
   
   
   
 
viiVANADIUM
QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets,
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?  
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?  
Section 3.7 Children’s Susceptibility  
Section 6.6 Exposures of Children  
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure
history is provided.  Other case studies of interest include Reproductive and Developmental
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide













    
    
   
   
 










   
   
   

















    
    
 
   
viiiVANADIUM
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
1. 	 Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
2.	 Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
3.	 Data Needs Review. The Environmental Toxicology Branch (proposed) reviews data needs 
sections to assure consistency across profiles and adherence to instructions in the Guidance. 







































    
  
   
   
 
 
   
    
      
   
 
  
    
 
xiVANADIUM
PEER REVIEW  
A peer review panel was assembled for vanadium.  The panel consisted of the following members:
1.	 Janusz Z. Byczkowski, Ph.D., DABT, Independent Consultant, Fairborn, Ohio;
2.	 David Dorman, Ph.D., D.V.M., DABT, Associate Dean for Research and Graduate Studies, North 
Carolina State University, Raleigh, North Carolina; and
3.	 Anna Fan, Ph.D., DABT, Chief, Pesticide and Environmental Toxicology Branch, Office of
Environmental Health Hazard Assessment, California Environmental Protection Agency, 
Oakland/Sacramento, California.
These experts collectively have knowledge of vandium’s physical and chemical properties, toxicokinetics,
key health end points, mechanisms of action, human and animal exposure, and quantification of risk to 
humans.  All reviewers were selected in conformity with the conditions for peer review specified in
Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as
amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final
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1.  PUBLIC HEALTH STATEMENT
This public health statement tells you about vanadium and the effects of exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities.  Vanadium has been found in at least 319 of the 1,699 current or former NPL
sites.  Although the total number of NPL sites evaluated for this substance is not known, the possibility
exists that the number of sites at which vanadium is found may increase in the future as more sites are 
evaluated.  This information is important because these sites may be sources of exposure and exposure to
this substance may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container,
such as a drum or bottle, it enters the environment.  Such a release does not always lead to exposure.  You 
can be exposed to a substance only when you come in contact with it.  You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact.
If you are exposed to vanadium, many factors will determine whether you will be harmed.  These factors 
include the dose (how much), the duration (how long), and how you come in contact with it.  You must
also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and
state of health.
1.1  WHAT IS VANADIUM?
Description Vanadium is a naturally occurring element.  It is
widely distributed in the earth’s crust at an 
average concentration of approximately
100 mg/kg.  Vanadium is found in about
65 different minerals.
Depending on its form, vanadium can be a 
gray-white metal or light gray or white lustrous
powder.  Pure vanadium is a bright white, soft,
and ductile metal.
   
 
































   
 

















• Vanadyl sulfate and sodium metavanadate
Vanadium is used in producing rust-resistant, 
spring, and high-speed tool steels.  It is an 
important carbide stabilizer in making steels.
Vanadium pentoxide is used in ceramics and 
as a catalyst as well as in the production of
superconductive magnets.
Vanadyl sulfate and sodium metavanadate 
have been used in dietary supplements.
For more information on the physical and chemical properties of vanadium and its production, disposal
and use, see Chapters 4 and 5.
1.2  WHAT HAPPENS TO VANADIUM WHEN IT ENTERS THE ENVIRONMENT?
Sources Vanadium occurs naturally in soil, water, and 
air.  Natural sources of atmospheric vanadium
include continental dust, marine aerosol, and 
volcanic emissions.  
Releases of vanadium to the environment are 
mainly associated with industrial sources,
especially oil refineries and power plants using 
vanadium rich fuel oil and coal.  Global human-
made atmospheric releases of vanadium have
been estimated to be greater than vanadium
releases due to natural sources.  Natural
releases to water and soil are far greater overall
than human-made releases to the atmosphere.
   
 


































   





1.  PUBLIC HEALTH STATEMENT
Break down Vanadium cannot be destroyed in the
environment.  It can only change its form or
become attached or separated from airborne 
particulate, soil, particulate in water, and 
sediment.
• Air Vanadium particles in the air settle to the 
ground or are washed out of the air by rain.
Smaller particles, such as those emitted from
oil-fueled power plants, may stay in the air for
longer times and are more likely to be 
transported farther away from the site of
release.
• Water and soil
The transport and partitioning of vanadium in 
water and soil is influenced by many factors
including acidity of the water or soil and the
presence of particulates. Vanadium can either
be dissolved in water as ions or may become 
adsorbed to particulate matter.
   
 























   






   
 



















1.  PUBLIC HEALTH STATEMENT
1.3  HOW MIGHT I BE EXPOSED TO VANADIUM?
Food–primary source of exposure Most foods have naturally occurring low
concentrations of vanadium.  Seafood generally
contains higher concentrations of vanadium than 
meat from land animals.
Daily intakes of vanadium from food ranging from
0.01 to 0.02 mg have been reported.  Average 
vanadium concentrations in tap water are 
approximately 0.001 mg/L.  Assuming that you 
drink approximately 2 L of water a day, a daily
intake of approximately 0.002 mg of vanadium
from tap water can be estimated for adults.
Vanadium also may be found in various
commercial nutritional supplements and 
multivitamins in amounts ranging from 0.0004 to
12.5 mg, depending on the serving size 
recommended by the manufacturer.
Consumption of some vanadium-containing 
supplements may result in intakes of vanadium
that would exceed intakes from food and water.
Populations in areas with high levels of residual
fuel oil consumption may also be exposed to 
above-background levels of vanadium, from
increased particulate deposition upon food crops
and soil in the vicinity of power plants.
Air Most people take in very little vanadium from
breathing.  The general population may also be
exposed to airborne vanadium through 
inhalation, particularly in areas where a large
number of oil fired power plants are using 
residual fuel oils for energy production.
Individuals exposed to cigarette smoke may also 
be exposed to higher than background levels of
vanadium.  Approximately 0.0004 mg of
vanadium is released in the smoke of one 
cigarette.
Water and soil Vanadium concentrations in surface water can 
range from approximately 0.04 to 220 µg/L 
depending on geographical location.
For more information on how you might be exposed to vanadium, see Chapter 6.
   
 




























    
  





































1.  PUBLIC HEALTH STATEMENT
1.4  HOW CAN VANADIUM ENTER AND LEAVE MY BODY?
Enter your body
• Inhalation Some of the vanadium you breathe will enter
your body through your lungs; however, we do 
not know how much will enter.
• Ingestion A small amount of vanadium in food and water
(3–20%) will enter your body through the
digestive tract.  The vanadium compounds you 
are exposed to will determine how much is
absorbed.
• Dermal contact We do not know how much vanadium will enter
your body through your skin.  It is likely that
very little will pass through the skin.
For more information about how vanadium enters and leaves your body, see Chapter 3.
1.5  HOW CAN VANADIUM AFFECT MY HEALTH?
This section looks at studies concerning potential health effects in animal and human studies.
Workers
• Inhalation
Breathing air with vanadium pentoxide can 




Damage to the lungs, throat, and nose have 




Nausea, mild diarrhea, and stomach cramps
have been reported in people taking sodium
metavanadate or vanadyl sulfate for the 
experimental treatment of diabetes.
Stomach cramps were also reported in a study
of people taking about 13 mg vanadium/day.
   
 













   
   
   















   
   
 
    
 
   
   
 












1.  PUBLIC HEALTH STATEMENT
Laboratory animals
• Oral
A number of effects have been found in rats
and mice ingesting several vanadium
compounds.  The effects include:
• Decreases in number of red blood cells
• Increased blood pressure
• Mild neurological effects
• Developmental effects in animals
Cancer Lung cancer has been found in mice exposed 
to vanadium pentoxide.
The International Agency for Research on
Cancer (IARC) has determined that vanadium
is possibly carcinogenic to humans.
For more information on health effects in people and animals after breathing, eating, or touching
vanadium, see Chapter 3.
1.6  HOW CAN VANADIUM AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from
conception to maturity at 18 years of age.
Effects in children The health effects seen in children from
exposure to toxic levels of vanadium are 
expected to be similar to the effects seen in 
adults. We do not know if children will be more 
sensitive to vanadium toxicity than adults.
Birth defects We do not know whether vanadium can cause 
birth defects in people.
Studies in animals exposed during pregnancy
have shown that vanadium can cause 
decreases in growth and increases in the 
occurrence of birth defects.  These effects are 
usually observed at levels which cause effects
in the mother. Effects have also been observed 
at vanadium doses which did not cause effects
in the mother.
   
 










   









   


















   




1.  PUBLIC HEALTH STATEMENT
1.7  HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO VANADIUM?
Food Vanadium is a naturally occurring element that
is widely distributed in the environment.  It is
found in many foods, typically in small amounts.
You cannot avoid exposure to vanadium.
Exposure to the levels of vanadium that are
naturally present in food and water are not
considered to be harmful.
Consumer products Consumption of some vanadium-containing 
supplements may result in intakes of vanadium
that would exceed intakes from food and water.
You should check with your physician before 
taking supplements containing vanadium to 
determine if such supplements are appropriate 
for you.
As a precaution, such products should have
child-proof caps or should be kept out of reach 
of children so that children will not accidentally
ingest them.
Air Individuals exposed to cigarette smoke may
also be exposed to higher-than-background 
levels of vanadium.  Avoiding exposure to
cigarette smoke may reduce exposure of you 
and your family to vanadium.
To limit exposure to vanadium particles in the 
air, use a wet mop on non-carpeted floors, use 
a wet rag instead of a dry rag or duster to dust,
vacuum your carpet often using a vacuum with 
a high-efficiency HEPA filter, and keep windows
and doors closed on windy days.
If your doctor finds that you have been exposed to significant amounts of vanadium, ask whether your
children might also be exposed.  Your doctor might need to ask your state health department to
investigate.
   
 































   
 
 
   
  
   
  
      
     
  
 
   
      
    
  
   
 
   
    
8VANADIUM
1.  PUBLIC HEALTH STATEMENT
1.8  	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
VANADIUM?
Detecting exposure All people have small amounts of vanadium in 
their bodies.  It can be measured in blood, urine,
and hair. Measurement of vanadium levels
require special methods and equipment, which 
can be found in a specialized clinical laboratory.
Measuring exposure Measurements of vanadium concentrations in 
blood and urine can tell you whether you have 
been exposed to larger-than-normal amounts of
vanadium.  Blood and urinary vanadium levels
are considered the most reliable indicators of
occupational exposure to vanadium.  
Measuring vanadium levels in hair is not a good 
indicator of occupational or environmental
exposure to vanadium.
For more information on ways to tell whether you have been exposed to vanadium see Chapters 3 and 7.
1.9  	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health. Regulations
can be enforced by law.  The EPA, the Occupational Safety and Health Administration (OSHA), and the
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic
substances.  Recommendations provide valuable guidelines to protect public health, but cannot be
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels. These are levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value. This critical value is usually based
on levels that affect animals; they are then adjusted to levels that will help protect humans.  Sometimes 
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available.
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1. PUBLIC HEALTH STATEMENT 
Some regulations and recommendations for vanadium include the following:
Workplace air OSHA set a legal limit of 0.5 mg/m3 for 
vanadium pentoxide respirable dust as a ceiling 
not to be exceeded during the work day.  A 
ceiling limit of 0.1 mg/m3 for vanadium
pentoxide fume has also been established.
1.10 WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location of occupational and environmental health clinics.  These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You may
request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical 
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to: 
Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Human Health Sciences (proposed)
  1600 Clifton Road NE 
  Mailstop F-62 
  Atlanta, GA 30333
  Fax: 1-770-488-4178
Organizations for-profit may request copies of final Toxicological Profiles from the following: 
National Technical Information Service (NTIS)  
5285 Port Royal Road
  Springfield, VA 22161
  Phone: 1-800-553-6847 or 1-703-605-6000  
Web site: http://www.ntis.gov/  
   
 











1.  PUBLIC HEALTH STATEMENT
This page is intentionally blank.















   
          
 
     
    
 
   
    
   
  
   
   
   
    









   
    
 
  
    
 
11VANADIUM
2. RELEVANCE TO PUBLIC HEALTH
2.1  	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO VANADIUM IN THE
UNITED STATES
Vanadium is the 22nd most abundant element in the earth’s crust with an average concentration of
100 ppm. It exists in oxidation states ranging from 2- to 5+ with 3+, 4+, and 5+ being the most common 
oxidation states.  Vanadium is primarily used in the production of rust-resistant, spring, and high-speed
tool steels; vanadium pentoxide is used in ceramics.  Vanadium is released to the environment by
continental dust, marine aerosols, volcanic emissions, and the combustion of coal and petroleum crude
oils.  It is naturally released into water and soil as a result of weathering of rock and soil erosion.  
Ambient air concentrations of vanadium are low, with urban areas having higher concentrations.  Average
vanadium concentrations were 3.0–3.7 ng/m3 in urban areas of Illinois; in rural areas, the vanadium
concentrations were 0.8–1.2 ng/m3.  Higher vanadium levels have been measured in the eastern United
States due to the high density of oil fired power plants using vanadium-rich residual fuel oil.  An average 
vanadium air concentration of 620 ng/m3 was measured in Eastern cities compared to 11 ng/m3 in cities 
throughout the United States.  Vanadium residence time in the environment is inversely related to the 
particle size.  In water, vanadium is converted from trivalent forms to pentavalent forms.  The levels of
vanadium in surface water range from 0.04 to 104 µg/L.  Vanadium levels of 1.2–1.0 µg/L were
measured in tap water samples collected in several U.S. states.
Food is the primary route of exposure for the general population; foods with the highest vanadium content
include ground parsley, freeze-dried spinach, wild mushrooms, and oysters.  Vanadium in food is mainly
ingested as VO2+ (vanadyl, V4+) or HVO42 (vanadate, V5+).  Estimates of dietary vanadium intake range 
from 0.09 to 0.34 µg/kg/day in adults.  Humans are potentially exposed to a variety of vanadium
compounds, the most common being vanadium pentoxide, sodium metavanadate, sodium orthovanadate, 
vanadyl sulfate, and ammonium metavanadate.  Organic anthropogenic vanadium compounds, such as
bis(maltolato)oxyvanadium (IV) or vanadyl acetyl acetonate, are used in the treatment of diabetes and 
cancer; these compounds have different toxicokinetic properties than inorganic vanadium compounds and 
are not discussed in this toxicological profile.
Although there is some evidence to suggest that vanadium is an essential nutrient, a functional role for
vanadium in humans has not been established; increases in abortion rates and decreased milk production 
have been observed in vanadium-deprived goats. Vanadium mimics insulin and stimulates cell 
proliferation and differentiation.  In animal models, particularly streptozotoxin-induced diabetes in rats,
   
 




















      
   
    
     
  
    
    
     
      
    
       
    
 
   
  
  
    
  
   
      
12VANADIUM
2. RELEVANCE TO PUBLIC HEALTH
vanadium has been shown to normalize blood glucose and lipid levels, improve insulin sensitivity, and 
prevent or reverse secondary complications such as cardiomyopathy, cataract development, and impaired
antioxidant status.
2.2  SUMMARY OF HEALTH EFFECTS 
The general population can be exposed to vanadium primarily through oral (ingestion of vanadium in 
food) and inhalation routes of exposure.  Based on occupational exposure studies, human experimental
studies, and studies in laboratory animals, the respiratory tract following inhalation exposure and the
gastrointestinal tract, hematological system, and developing organism following oral exposure are the
primary targets of toxicity.
Adverse respiratory effects have been reported in humans and animals exposed to vanadium compounds
at concentrations much higher than those typically found in the environment.  Although the available data
in humans are limited, signs of airway irritation (e.g., coughing, wheezing, sore throat) have been 
reported in subjects acutely exposed to 0.6 mg vanadium/m3 and in workers exposed to vanadium
pentoxide dust. These effects have persisted for days to weeks after exposure termination and are often
not associated with alterations in lung function.  Studies in laboratory animals provide strong support that
the respiratory tract is the most sensitive target following inhalation exposure to vanadium.  A variety of
lung lesions including alveolar/bronchiolar hyperplasia, inflammation, and fibrosis have been observed in 
rats and mice exposed to vanadium pentoxide; the severity of the lesions is related to concentration and
duration.  The lung effects have been observed following acute exposure to 0.56 mg vanadium/m3 and 
chronic exposures to 0.28 mg vanadium/m3 and have been observed after 2 days of exposure.  Longer
duration exposures also result in inflammation and hyperplasia in the larynx and hyperplasia in nasal
goblet cells. These histological alterations result in restrictive impairments in lung function; respiratory
distress is observed at vanadium pentoxide concentrations of ≥4.5 mg vanadium/m3.
Other sensitive targets of vanadium toxicity include the gastrointestinal system following oral exposure
and hematological system following inhalation or oral exposure.  Symptoms of gastrointestinal irritation
(diarrhea, cramps, nausea) have been observed in humans following bolus administration of sodium
metavanadate, vanadyl sulfate, ammonium vanadyl tartrate, or diammonium vanado-tartrate as a 
treatment in noninsulin-dependent diabetics or patients with ischemic heart disease.  The gastrointestinal
effects occurred following ingestion of ≥14 mg vanadium and no effects were observed in subjects
ingesting capsules containing 7.8 mg vanadium. In most studies, the gastrointestinal effects only
   
 








   
     
  
 
   
  





    
   
  
 




   
   
    
 
   
 
  
   
   
    





2. RELEVANCE TO PUBLIC HEALTH
occurred during the first week or two of the study suggesting that with repeated exposure, humans
develop a tolerance to these effects.  Diarrhea has also been observed in rats and mice orally exposed to
lethal doses of vanadium.  Microcytic erythrocytosis (evidenced by decreases in hematocrit, hemoglobin,
and mean cell volume and increases in reticulocytes and nucleated erythrocytes) has been observed in rats 
exposed to 1.1 mg vanadium/m3 as vanadium pentoxide for at least 4 days.  Hematological effects,
including decreases in erythrocyte levels, decreases in hemoglobin, and increases in reticulocytes have 
also been observed in rats orally exposed to 1.18 mg vanadium/kg/day as ammonium metavanadate for
4 weeks.
Information on the potential of vanadium to induce developmental effects in humans is limited, but
developmental effects have been observed in laboratory animals.  Decreases in pup growth have been 
observed at maternal doses of ≥2.1 mg vanadium/kg/day. At higher doses, decreases in pup survival and
gross, skeletal, and visceral malformations and anomalies have been reported; marked decreases in 
maternal body weight are also observed at these dose levels.
No studies have examined the carcinogenic potential of vanadium in humans.  An increase in lung
carcinoma incidence has been observed in mice chronically exposed to vanadium pentoxide; there is also
marginal evidence for lung cancer in male rats (incidence of carcinoma was higher than historical controls 
but not concurrent controls).  Carcinogenicity has not been adequately assessed in laboratory animals 
following oral exposure.  IARC classified vanadium pentoxide in group 2B (possibly carcinogenic to
humans) based on inadequate evidence in humans and sufficient evidence in animals.  The Department of
Health and Human Services and EPA have not classified carcinogenicity of vanadium.
2.3 MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for vanadium.  An
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
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2. RELEVANCE TO PUBLIC HEALTH
Although methods have been established to derive these types of levels (Barnes and Dourson 1988; EPA
1990), uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
Inhalation MRLs
Acute-Duration Inhalation MRL
•	 An MRL of 0.0008 mg vanadium/m3 has been derived for acute-duration inhalation exposure
(14 days or less) to vanadium pentoxide dust.
Data on acute toxicity of vanadium in humans are limited to an experimental study in which a small
number of subjects were exposed to vanadium pentoxide dust for 8 hours (Zenz and Berg 1967).  A
persistent cough lasting for 8 days developed in two subjects exposed to 0.6 mg vanadium/m3; at 0.1 mg
vanadium/m3, a productive cough without any subjective complaints or impact on work or home activities 
were observed in five subjects. The available studies in laboratory animals focused on potential
respiratory tract effects.  Impaired lung function, characterized as airway obstructive changes (increased
resistance and decreased airflow), was observed in monkeys exposed to 2.5 or 1.7 mg vanadium/m3 as 
vanadium pentoxide for 6 hours (Knecht et al. 1985, 1992); the highest no-observed-adverse-effect level
(NOAEL) for this effect was 0.34 mg vanadium/m3. In female rats exposed to 0.56 mg vanadium/m3 
6 hours/day, 5 days/week for 13 days, minimal inflammation and histiocytic infiltration were observed 
(NTP 2002).  Alveolar and bronchiolar epithelial hyperplasia and inflammation were observed in the
lungs of mice similarly exposed to 1.1 mg vanadium/m3 as vanadium pentoxide (NTP 2002).  Although 
the Knecht et al. (1985, 1992) or NTP (2002) studies did not include examination of potential end points
outside of the respiratory tract, longer-duration studies have identified the respiratory tract as the most
sensitive target of toxicity (NTP 2002). The NTP (2002) rat study was selected as the basis of the acute-
duration inhalation MRL.  
In the NTP (2002) study, groups of male and female F344 rats received whole-body exposure to 0, 1, 2, 
or 4 mg vanadium pentoxide/m3 (0, 0.56, 1.1, or 2.2 mg vanadium/m3) as particulate aerosols 6 hours/day,
5 days/week.  On days 6 and 13, 10 rats/group were killed and a histopathological examination of the
lungs was conducted.  Four rats per group were killed for examination of the onset and extent of lung
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2. RELEVANCE TO PUBLIC HEALTH
lesions after 1, 2, 5, 10, or 16 days of exposure.  Hyperplasia of alveolar epithelium and bronchiole
epithelium were observed in 100% of the female rats exposed to 1.1 or 2.2 mg vanadium/m3 for 6 or
13 days.  Significant increases in the incidence of histiocytic infiltrate and inflammation were observed in 
rats exposed to 1.1 or 2.2 mg vanadium/m3 for 6 or 13 days and in rats exposed to 0.56 mg vanadium/m3 
for 13 days.  A significant increase in fibrosis was observed in rats exposed to 2.2 mg vanadium/m3 for 
13 days.  No histopathological alterations were observed in the four female rats killed after 1 day of
exposure; by day 2, inflammation and histiocytic infiltrates (increased number of alveolar macrophages)
were observed in the rats exposed to 2.2 mg vanadium/m3. Hyperplasia of the alveolar and bronchiolar
epidthelium was first observed on day 5 in rats exposed to 1.1 or 2.2 mg vanadium/m3. 
A benchmark dose (BMD) approach was considered for derivation of the acute-duration inhalation MRL;
however, the fit was not considered adequate due to the limited amount of information from the study on 
the shape of the exposure-response curve for lung inflammation; more information regarding the BMD
analysis is presented in Appendix A.  A NOAEL/lowest-observed-adverse-effect level (LOAEL)
approach was used to derive the MRL.  The LOAEL of 0.56 mg vanadium/m3 for lung inflammation was
selected as the point of departure for the MRL. This LOAEL was converted to a human equivalent 
concentration (LOAELHEC) of 0.073 mg vanadium/m3 (see Appendix A for more information on the
calculation of the LOAELHEC) and divided by an uncertainty factor of 90 (3 for use of a minimal LOAEL, 
3 for animal to human extrapolation using dosimetric adjustments, and 10 for human variability), 
resulting in an acute-duration inhalation MRL of 0.0008 mg vanadium/m3.
Intermediate-Duration Inhalation MRL
The available data on the toxicity of vanadium following intermediate-duration inhalation exposure are
limited to several rat and mouse studies (NTP 2002) involving exposure to vanadium pentoxide for
6 hours/day, 5 days/week.  These studies demonstrate that the respiratory tract is the most sensitive target
of toxicity.  Signs of respiratory distress (rapid respiration, difficulty breathing) have been observed in
rats exposed to 4.4 mg vanadium/m3 as vanadium pentoxide for at least 4 weeks (NTP 2002).  A 3-month 
exposure resulted in increased incidences of lung lesions in rats and mice and nasal lesions in rats.  Lung
effects included alveolar and bronchiolar epithelial hyperplasia, histiocytic infiltrates, inflammation, and
fibrosis.  A NOAEL of 0.56 mg vanadium/m3 was identified in both species.  At 1.1 mg vanadium/m3, 
epithelial hyperplasia and inflammation (male rats and female mice only) were observed.  In mice, the 
severity of the lesions was graded as minimal.  In rats, the epithelial hyperplasia was graded as mild in
males and minimal to mild in females and the inflammation was graded as mild. These data suggest that
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at a given air concentration, rats are more sensitive than mice based on the severity of the lesions.  In both
species, the severity of the lesions increased with increasing concentrations.  Significant alterations in
pulmonary function suggestive of a restrictive disease were observed in rats exposed to 2.2 or 4.4 mg
vanadium/m3; lung function tests were not performed in mice.  Nasal effects in rats included hyperplasia 
and squamous metaplasia of the respiratory epithelium and inflammation. The NOAEL and LOAEL for
nasal effects were 2.2 and 4.5 mg vanadium/m3 in males and 1.1 and 2.2 mg vanadium/m3 in females.  In
addition to the respiratory tract effects, mild microcytic erythrocytosis was observed in rats exposed to
≥1.1 mg vanadium/m3.
The lowest LOAEL identified in intermediate-duration studies is 1.1 mg vanadium/m3 for lung epithelial
hyperplasia and inflammation in rats exposed 6 hours/day, 5 days/week for 13 weeks (NTP 2002); the
NOAEL for these effects is 0.56 mg vanadium/m3.  However, this NOAEL is the same as the LOAEL for
lung inflammation in rats exposed for 13 days (NTP 2002).  As summarized in Table 2-1, lung
inflammation was observed in rats exposed to 0.56 mg vanadium/m3 for 6 days (not significant), 13 days, 
and 2 years.  Although the three studies were conducted for the National Toxicology Program (NTP), the
13-week study was conducted at a different laboratory using the same strain of rats and vanadium
pentoxide dusts with similar particles sizes as the acute and chronic studies.  An explanation for the
inconsistent findings is not apparent from the available data.  Because an intermediate-duration inhalation 
MRL based on the NOAEL identified in the 13-week study would be higher than the acute-duration 
inhalation MRL, the database is not considered adequate for derivation of an intermediate-duration 
inhalation MRL.  However, it would be expected that the acute-duration inhalation MRL would be
protective of intermediate-duration exposure to vanadium.
Chronic-Duration Inhalation MRL
•	 An MRL of 0.0001 mg vanadium/m3 has been derived for chronic-duration inhalation exposure
(1 year or longer) to vanadium pentoxide dust.
Two-year rat and mouse studies conducted by NTP (2002) examined the chronic toxicity of inhaled 
vanadium pentoxide 6 hours/day, 5 days/week for 2 years.  At the lowest concentration tested in rats
(0.28 mg vanadium/m3), lung (increases in the incidence of alveolar and bronchiolar epithelial
hyperplasia), larynx (degeneration and hyperplasia of the epiglottis epithelium), and nasal (goblet cell
hyperplasia in respiratory epithelium) effects were observed.  Similar lung and larynx effects were 
observed in mice at the lowest concentration tested (0.56 mg vanadium/m3).  The nasal effects observed 
in mice exposed to 0.56 mg vanadium/m3 included goblet cell hyperplasia in the respiratory epithelium
   
 














        
 
     
 
    
 







































         
  







































2. RELEVANCE TO PUBLIC HEALTH
Table 2-1.  Lung Effects Observed in Rats Exposed to Vanadium  
Pentoxide 6 Hours/day, 5 Days/week for 6 or
13 Days, 13 Weeks, or 2 Years  
mg vanadium/m3 
Air concentration 0 0.28 0.56 1.1 2.2 4.5 9.0
6-Day study 
Alveolar hyperplasia 0/10 0/10 10/10a 
(1.1)b
8/10a (1.4)
Bronchiole 1/10 (1.0) 0/10 10/10a 10/10a 
hyperplasia (1.7) (1.8)
Histiocytic infiltrate 2/10 (1.0) 6/10 (1.3) 10/10a 10/10a 
(1.4) (1.8)
Inflammation 0/10 3/10 (1.0) 10/10a 10/10a 
(1.5) (2.5)
13-Day study 
Alveolar hyperplasia 0/10 3/10 (1.0) 10/10a 10/10a 
(1.0) (2.0)
Bronchiole 0/10 0/10 10/10a 10/10a 
hyperplasia (1.0) (1.8)
Histiocytic infiltrate 0/10 10/10a 10/10a 10/10a 
(1.3) (1.9) (2.2)
Inflammationc 0/10 8/10a (1.3) 10/10a 10/10a 
(1.7) (2.0)
Fibrosis 0/10 0/10 0/10 6/10a (1.5)
13-Week study (males)
Epithelial hyperplasiad 0/10 0/10 10/10a 10/10a 10/10a 10/10a 
(2.0) (3.0) (3.6) (3.3)
Inflammationd 0/10 0/10 9/10a (1.0) 10/10a 10/10 (1.6) 10/10a 
(1.0) (2.1)
Fibrosis 0/10 0/10 2/10 (1.0) 10/10a 10/10a 10/10 (3.1)
(1.9) (3.2)
13 Week study (females)
Epithelial hyperplasia 0/10 0/10 10/10a 10/10a 10/10a 10/10a 
(1.3) (2.9) (3.5) (3.2)
Inflammation 0/10 0/10 0/10 10/10a 10/10a 10/10a 
(1.0) (1.9) (1.2)
Fibrosis 0/10 0/10 0/10 10/10a 10/10a 10/10a 
(1.0) (2.9) (3.2)
   
 













        
 














   




   













   
 




   
 




   
 
 
   
 
   
 
 
    
 



















2. RELEVANCE TO PUBLIC HEALTH
Table 2-1.  Lung Effects Observed in Rats Exposed to Vanadium  
Pentoxide 6 Hours/day, 5 Days/week for 6 or
13 Days, 13 Weeks, or 2 Years  
mg vanadium/m3 
Air concentration 0 0.28 0.56 1.1 2.2 4.5 9.0
2-Year study (males)
Alveolar hyperplasia 7/50 (2.3) 24/49a 
(2.0)
Bronchiole 3/50 (2.3) 17/49a 
hyperplasia (2.2)
Inflammation 5/50 (1.6) 8/49 (1.8)
Fibrosis 7/50 (1.4) 7/49 (2.0)























Alveolar hyperplasia 4/49 (1.0) 8/49 (1.8) 21/50a 50/50a 
(1.2) (3.1)
Bronchiole 6/49 (1.5) 5/49 (1.6) 14/50a 48/50a 
hyperplasia (1.3) (3.0)
Inflammation 10/49 10/49 (1.1) 14/50 (1.2) 40/50a 
(1.5) (1.7)
Fibrosis 19/49 7/49a (1.3) 12/50 (1.6) 32/50a 
(1.4) (1.4)
Histiocyte infiltration 26/49 35/49a 44/50a 50/50a 
(1.4) (1.3) (2.0) (1.9)
ap≤0.05
bAverage severity grade of lesions in affected animals: 1=minimal; 2=mild, 3=moderate; 4=marked
cBasis of acute-duration inhalation MRL
dConsidered as the basis for the intermediate-duration inhalation MRL
Source:  NTP 2002
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and nasal olfactory epithelial atrophy and hyaline degeneration.  In addition to these effects, a significant
increase in alveolar/bronchiolar carcinoma incidence was also observed in mice exposed to ≥0.56 mg
vanadium/m3. In male rats, an increased combined incidence of alveolar/bronchiolar adenoma or
carcinoma was also observed; however, the incidence was not significantly higher than concurrent
controls, but was higher than historical controls.  Because the rat study identified a lower LOAEL for
lung, larynx, and nasal effects, it was selected as the basis of a chronic-duration inhalation MRL. 
In the NTP (2002) study, groups of 50 male and 50 female F344 rats were exposed to 0, 0.5, 1, or 2 mg
vanadium pentoxide/m3 (0, 0.28, 0.56, and 1.1 mg vanadium/m3) 6 hours/day, 5 days/week for 104 weeks.
No significant alterations in survival or body weight gain were observed in the vanadium-exposed rats.  
Alveolar histiocytic infiltrates were observed in males and females exposed to ≥0.28 mg vanadium/m3. 
Significant increases in the incidence of hyperplasia of the alveolar and bronchiolar epithelium were 
observed in males exposed to ≥0.28 mg vanadium/m3 and females exposed to ≥0.56 mg vanadium/m3. 
Squamous metaplasia was observed in alveolar epithelium of males and females exposed to 1.1 mg
vanadium/m3 and in the bronchiolar epithelium of males exposed to 1.1 mg vanadium/m3. Chronic
inflammation was observed in males exposed to 0.56 or 1.1 mg vanadium/m3 and females exposed to 
1.1 mg vanadium/m3 and interstitial fibrosis was observed in males exposed to 1.1 mg vanadium/m3 and 
females exposed to 0.28 or 1.1 mg vanadium/m3. An increased incidence of brownish pigment in alveolar
macrophages was observed in males exposed to 1.1 mg vanadium/m3 and females exposed to 0.56 or
1.1 mg vanadium/m3; this effect was considered to be of little biological relevance.  Chronic
inflammation, degeneration and hyperplasia of the epiglottis were observed in the larynx of males and 
females exposed to ≥0.28 mg vanadium/m3; squamous metaplasia of the epiglottis respiratory epithelium
was also observed in males exposed to ≥0.28 mg vanadium/m3 and in females exposed to 1.1 mg
vanadium/m3. Goblet cell hyperplasia of the nasal respiratory epithelium was observed in males exposed 
to ≥0.28 mg vanadium/m3 and in females exposed to 1.1 mg vanadium/m3. 
BMD analyses of the incidence data for alveolar and bronchiolar epithelial hyperplasia, chronic 
inflammation of the larynx, degeneration of epiglottis respiratory epithelium, and hyperplasia of nasal
respiratory epithelial goblet cells in male rats were used to determine the point of departure for the MRL.  
As described in greater detail in Appendix A, the BMCL10 values for these effects were 0.09, 0.10, 0.07, 
0.04, and 0.16 mg vanadium/m3, respectively.
These BMCL10 values were converted to a human equivalent concentrations (as described in detail in
Appendix A); the BMCLHEC values were 0.008, 0.017, 0.005, 0.003, and 0.012 mg vanadium/m3 for 
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alveolar epithelial hyperplasia, bronchiolar epithelial hyperplasia, chronic inflammation of the larynx, 
degeneration of epiglottis respiratory epithelium, and hyperplasia of nasal respiratory epithelial goblet
cells, respectively.  The BMCLHEC of 0.003 mg vanadium/m3 for degeneration of epiglottis respiratory
epithelium was selected as the point of departure. This value was divided by an uncertainty factor of
30 (3 for animal to human extrapolation with dosimetric adjustment and 10 for human variability), 
resulting in a chronic-duration inhalation MRL of 0.0001 mg vanadium/m3.
Oral MRLs
Acute-Duration Oral MRL
Gastrointestinal effects (diarrhea, cramps, nausea, and vomiting) have been observed in noninsulin-
dependent diabetic patients administered vanadyl sulfate or sodium metavanadate capsules as a 
supplement to their diabetes treatment (Afkhami-Ardekani et al. 2008; Boden et al. 1996; Cohen et al. 
1995; Cusi et al. 2001; Goldfine et al. 1995, 2000) and in patients with ischemic heart disease
administered diammonium vanado-tartrate for lowering serum cholesterol levels (Somerville and Davies 
1962); the results of these studies are summarized in Table 2-2.  Gastrointestinal effects were observed in
subjects ingesting capsules containing 14–42 mg vanadium and no effects were observed at 7.8–10 mg 
vanadium.  In most studies, the effects subsided within the first couple of weeks of exposure.  Information
on the dose-response relationship comes from a study by Goldfine et al. (2000), which used three dose
levels of 7.8, 16, or 31 mg vanadium administered as capsules 3 times/day. No gastrointestinal effects 
were observed at the lowest dose and mild effects were reported in some subjects exposed to the mid dose 
level.  At the highest dose, all subjects reported cramping, abdominal discomfort, and/or diarrhea, which 
required the use of over-the-counter medication.  A small number of studies in laboratory animals have 
examined the acute toxicity of vanadium following oral exposure.  Significant increases in reticulocyte
levels in peripheral blood and polychromatophilic erythroblasts in the bone marrow were observed in rats 
exposed to 27.72 mg vanadium/kg/day as ammonium metavanadate in drinking water for 2 weeks
(Zaporowska and Wasilewski 1989).  The remaining nonlethality studies reported developmental effects
in the offspring of rats and mice administered 7.5–8.4 mg vanadium/kg/day via gavage during gestation 
(Paternain et al. 1987, 1990; Sanchez et al. 1991). The observed developmental effects included 
decreases in fetal growth, increases in resorptions, and gross, visceral, and skeletal malformations and
anomalies.
Although the human studies have a number of limitations, particularly the small number of subjects
(typically <10 subjects per study) and no control group, they provide consistent evidence that bolus
   
 




































































































2. RELEVANCE TO PUBLIC HEALTH
Table 2-2.  Summary of Human Studies Reporting Gastrointestinal Effects  
Following Oral Exposure to Vanadium  
Daily dose, Frequency of Exposure 

























21 mg 2 times/day
10 mg 1 time/day
14 mg 2 times/day
16 mg 2 times/day
7.8 mg 3 times/day
16 mg 3 times/day
31 mg 3 times/day
8 mg 2 times/day,























4/10 subjects reported mild
diarrhea, effects “rapidly
dissipated”; no effects at
10 mg/day
Five of six subjects reported 
effects (nausea in three subjects,
diarrhea in four subjects, and 
abdominal cramping in three 
subjects); all effects only reported 
during first week
Six of eight subjects reported 
symptoms including diarrhea and 
abdominal cramps during first
week
No effects; three subjects tested
Gastrointestinal complaints
reported in “several subjects”; five 
subjects tested
Eight of eight subjects reported 
cramping, abdominal discomfort,
and/or diarrhea
4/11 subjects reported effects
(diarrhea in 4 subjects and 
abdominal cramps in 2 subjects);
effects only reported during first
2 weeks in 3/4 affected subjects
17/20 subjects reported nausea 
during first 3 weeks;
8/20 subjects reported vomiting
Diarrhea and cramps noted at
higher doses (no additional
information provided); six
subjects tested
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administration of vanadium results in gastrointestinal irritation.  However, there is no evidence to support
extrapolating the bolus amount to a daily dose expressed per unit of body weight.  Goldfine et al. (2000)
identified a NOAEL of 7.8 mg vanadium administered 3 times/day as vanadyl sulfate capsules in three 
subjects.  Dividing the daily dose of 23.4 mg vanadium by the average body weight of 109 kg would 
result in a dose of 0.2 mg vanadium/kg/dose.  The lowest LOAEL value is 14 mg vanadium taken twice a
day (Cohen et al. 1995); this corresponds to a daily dose of 28 mg vanadium/day or 0.35 mg
vanadium/kg/day (average body weight was 80.6 kg).  This dose is 20 times lower than the lowest
LOAEL of 7.5 mg vanadium/kg/day for developmental effects identified in animal studies (Paternain et
al. 1990).  However, it is very likely that the observed effects are due to local irritation rather than a 
systemic effect; thus, the amount of vanadium in the gastrointestinal tract is more important than the
mg/kg/day dose.  Deriving an MRL based the NOAEL of 0.2 mg/kg and an uncertainty factor of 10 for
human variability would result in an MRL that is likely to be overly conservative.  Thus, the available 
human data were not considered suitable for derivation of an acute-duration oral MRL.
As noted previously, Paternain et al. (1990) identified the lowest adverse effect level in animals.  In this
study, significant increases in early resorptions, decreases in fetal body weight and length, and increases 
in the incidence of soft tissue anomalies/malformations (hematomas in facial area, neck, and dorsal area,
cleft palate), and skeletal defects (delayed ossification of supraoccipital bone, carpus, tarsus, and
sternebrae) were observed in the offspring of Swiss mice administered via gavage 7.5 mg
vanadium/kg/day as vanadyl sulfate on gestation days 6–15. This dose was also associated with 
significant decreases in maternal body weight gain (during gestation days 6–15, the dams gained 46% less 
weight than controls); no significant alterations in food intake were observed.  Because 7.5 mg
vanadium/kg/day is a serious LOAEL in the dams (ATSDR defines serious effects as those that evoke 
failure in a biological system and can lead to morbidity or mortality), this study is not suitable for
derivation of an acute-duration oral MRL.  It is ATSDR’s policy to not use a LOAEL for serious health
effects as the basis of an MRL.
Intermediate-Duration Oral MRL
•	 An MRL of 0.01 mg vanadium/kg/day has been derived for intermediate-duration oral exposure
(15–364 days) to vanadium.
Two human studies have examined the oral toxicity of vanadium.  No significant alterations in
hematological parameters, liver function (as measured by serum enzymes), cholesterol and triglyceride 
levels, kidney function (as measured by blood urea nitrogen), body weight, or blood pressure were
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observed in subjects administered via capsule 0.12 or 0.19 mg vanadium as ammonium vanadyl tartrate or
vanadyl sulfate for 6–12 weeks (Dimond et al. 1963; Fawcett et al. 1997).  Several studies have reported 
gastrointestinal effects in noninsulin-dependent diabetics that persisted for >2 weeks (Afkhami-Ardekani
et al. 2008; Goldfine et al. 2000).  The effects were observed at 31.3 mg vanadium (administered 
3 times/day) and no effects were observed at 7.8 mg vanadium (Goldfine et al. 2000). Studies in 
laboratory animals have identified several sensitive effects including alterations in erythrocyte and
reticulocyte levels, increased blood pressure, neurobehavioral alterations, and developmental toxicity.
The lowest LOAEL identified in an intermediate-duration study was 0.12 mg vanadium/kg/day for
increases in blood pressure observed in rats exposed to sodium metavanadate in drinking water for
210 days (Boscolo et al. 1994); several other studies by these investigators have reported similar effects at
higher doses (Carmagnani et al. 1991, 1992).  However, other studies have not found significant
alterations in blood pressure at higher doses (Bursztyn and Mekler 1993; Sušić and Kentera 1986, 1988).  
Significant decreases in erythrocyte levels have been observed in rats exposed to 1.18 mg
vanadium/kg/day as ammonium metavanadate in drinking water for 4 weeks (Zaporowska et al. 1993); at
higher concentrations, decreases in hemoglobin and increases in reticulocyte levels have been observed
(Ścibior 2005; Ścibior et al. 2006; Zaporowska and Wasilewski 1990, 1991, 1992a, 1992b; Zaporowska
et al. 1993).  However, other intermediate-duration studies have not found significant alterations at doses
as high as 9.7 mg vanadium/kg/day (Dai et al. 1995; Mountain et al. 1953).  At 1.72 mg
vanadium/kg/day, impaired performance on neurobehavioral tests (open field and active avoidance tests)
was observed in rats exposed to administered sodium metavanadate for 8 weeks (Sanchez et al. 1998).  
No other studies have examined the neurotoxic potential of vanadium.  As with acute-duration exposure, 
the developing organism is a sensitive target of vanadium toxicity.  Decreases in pup body weight and
length were observed in the offspring of rats administered 2.1 mg vanadium/kg/day as sodium
metavanadate for 14 days prior to mating and throughout gestation and lactation (Domingo et al. 1986).  
At higher doses (6, 10, or 12 mg vanadium/kg/day), decreases in pup survival, and increases in the
occurrence of gross, visceral, or skeletal malformations and anomalies were observed (Elfant and Keen 
1987; Morgan and El-Tawil 2003; Poggioli et al. 2001).  
The animal database suggests that the most sensitive targets of vanadium toxicity are blood pressure,
erythroctyes, nervous system, and the developing organism with LOAEL values of 0.12, 1.18, 1.72, and 
2.1 mg vanadium/kg/day, respectively.  Two approaches for derivation of an intermediate-duration oral
MRL were considered.  In the first approach, the NOAEL of 0.12 mg vanadium/kg/day identified in the
Fawcett et al. (1997) study was used as the point of departure for the MRL.  The Fawcett et al. (1997)
study was selected over the Dimond et al. (1963) study, which identified a slightly higher NOAEL
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(0.19 mg vanadium/kg/day) because more subjects (six subjects in Dimond study compared to 15– 
16 subjects in Fawcett study) were examined and the results of the study are described in greater detail.
In the Fawcett et al. (1997) study, groups of men and women enrolled in a weight training program for at
least 1 year were administered capsules containing 0 (11 men and 4 women) or 0.12 mg vanadium/kg/day
as vanadyl sulfate trihydrate (12 men and 4 women) for 12 weeks.  Fasting blood samples were collected
at 0 and 12 weeks and analyzed for hematological (erythrocyte count, hemoglobin, hematocrit, mean cell
volume, mean cell hemoglobin, platelet count, and total and differential leukocyte count) and serum
chemistry (cholesterol, high density lipoprotein, triglycerides, albumin, total protein, total and direct
bilirubin, alkaline phosphatase, alanine amino-transferase) parameters.  Body weight and blood pressure
were measured at weeks 4, 8, and 12.  No significant alterations in blood pressure, body weight, or
hematological or clinical chemistry parameters were found.  Using the NOAEL of 0.12 mg vanadium/kg/ 
day and an uncertainty factor of 10 for human variability, the MRL would be 0.01 mg vanadium/kg/day.  
As discussed previously, the studies of diabetics reporting gastrointestinal effects were not considered a 
suitable basis for an MRL because the effects are likely due to bolus administration of a large amount of
vanadium.
Several animal studies were also considered as the basis of an MRL.  Although an increase in blood
pressure was observed at the lowest adverse effect level (0.12 mg vanadium/kg/day; Boscolo et al. 1994),
this end point was not selected as the basis for an intermediate-duration oral MRL.  This effect has not
been consistently observed among rat studies and no alterations in blood pressure were observed in a 
study of healthy adults exposed to 0.12 mg vanadium/kg/day for 12 weeks (Fawcett et al. 1997).  The
next highest LOAEL of 1.18 mg vanadium/kg/day for a decrease in erythrocyte levels in rats (Zaporowski
et al. 1993) was considered as the principal study for the MRL.  In the Zaporowski et al. (1993) study, 
groups of 2-month-old male and female Wistar rats (15–16/sex/group) were exposed to ammonium
metavanadate in drinking water for 4 weeks at doses of 0, 1.18, and 4.93 mg vanadium/kg/day (males) or
1.50 and 6.65 mg vanadium/kg/day (females).  No alterations in behavior or motor activity were 
observed.  A significant decrease in water consumption (14% less than controls) was observed in males 
exposed to 4.93 mg vanadium/kg/day.  No significant alterations in body weight gain were observed.  As 
summarized in Table 2-3, alterations in erythrocyte, hemoglobin, hematocrit, and reticulocyte levels were
observed.  This study identified a minimal LOAEL of 1.18 mg vanadium/kg/day for decreases in 
erythrocyte and hematocrit levels in male rats.  The alteration in erythrocyte levels was considered
minimally adverse because the magnitude of the change was small (approximately 11%).  Dividing this
minimal LOAEL by an uncertainty factor of 300 (3 for the use of a minimal LOAEL, 10 for animal to 
human extrapolation, and 10 for human variability) results in an MRL of 0.004 mg vanadium/kg/day.
   
 













    
     
     
     
     
    
     
     
     
     
 
   
   





2. RELEVANCE TO PUBLIC HEALTH
Table 2-3.  Hematological Effects in Rats Exposed to Ammonium Metavanadate 
for 4 Weeks
Dose (mg vanadium/kg/day)
Males 0 1.18 4.93
Erythrocytes (x1012/dm3) 8.32 7.38a 7.47b 
Hemoglobin (mmol/L) 9.37 8.94 8.65a 
Hematocrit (L) 0.48 0.47b 0.47a 
Reticulocytes (%) 2.55 2.64 3.82b 
Females 0 1.50 6.65
Erythrocytes (x1012/dm3) 8.24 7.38c 7.12c 
Hemoglobin (mmol/L) 9.41 8.76 8.72a 
Hematocrit (L) 0.48 0.47 0.47
Reticulocytes (%) 2.55 2.91 3.64b 
aSignificantly different from control group (p<0.01)
bSignificantly different from control group (p<0.05)
cSignificantly different from control group (p<0.001)
Source:  Zaporowska et al. 1993
   
 










   
    





   
 
      
   
  
  






2. RELEVANCE TO PUBLIC HEALTH
Although an MRL based on the Zaporwska et al. (1993) rat study would be approximately 3 times lower
than an MRL based on the Fawcett et al. (1997) human study, the Fawcett et al. (1997) study was selected 
as the basis of the intermediate-duration oral MRL because greater confidence was given to an MRL
based on a reliable human study. Thus, the intermediate-duration oral MRL is 0.01 mg vanadium/kg/day.
Chronic-Duration Oral MRL
No studies examining the chronic toxicity of vanadium in humans were identified.  Although several
laboratory animal studies have examined chronic toxicity, most tested low doses and did not find effects.  
No adverse effects were observed in rats and mice exposed to 0.7 or 4.1 mg vanadium/kg/day, 
respectively, as vanadyl sulfate in drinking water for 2–2.5 years (Schroeder et al. 1970; Schroeder and
Balassa 1967).  In rats exposed to 28 mg vanadium/kg/day as vanadyl sulfate in drinking water, a 20%
decrease in body weight gain was observed; no alterations in lungs, heart, liver, or kidneys
histopathology, hematological parameters, or blood pressure were observed at 19 mg vanadium/kg/day
(Dai and McNeill 1994; Dai et al. 1994a, 1994b).  Because the most sensitive target of vanadium toxicity
following chronic-duration oral exposure have not been identified, the animal studies that mostly
identified free-standing NOAEL values were not considered suitable for derivation of an MRL.














   
    
    
  
 
   
    
    
 
    
  
 
     
    
   
 
   
 
   
 
     
   
 
      
     
 
  
   
    




3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of vanadium.  It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
Elemental vanadium does not occur in nature; however, vanadium compounds exist in 65 different
mineral ores and in association with fossil fuels.  It has six oxidation states (2-, 1-, 0, 2+, 3+, 4+, and 5+)
of which 3+, 4+, and 5+ are the most common (Crans et al. 1998). The toxicologically significant 
compounds are vanadium pentoxide (V2O5), sodium metavanadate (NaVO3), sodium orthovanadate 
(Na3VO4), vanadyl sulfate (VOSO4), and ammonium vanadate (NH4VO3).  Vanadium pentoxide dust is
usually encountered in occupational settings, and humans would be exposed via the inhalation route.  
Organic vanadium compounds, such as bis(maltolato)oxyvanadium (IV), bis(ethylmaltolato)oxyvanadium
(IV), and vanadyl acetyl acetonate, have been synthesized for use in the treatment of diabetes and cancer.
Because these compounds likely have different toxicokinetic properties from inorganic vanadium
compounds, they are not included in this toxicological profile.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
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or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration, and place into perspective the possible significance of these
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and the general population
alike.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure 
3.2.1.1  Death 
No studies were located regarding death in humans after inhalation exposure to vanadium.
Increases in mortality have been observed in several studies of laboratory animals exposed to vanadium
pentoxide.  Deaths occurred in rabbits exposed to 114 mg vanadium/m3 for 1 hour, but not in rabbits
exposed to 43 mg vanadium/m3 (Sjöberg 1950).  Exposure to 18 mg vanadium/m3 as vanadium pentoxide
resulted in death in three of five rats exposed for 6 days (NTP 2002).  Intermediate-duration exposure
resulted in deaths in rats exposed to 9 mg vanadium/m3 and mice exposed to 18 mg vanadium/m3 (NTP
   
 








   
   
 





      
  




     
   
      
   
  
   
 
  
   
   
     
  




    




2002).  A decrease in survival was observed in mice chronically exposed to 2.2 mg vanadium/m3 (NTP
2002).  The LOAEL values are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.1.2  Systemic Effects
The highest NOAEL values and all reliable LOAEL values for each species and duration category are 
recorded in Table 3-1 and plotted in Figure 3-1.
Respiratory Effects. Although a number of studies have reported respiratory effects in humans
exposed to vanadium, in particular vanadium pentoxide, very few provide reliable quantitative exposure
data.  In an experimental study, persistent coughing lasting 8 days after exposure termination was
observed in two subjects exposed to 0.6 mg vanadium/m3 for 8 hours; no alterations in lung function 
(lung function parameters assessed: forced vital capacity, 0.5 and 1 second forced expiratory volume, 
maximal expiratory flow, 200–1,200 cc flow rate, maximal midexpiratory time, and forced inspiratory
vital capacity) were observed (Zenz and Berg 1967).  At 0.1 mg vanadium/m3, five subjects reported
productive coughing without other subjective complaints, alterations in lung function, or changes in daily
activities; this concentration level was considered a NOAEL.  Workers exposed to a range of vanadium
pentoxide dust levels for as little as 1 day (Levy et al. 1984; Musk and Tees 1982; Thomas and Stiebris
1956; Zenz et al. 1962) or as long as ≥6 years (Irsigler et al. 1999; Lewis 1959; NIOSH 1983; Sjöberg
1956; Vintinner et al. 1955; Wyers 1946), show mild respiratory distress, such as cough, wheezing, chest
pain, runny nose, or sore throat.  One study of chronically-exposed workers showed increased neutrophils
in the nasal mucosa (Kiviluoto 1980; Kiviluoto et al. 1979b, 1981a).  More severe pathology has not been 
reported.  Symptoms are reversible within days or weeks after exposure ceases.  Data were not located to
assess the relationship of exposure level or duration to severity of response.  Chest x-rays and pulmonary
function tests were normal in most cases.  Chronic effects were infrequently reported.  In a study of
40 vanadium pentoxide workers with persistent respiratory symptoms (Irsigler et al. 1999), 12 were found
to have bronchial hyperresponsiveness to inhaled histamine or exercise challenge.  No significant
alterations in baseline lung function were found.  The mean urine vanadium level (assessed via spot urine
samples) in the hyperresponsive group was 52.7 µg/g creatinine compared to 30.7 µg/g creatinine in 
12 matched subjects with persistent respiratory symptoms and without bronchial hyperreactivity;
statistical comparisons of the two groups were not made.  Five to 23 months after removal from exposure, 
bronchial hyperreactivity was still present in nine of the subjects, although the response was less severe in
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Key to Species Frequency 































Chemical Form Comments 
18 M (5/5 males died)	 NTP 2002 
VANADIUM PENTOXIDE 
0.62 M (audible wheezing and	 Knecht et al. 1992 
coughing in 3/8 VANADIUM PENTOXIDE 
monkeys) 
1.1	 2.2 (localized inflammatory NTP 2002 
response) VANADIUM PENTOXIDE 
4.5	 9 (12-13% decreased body 9 (25-40% decreased body 
weight gain) weight gain) 
0.56	 1.1 (epithelial hyperplasia NTP 2002 




















































































Resp 1.1 2.2 (lung inflammation) NTP 2002 
VANADIUM PENTOXIDE 
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Key to Species Frequency 
Figure (Strain) (Route) 




21 Rat 6 hr/d 











Chemical Form Comments 
Resp 0.56 (hyperplasia and chronic 
inflammation in lungs; 
squamous metaplasia of 
epiglottis epithelium and 
nasal respiratory 
epithelium; atrophy and 









Bd Wt 0.56 1.1 (15-20% decreased body 
weight gain) 
2.2 (20-29% decreased body 
weight gain) 
0.28 M (lung tumor incidence 




































a The number corresponds to entries in Figure 3-1 
b Used to derive an acute-duration inhalation minimal risk level (MRL) of 0.0008 mg vanadium/m3; concentration adjusted for intermittent exposure (6 hours/24 hours, 5 days/7 
days), multiplied by the Regional Deposited Dose Ratio (RDDR) of 0.732 for the thoracic region, and divided by an uncertainty factor of 90 (3 for the use of a minimal LOAEL, 3 for 
extrapolation from animals to human with dosimetric adjustment, and 10 for human variability). 
� 
c Used to derive a chronic-duration inhalation MRL of 0.0001 mg vanadium/m3 calculated using benchmark dose analysis. The BMCL10  of 0.04 mg vanadium/m3 was adjusted for 
intermittent exposure (6 hours/24 hours, 5 days/7 days), multiplied by the RDDR of 0.423 for the extrathoracic region, and divided by an uncertainty factor of 30 (3 for extrapolation 
from animals to humans with dosimetric adjustment and 10 for human variability). 
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); F = Female; Gastro = gastrointestinal hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LOAEL = 
lowest-observed-adverse-effect level; M = male; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; Resp = respiratory; wk 
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39VANADIUM
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Animal data support the human findings and provide additional evidence that vanadium compounds are
respiratory toxicants.  Signs of respiratory distress, impaired lung function, increased pulmonary
reactivity, and histological alterations in the lungs, larynx, and nasal cavity have been observed in
laboratory animals.  Rapid respiration during the exposure period was observed in rats exposed to 9.0 mg
vanadium/m3 as vanadium pentoxide for 16 days or 4.5 mg vanadium/m3 for 4 weeks.  In rats exposed to 
9.0 mg vanadium/m3 for 9 weeks, abnormal respiration was also observed during periods between
vanadium exposures (NTP 2002).  Audible wheezing and coughing were observed in monkeys exposed to 
0.62 mg vanadium/m3 for 6 hours; respiratory symptoms were not observed at 0.14 or 0.028 mg
vanadium/m3 as vanadium pentoxide (Knecht et al. 1992).
Decreases in pulmonary function were observed in rats exposed to ≥2.2 mg vanadium/m3 6 hours/day, 
5 days/week for 13 weeks (NTP 2002).  Exposure to 2.2 or 4.5 mg vanadium/m3 resulted in alterations
characterized as restrictive based on reduced lung compliance, changes in breathing measurements,
impaired capacity to diffuse carbon monoxide, reduced static and dynamic lung volumes, and exaggerated 
airflow. The changes in breathing mechanics, static lung volumes, and forced expiratory maneuvers
observed at 9.0 mg vanadium/m3 were suggestive of an obstructive lung disease; however, the 
investigators noted that these alterations may have been due to the deteriorating condition of the rats
rather than an obstructive disease.  Increased pulmonary resistance was observed in monkeys 1 day after a 
6-hour exposure to 2.8 mg vanadium/m3 (Knecht et al. 1985).  Pulmonary reactivity, as evidenced by an 
obstructive pattern of impaired pulmonary function, was also observed in monkeys following a 6-hour
exposure to 1.7 mg vanadium/m3 as vanadium pentoxide (Knecht et al. 1992); an increase in the total
number of inflammatory cells present in the lungs was also observed.  A similar degree of pulmonary
reactivity was observed when the monkeys were re-challenged with methacholine following a 26-week
exposure to 0.28 mg vanadium/m3 (6 hours/day, 5 days/week).  Pulmonary reactivity was not
significantly affected by a provocation challenge with 0.28 mg vanadium/m3 before or after the 26-week
exposure (Knecht et al. 1992).  
Histological alterations were observed in the lungs, larynx, and nose of rats and mice exposed to 
vanadium pentoxide 6 hours/day, 5 days/week for acute, intermediate, and chronic durations (NTP 2002).  
In the lungs, hyperplasia of alveolar and bronchiolar epithelium occurred at 1.1 mg vanadium/m3 in rats 
and mice exposed for 6, 13, or 90 days, 0.28 mg vanadium/m3 in rats exposed for 2 years, and 0.56 mg
vanadium/m3 in mice exposed for 2 years.  Lung inflammation and histiocytic infiltration (alveolar
macrophages) were observed at similar concentrations in the acute, intermediate, and chronic duration 
studies.  Fibrosis was also observed in rats exposed to 2.2 mg vanadium/m3 for 13 or 90 days or 0.28 mg
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vanadium/m3 for 2 years and in mice exposed to 1.1 mg vanadium/m3 for 2 years.  In both species, the
severity of the lung lesions increased with increasing exposure duration and vanadium pentoxide
exposure level.  NTP (2002) also conducted several studies to examine the time course of the lung
lesions.  In rats exposed to 2.2 mg vanadium/m3, histiocytic infiltrates and inflammation were observed
after 2 days of exposure and alveolar and bronchiolar epithelial hyperplasia were first observed after
5 days of exposure to 1.1 or 2.2 mg vanadium/m3. In rats exposed to 0.56 mg vanadium/m3, hyperplasia
was only observed in a few animals after 542 days of exposure; however, at the end of the 2-year study, 
there was a significant increase in the incidence at this exposure level.  In mice, lung lesions were not
observed after 1 or 2 days of exposure.  Bronchiolar epithelial hyperplasia and inflammation were 
observed after 5 days of exposure to 2.2 mg vanadium/m3. At the lower exposure levels, lung lesions
were observed after 12 days of exposure to 1.1 mg vanadium/m3 and 54 days of exposure to 0.56 mg
vanadium/m3. Severe lung inflammation and mucous cell metaplasia were observed in mice exposed to 
vanadium pentoxide via laryngeal aspiration (Rondini et al. 2010; Yu et al. 2011) and lung inflammation 
and interstitial fibrosis were observed in mice administered vanadium pentoxide via intranasal
administration (Turpin et al. 2010). Bronchoalveolar lavage fluid from rats nose-only exposed to 2 mg
vanadium/m3 as ammonium metavanadate 8 hours/day for 4 days contained higher levels of neutrophils,
small macrophages, and protein levels and increased lactate dehydrogenase activity than air-exposed 
controls (Cohen et al. 1996); these alterations are suggestive of lung inflammation.  Vanadium exposure
also resulted in alterations in the ability of pulmonary alveolar macrophages to respond to
immunoregulating cytokines
The nasal effects observed in rats consisted of hyperplasia and squamous metaplasia of respiratory
epithelium at 2.2 mg vanadium/m3 for 13 weeks, inflammation at 9.0 mg vanadium/m3 for 13 weeks, and 
goblet cell hyperplasia of the respiratory epithelium at 0.28 mg vanadium/m3 for 2 years.  In mice exposed
to vanadium pentoxide for 2 years, the nasal effects included suppurative inflammation at 1.1 mg
vanadium/m3, olfactory epithelium atrophy at 0.56 mg vanadium/m3, hyaline degeneration of olfactory
and respiratory epithelium at 0.56 mg vanadium/m3, and squamous metaplasia of respiratory epithelium at
0.56 mg vanadium/m3. Chronic exposure also resulted in damage to the larynx; degeneration and 
hyperplasia of the epiglottis epithelium were observed in rats exposed to 0.28 mg vanadium/m3 and 
squamous metaplasia of epiglottis epithelium was observed in rats exposed to 1.1 mg vanadium/m3 and 
mice exposed to 0.56 mg vanadium/m3. 
Cardiovascular Effects. Workers exposed chronically to vanadium pentoxide dusts at incompletely
documented exposure levels had normal blood pressure values (Vintinner et al. 1955).  No other
   
 












    
  
   




        
  
  
   
   
   




       
   
  
 
   
  
   
   
    
 




cardiovascular parameters were investigated in this study, but another study revealed normal
electrocardiograms in vanadium workers (Sjöberg 1950).
No significant alterations in heart rate, blood pressure, or electrocardiogram readings were observed in
rats exposed to 4.5 mg vanadium/m3 as vanadium pentoxide 6 hours/day, 5 days/week for 13 weeks (NTP
2002).  Decreases in heart rate and blood pressure were found in rats exposed to 9.0 mg vanadium/m3; 
however, this was attributed to the poor condition of the animals rather than a direct cardiotoxic effect.
No histological alterations were observed in the hearts of rats exposed to 4.5 or 1.1 mg vanadium/m3 
6 hours/day, 5 days/week for 13 weeks or 2 years, respectively, or mice exposed to 9.0 or 2.2 mg
vanadium/m3 for 13 weeks or 2 years, respectively (NTP 2002).
Gastrointestinal Effects. No gastrointestinal complaints were reported by subjects exposed to 0.6 or
0.1 mg vanadium/m3 vanadium pentoxide dusts for 8 hours (Zenz and Berg 1967).  Workers exposed to 
vanadium in oil-burner ashes also did not show gastrointestinal symptoms (Sjöberg 1950).  One study
found that workers exposed chronically to vanadium dusts in factories sometimes complained of nausea
and vomiting (Levy et al. 1984), but these symptoms can have a number of causes (such as exposure to 
other substances) and cannot be directly attributed to the vanadium.  No histological alterations were
observed in the gastrointestinal tract of rats exposed to 4.5 or 1.1 mg vanadium/m3 as vanadium pentoxide
6 hours/day, 5 days/week for 13 weeks or 2 years, respectively, or mice exposed to 9.0 or 2.2 mg
vanadium/m3 for 13 weeks or 2 years, respectively (NTP 2002). 
Hematological Effects. No hematological alterations were observed in humans following acute
(Zenz and Berg 1967) or occupational exposure (Kiviluoto et al. 1981a; Sjöberg 1950; Vintinner et al. 
1955) to vanadium dusts.
During the first 23 days of a 13-week study, minimal erythrocyte microcytosis (as evidenced by decreases 
in hematocrit values, hemoglobin, mean cell volume, and mean cell hemoglobin) was observed in rats 
exposed to vanadium pentoxide 6 hours/day, 5 days/week (NTP 2002). The alterations in hematocrit and 
hemoglobin were observed after 4 days of exposure to 1.1 mg vanadium/m3, mean cell volume and mean 
cell hemoglobin were decreased after 23 or 90 days of exposure to 2.2 mg vanadium/m3. At 13 weeks, 
the microcytosis was replaced by erythrocytosis (as evidenced by increases in hemoglobin, hematocrit,
nucleated erythrocytes, and reticulocytes) in rats exposed to 4.5 or 9.0 mg vanadium/m3. 
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Musculoskeletal Effects. Muscular strength was not altered in one study of workers exposed to 
vanadium pentoxide (Vintinner et al. 1955).  No significant histological alterations were observed in the
bone or muscle following a 13-week or 2-year exposure of rats to 9.0 or 1.1 mg vanadium/m3 as 
vanadium pentoxide, respectively, or mice to 9.0 or 2.2 mg vanadium/m3, respectively.
Hepatic Effects. Workers exposed chronically to 0.01–0.5 mg/m3 of vanadium dusts had normal
serum levels of four enzymes (serum alkaline phosphatase, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and lactate dehydrogenase) that are commonly used to detect possible liver
damage (Kiviluoto et al. 1981a).
Significant increases in serum ALT levels were observed in rats exposed to 4.5 mg vanadium/m3 
6 hours/day, 5 days/week for 13 weeks (NTP 2002).  However, this alteration was not considered to be
biologically relevant because it was not associated with histological alterations in the liver.  No
histological alterations were observed in the livers of rats exposed to 4.5 or 1.1 mg vanadium/m3 as 
vanadium pentoxide 6 hours/day, 5 days/week for 13 weeks or 2 years, respectively, or mice exposed to 
9.0 or 2.2 mg vanadium/m3 for 13 weeks or 2 years, respectively (NTP 2002).
Renal Effects. Workers exposed chronically to 0.01–0.5 mg/m3 of vanadium dusts had normal serum
levels of electrolytes, creatinine, and urea, suggesting no alterations in renal function (Kiviluoto et al. 
1981b).  Workers in other studies of chronic exposure to vanadium had normal urine levels of substances
used to detect kidney disease (casts, protein levels, urea) (Sjöberg 1950; Vintinner et al. 1955).
Significant increases in serum urea nitrogen concentration were observed in male rats exposed to 4.5 mg
vanadium/m3 for 13 weeks and females exposed to 2.2 mg vanadium/m3 for 23 days (but not after
13 weeks of exposure) (NTP 2002).  However, because decreases in total protein and creatinine
concentration were also observed, the urea nitrogen alteration was attributed to decreased body weight
rather than an effect on renal clearance.  A decrease in overnight urine volumes and increase in urine 
specific gravity were observed in rats exposed to 2.2 mg vanadium/m3 for 13 weeks (NTP 2002).  No 
alterations in urine volume or specific gravity were observed in urine samples collected after a 16-hour
water deprivation period, suggesting that the alterations observed in the overnight urine sample were 
reflective of dehydration rather than altered kidney function.  No histological alterations were observed in 
the kidneys of rats exposed to 4.5 or 1.1 mg vanadium/m3 as vanadium pentoxide 6 hours/day, 
5 days/week for 13 weeks or 2 years, respectively, or mice exposed to 9.0 or 2.2 mg vanadium/m3 for 
13 weeks or 2 years, respectively (NTP 2002).
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Dermal Effects. No increases in the occurrence of dermatitis were observed in vanadium pentoxide 
workers (Vintinner et al. 1955); increases in skin rashes were observed in some workers (NIOSH 1983).  
No histological alterations of the skin were observed in rats and mice following intermediate- or chronic-
duration exposure to vanadium pentoxide (NTP 2002).
Ocular Effects. Workers chronically exposed to vanadium dusts in factories had slight to moderate 
eye irritation (Levy et al. 1984; Lewis 1959; Sjöberg 1950; Thomas and Stiebris 1956; Vintinner et al. 
1955).  Brief exposure to vanadium dust can also cause conjunctivitis (Zenz et al. 1962).  
Body Weight Effects. Workers exposed to vanadium ore dust reported weight loss (Vintinner et al.
1955).  Significant decreases in body weight gain have been observed in rats and mice exposed to 
vanadium pentoxide (6 hours/day, 5 days/week) for intermediate or chronic durations (NTP 2002).  The
LOAELs were 9.0 mg vanadium/m3 for rats exposed for 16 or 90 days, 18 mg vanadium/m3 for mice 
exposed for 16 days,  9.0 mg vanadium/m3 for mice exposed for 90 days, and 1.1 mg vanadium/m3 for 
mice exposed for 2 years. At lower concentrations, the decreases were within 10% of the controls.  
Marked decreases in body weight gain (approximately 30% or higher) were observed at lethal
concentrations.
3.2.1.3  Immunological and Lymphoreticular Effects 
There are limited human studies on the potential immunotoxicity of vanadium.  One study found that
workers chronically exposed to unspecified levels of vanadium dusts in factories showed no significant
signs of allergic reactions on the skin or in the respiratory system (Sjöberg 1950).  This, however, cannot
be considered to be an adequate evaluation of immunological function.  A study of children (10–12 years 
of age) living in the vicinity of a facility involved in hydrometallurgical processing of vanadium-rich slag
found significant decreases in lymphocyte stimulation with phytohemagglutinin, Concanavalin A, and 
pokeweed mitogens and an increase in the incidence of viral and bacterial respiratory infections (Lener et
al. 1998).  Alterations in immunoglobulin A and G levels were also found; however, the effect was only
observed in the children with moderate exposure and not in the high exposure group.
Systemic immunity was evaluated in rats and mice exposed to vanadium pentoxide 6 hours/day, 
5 days/week for 16 days (NTP 2002).  Significant decreases in in vitro phagocytosis and increases in vivo
bactericidal activity were observed in rats exposed to ≥2.2 mg vanadium/m3. No adverse effect on the
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response to Klebsiella pneumoniae or to the influenza virus were observed in mice exposed to 18 mg
vanadium/m3. 
3.2.1.4  Neurological Effects 
Most workers exposed to vanadium dusts did not report major adverse neurological signs (Sjöberg 1956;
Vintinner et al. 1955).  However, some workers complained of dizziness, depression, headache, or
tremors of the fingers and arms (Levy et al. 1984; Vintinner et al. 1955), which may or may not have been 
specifically due to vanadium exposure.  No histological alterations were observed in the nervous system
following a 13-week or 2-year exposure of rats to 4.5 or 1.1 mg vanadium/m3, respectively, or mice to
9.0 or 2.2 mg vanadium/m3, respectively (NTP 2002).  Because the NTP (2002) study did not assess
neurological function, these NOAELs are not listed in Table 3-1 or Figure 3-1.
3.2.1.5  Reproductive Effects
No studies were located regarding the reproductive effects in humans after inhalation exposure to 
vanadium.  There are limited data on the potential reproductive toxicity of vanadium in animals following
inhalation exposure.  No histological alterations were observed in rats exposed to 9.0 mg vanadium/m3 as 
vanadium pentoxide for 3 months or 1.1 mg vanadium/m3 for 2 years or in mice exposed to 9.0 mg
vanadium/m3 for 3 months or 2.2 mg vanadium/m3 for 2 years (NTP 2002).  No significant alterations in 
sperm count, motility, or concentration were observed in rats exposed to 9.0 mg vanadium/m3 for 
3 months (NTP 2002).  In females exposed to 4.5 mg vanadium/m3 as vanadium pentoxide for 3 months, 
significant increases in estrous cycle length were observed (NTP 2002); at 9.0 mg vanadium/m3, the
number of cycling females was significantly reduced.  No studies examined reproductive function.  
3.2.1.6  Developmental Effects 
No studies were located regarding the developmental effects in humans or animals after inhalation
exposure to vanadium.
3.2.1.7  Cancer
No studies were located regarding the carcinogenicity in humans after inhalation exposure to vanadium.  
NTP (2002) examined the carcinogenic potential of vanadium in rats and mice exposed to vanadium
pentoxide 6 hours/day, 5 days/week for 2 years.  Increases in the incidence of alveolar/bronchiolar
   
 









   
    




     
     
    
    
  
    
 
   
   
  
    
   
    
  
  
   
    
 
 








adenoma, carcinoma, or the combined incidences of adenoma and carcinoma were observed in male rats.
As indicated in Table 3-2, the incidences of these tumors were not statistically different from controls; 
however, the incidence of adenomas at 0.28 mg vanadium/m3 and combined incidence of adenoma and 
carcinoma at 0.56 or 1.1 mg vanadium/m3 were greater than historical control levels.  Due to the rarity of
these tumors, NTP considered the increases in adenoma and carcinoma observed in male rats to be related
to vanadium pentoxide exposure.  In female rats, no significant increases in lung tumors were observed.  
In the 0.28 mg vanadium/m3 group, the incidence of alveolar/bronchiolar adenoma exceeded the historical
control range.  NTP (2002) noted that this may be related to vanadium pentoxide exposure; however, 
because it was only observed at the lowest vanadium pentoxide concentration, a clear relationship 
between lung neoplasms and vanadium pentoxide could not be determined in female rats.  In male mice,
significant increases in the incidence of alveolar/bronchiolar carcinoma and the combined incidence of
alveolar/bronchiolar adenoma and carcinoma were observed at 0.56, 1.1, and 2.2 mg vanadium/m3; an 
increased incidence of alveolar/bronchiolar adenoma was observed at 1.1 mg vanadium/m3. In female
mice, the incidences of alveolar/bronchiolar adenoma or carcinoma and the combined incidence of
adenoma and carcinoma were significantly elevated in the 0.56, 1.1, and 2.2 mg vanadium/m3 groups.  As
presented in Table 3-2, the tumor incidences in the male and female mice were not concentration-related.  
Based on vanadium lung burden studies in female rats and mice exposed to vanadium pentoxide, NTP
(2002) estimated that the total vanadium lung “doses” were 130, 175, and 308 µg vanadium in rats
exposed to 0.28, 0.56, or 1.1 mg vanadium/m3 for 540 days and 153, 162, and 225 µg vanadium in mice
exposed to 0.56, 1.1, or 2.2 mg vanadium/m3 for 553 days.  In both species, the similarity of the total dose
at the two lower concentrations (total lung doses of 130 and 175 µg vanadium in rats exposed to 0.28 and 
0.56 mg vanadium/m3 and 153 and 162 µg vanadium in mice exposed to 0.56 and 1.1 mg vanadium/m3) 
provides a partial explanation for the flat dose-response curve for lung tumors.  NTP (2002) also 
suggested that the differences in lung tumor responses between the rats and mice may be due to finding
that mice received considerably more vanadium on a body weight basis than rats.
3.2.2 Oral Exposure
3.2.2.1  Death 
No studies were located regarding death in humans after oral exposure to vanadium.
   
 













    
 
       
        
   
 
    
        
   
 
    
   
 
    
      
       
       
       
     
      
        
   
 
    
        
   
 
    
       
      
        
   
 
    
        
   
 
    
       
 
  
   
    
    






Table 3-2.  Incidence of Lung Tumors in Rats and Mice Exposed to Vanadium  
Pentoxide for 2 Yearsa  
Concentration (mg vanadium/m3)
0 0.28 0.56 1.1
Rats
Male
Alveolar/bronchiolar adenoma, multiple 0/50 2/49 0/48 0/50
Alveolar/bronchiolar adenoma (includes
multiple)b
4/50 8/49 5/48 6/50
Alveolar/bronchiolar carcinoma, multiple 0/50 1/49 0/48 0/50
Alveolar/bronchiolar  carcinoma (includes
multiple)c
0/50 3/49 1/48 3/50
Alveolar/bronchiolar adenoma or
carcinomad
4/50 10/49 6/48 9/50
Female 
Alveolar/bronchiolar adenoma 0/49 3/49 1/50 0/50
Alveolar/bronchiolar carcinoma 0/49 0/49 0/50 1/50
Alveolar/bronchiolar adenoma or carcinoma 0/49 3/49 1/50 1/50


















Alveolar/bronchiolar  carcinoma (includes
multiple)
12/50







Female 0 0.28 0.56 1.1




Alveolar/bronchiolar carcinoma, multiple 0/50
Alveolar/bronchiolar  carcinoma (includes
multiple)
0/50
















aAnimals were exposed for 6 hours/day, 5 days/week
bHistorical incidence for 2-year studies with controls given NTP-2000 diet (mean ±standard deviation):  4.2±3.5%,  
range 0–12%; with inhalation chamber controls given NIH-07 diet: 1.7±2.4%, range 0–10%  
cHistorical incidence for NTP-2000: diet 0.4±0.8%, range 0–2%; NIH-07 diet:  0.8±1.2%, range 0–10%  
dHistorical incidence for NTP-2000: diet 4.5±3.9%, range 0–14%; NIH-07 diet: 2.5±2.6%, range 0–10%  
ep≤0.01
Source:  NTP 2002
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The 14-day LD50 values for sodium metavanadate are 41 mg vanadium/kg in rats and 31.2 mg vanadium/ 
kg in mice (Llobet and Domingo 1984).  Deaths have been reported in rat dams exposed to 17 mg 
vanadium/kg/day as sodium orthovanadate on gestation days 6–15 (Sanchez et al. 1991) and in rats
exposed to 22.06 or 24.47 mg vanadium/kg/day as ammonium metavanadate for 4 weeks (Zaporowska
and Wasilewski 1989, 1990).  Although the cause of death was not determined, marked decreases in body 
weight, food intake, and water consumption and increases in the occurrence of diarrhea were observed in 
animals dying early.  Chronic exposures of up to 19 mg vanadium/kg as vanadyl sulfate in food or water
did not affect mortality in rats or mice (Dai et al. 1994a, 1994b; Schroeder and Balassa 1967; Schroeder et
al. 1970).
3.2.2.2  Systemic Effects
The highest NOAEL values and all reliable LOAEL values for systemic effects in each species and
duration category are recorded in Table 3-3 and plotted in Figure 3-2.
No studies were located regarding musculoskeletal or dermal/ocular effects in humans or animals 
following oral exposure to vanadium.
Respiratory Effects. No studies were located regarding respiratory effects in humans after oral
exposure to vanadium.  Rats receiving sodium metavanadate in the drinking water for 3 months had 
mononuclear cell infiltration, mostly perivascular, in the lungs; the investigators noted that the effects
were more evident at the highest dose level (3.5 mg vanadium/kg/day), but incidence data were not
reported (Domingo et al. 1985).
Cardiovascular Effects. No significant alterations in systolic or diastolic blood pressure were 
observed in adults exposed to 0.12 mg vanadium/kg/day as vanadyl sulfate for 4, 8, or 12 weeks via 
capsules taken at mealtime (Fawcett et al. 1997).
Several studies have examined the effects of vanadium on blood pressure in laboratory animals. The 
results are inconsistent; however, differences in the methods used to measure blood pressure and the
strains of rats tested complicate cross study comparisons.  Significant increases in systolic, diastolic,
and/or mean blood pressure were observed in Sprague-Dawley rats exposed to 0.12–12 mg vanadium/ 
kg/day as sodium metavanadate in drinking water for 180–210 days (measured in femoral artery of















































Llobet and Domingo 1984 
SODIUM METAVANADATE 
Comments 
2 Mouse once 
(GW) 











Hemato 27.72 M (increased reticulocytes, 
increased 
polychromatophilic 
erythroblasts in bone 
marrow) 
17 F (17/19 dams died) Sanchez et al. 1991 
SODIUM ORTHOVANADATE 









Bd Wt 7.5 F (46% decrease in 
maternal weight gain) 
Paternain et al. 1990 
VANADYL SULFATE 
Developmental 
6 Rat Gd 6-14 
(G) 























































7.5 F (increased early 
resorptions, decreased 
fetal growth, increased 
soft tissue and skeletal 
defects) 






4.2 8.3 (decreased number of 
ossified sacrococcygeal 
vertebrae) 






4 or 8 wk 
(W) 
24.47 M (10/32 animals died by 
week 4) 






















































Table 3-3 Levels of Significant Exposure to Vanadium - Oral	 (continued) 
a 

















































Fawcett et al. 1997 
VANADYL SULFATE 
1 F 2.1 F (decreased hemoglobin 
and hematocrit, 
increased reticulocyte) 
Adachi et al. 2000 
SODIUM METAVANADATE 
2.1 F 
31 M  (decreased aorta 
diameter) 
Akgun-Dar et al. 2007 
VANADYL SULFATE 
31 M 
4.7 M Boscolo et al. 1994 
SODIUM METAVANADATE 


































































































Bursztyn and Mekler 1993 
SODIUM METAVANADATE 
Cardio 12 M (increased blood 
pressure and heart rate) 
Carmagnani et al. 1991 
SODIUM METAVANADATE 
Cardio 1.2 M  (increased blood 
pressure) 













Dai et al. 1995 
VANADYL SULFATE 
Bd Wt 6 F (19% decrease in 
maternal body weight 
gain) 
Elefant and Keen 1987 
SODIUM METAVANADATE 





















































Chemical Form Comments 
23 Rat 
(Wistar) 





6.6 M 30 M (53% decrease in body 
weight gain) 







Bd Wt 3.42 M 6.84 M (10% decrease in body 
weight gain) 















Hemato 10.69 M (decreased erythrocyte 
and hemoglobin levels) 






Cardio 10 M (increased ventricular 
pressure) 





































Table 3-3 Levels of Significant Exposure to Vanadium - Oral (continued) 
a 

























Chemical Form Comments 
4 or 8 wk 
(W) 
Hemato 24.47 M (decreased erythroctyes, 
increased reticulocytes) 






Hemato 22.06 M  (decreased erythrocyte, 
increased reticulocyte) 






Hemato 19.73 M (decreased hemoglobin 
and erythrocyte and 
increased reticulocyte) 










Hemato 19.73 M (decreased hemoglobin 




Hemato 12.99 M (decreased hemoglobin 
and erythrocyte and 
increased reticulocyte) 


























































Hemato 1.18 M (decreased erythrocyte 
levels) 
Zaporowska et al. 1993 
AMMONIUM 
METAVANADATE 














2.1 F (decreased B-cell, IgG, 
and IgM levels) 
Kasibhatla and Rai 1993 
Not Reported 








1.72 M (impaired performance 
on neurobehavioral tests) 








6.84 M (impaired response in 
active avoidance tests) 






































Table 3-3 Levels of Significant Exposure to Vanadium - Oral	 (continued) 
a 





























Chemical Form Comments 
60 d 
(G) 
31 M (decreased fertility, 
sperm count, and 
motility) 
Jain et al. 2007 
VANADYL SULFATE 






10 M (decreased fertility) 
12 F (decreased fertility) 





17 M 25 M (decreased fertility and 
spermatozoa count) 




2.1 (reduced pup weight and 
length) 
Domingo et al. 1986 
SODIUM METAVANADATE 
Gd 0- Ld 21 
(F) 
6 (decreased pup survival 
and body weight) 


























































10 M (decreased viability, 
increased gross, skeletal 
and visceral anomalies, 
decreased pup body 
weight) 
Morgan and El-Tawil 2003 
AMMONIUM 
METAVANADATE 
12 F (decreased viability, 
increased gross, skeletal 
and visceral anomalies, 




Gd 19- Ld 25, 
pups exposed 




47 Rat 2.5 yr 
(W) 
0.7 
10 (decreased pup survival) Poggioli et al. 2001 
VANADYL SULFATE 
Schroeder et al. 1970 
VANADYL SULFATE 
48 Mouse 2 yr 
(F) 
4.1 Schroeder and Balassa 1967 
VANADYL SULFATE 
49 Mouse 2.5 yr 
(W) 






































Table 3-3 Levels of Significant Exposure to Vanadium - Oral (continued) 
a 


















































Dai and McNeill 1994; Dai et 
al. 1994a, 1994b 
VANADYL SULFATE 












Schroeder and Balassa 1967 
VANADYL SULFATE 







































Chemical Form Comments 
Immuno/ Lymphoret 
54 Mouse 2 yr 
(F) 
4.1 Schroeder and Balassa 1967 
VANADYL SULFATE 
a The number corresponds to entries in Figure 3-2 
b Used to derive an intermediate-duration oral MRL of 0.01 mg vanadium/kg/day; dose divided by an uncertainty factor of 10 for human variability. 
Bd Wt = body weight; (C) = capsule; Cardio = cardiovascular; d = day(s); (F) = feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd = gestation day; (GW) = gavage in 
water; Hemato = hematological; Immuno/Lymphoret = immunological/lymphoreticular; Ld = lactation day; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; 
M = male; Metab = metabolic; mo = month(s); NOAEL = no-observed-adverse-effect level; NS = not specified; pnd = post-natal day; Resp = respiratory; (W) = drinking water; wk = 
























































o-Other  Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans












Figure 3-2 Levels of Significant Exposure to Vanadium - Oral 
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sodium metavanadate in drinking water for 7 months (measured in the aorta of anesthetized rats;
Carmagnani et al. 1991, 1992), and Long-Evans rats exposed to 10 mg vanadium/kg/day as ammonium
vanadate in the diet for 60 days (measured in ventricle of anesthetized rats; Sušić and Kentera 1986).  In 
contrast, no alterations in blood pressure were observed in rats exposed to 10 mg vanadium/kg/day as
ammonium vanadate in the diet for 60 days (Long-Evans rats, measured in femoral artery; Sušić and 
Kentera 1986), 22 mg vanadium/kg/day as sodium metavanadate in drinking water for 4 weeks (Sabra 
rats, measured via tail cuff; Bursztyn and Mekler 1993), 32 mg vanadium/kg/day as vanadyl sulfate in 
drinking water for 52 weeks (Wistar rats, measured via tail cuff; Dai and McNeill 1994), or 63 mg
vanadium/kg/day as sodium metavanadate in the diet for 24 weeks (Long-Evans rats, measured via tail
cuff or femoral artery; Sušić and Kentera 1988).  Studies in compromised animals have also found
alterations in blood pressure.  Increases in arterial blood pressure (measured via tail cuff) were observed
in salt-induced hypertensive rats exposed to 22 mg vanadium/kg/day as sodium metavanadate in drinking
water for 4 weeks compared to hypertensive controls (Bursztyn and Mekler 1993).  Similar increases in
blood pressure (measured via tail cuff) were observed in uninephrectomized rats exposed to 6 mg
vanadium/kg/day as sodium metavanadate in the diet for 18 weeks (Sušić and Kentera 1988) or 5 mg
vanadium/kg/day as sodium orthovanadate in the diet (Steffen et al. 1981).  Alterations in the renin-
angiotensin-aldosterone system and alterations in urinary excretion of electrolytes observed in the
Boscolo et al. (1994) study provide suggestive evidence that altered renal function may play a role in 
vanadium-induced hypertension.  Significant increases in plasma renin activity, plasma aldosterone 
levels, and increases in kallikrein (enzyme that releases vasodilating kinins from plasma proteins), and
kininases I and II activities were observed in rats exposed to 1.2 or 4.7 mg vanadium/kg/day as sodium
metavanadate in the drinking water for 7 months.
Other alterations in the cardiovascular system included significant decreases in aorta diameter and the 
aorta tunica intima thickness in rats administered 31 mg vanadium/kg/day as vanadyl sulfate via gavage 
for 60 days (Akgün-Dar et al. 2007) and an increase in heart rate in rats exposed to 12 mg vanadium/kg/ 
day as sodium metavanadate in drinking water for 7 months (Carmagnani et al. 1991, 1992), but not in 
rats exposed to ≤4.7 mg vanadium/kg/day as sodium metavanadate in drinking water for 7 months
(Boscolo et al. 1994; Carmagnani et al. 1992) or 10 mg vanadium/kg/day as ammonium vanadate in the
diet for 2 months (Sušić and Kentera 1986).
Gastrointestinal Effects. The limited data available for assessing gastrointestinal effects suggest
that exposure to vanadium may cause mild gastrointestinal irritation.  Intestinal cramping and diarrhea
were observed in subjects administered capsules containing 5 mg vanadium as ammonium vanadyl
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tartrate administered 2–4 times/day for 45–68 days (Dimond et al. 1963).  Several clinical studies
investigating the efficacy and mechanism of action of sodium metavanadate and vanadyl sulfate for the 
treatment of diabetes mellitus have found mild gastrointestinal effects (Afkhami-Ardekani et al. 2008;
Boden et al. 1996; Cohen et al. 1995; Cusi et al. 2001; Goldfine et al. 1995, 2000).  Mild diarrhea was
reported by 4/10 insulin- and noninsulin-dependent diabetes patients administered sodium metavanadate 
as capsules 3 times/day for 14 days; capsules taken at breakfast and lunch contained 21 mg vanadium and 
the capsule taken at dinner contained 10 mg vanadium (Goldfine et al. 1995); although the duration of the
effects were not reported, the investigators noted that they “rapidly dissipated”.  One of the subjects 
reported nausea and vomiting that subsided when the dose was changed to 10 mg vanadium 3 times/day.  
In a subsequent study by this group (Goldfine et al. 2000), noninsulin-dependent diabetics were 
administered capsules containing 7.8, 16, or 31 mg vanadium as vanadyl sulfate administered 3 times/day.
No gastrointestinal effects were observed in the subjects taking 7.8 mg capsules; in the subjects taking
16 mg capsules, “several subjects” had gastrointestinal complaints (no additional information provided).
At the highest dose, 8/8 subjects reported cramping, abdominal discomfort, and/or diarrhea; the
investigators noted that these subjects were treated with over-the-counter medication for the
gastrointestinal effects.  During the first week of a 3-week exposure, mild gastrointestinal symptoms
(nausea in three subjects, mild diarrhea in four subjects, and abdominal cramps in three subjects) were
reported by five of six noninsulin dependent diabetics administered twice daily capsules containing 14 mg
vanadium as vanadyl sulfate hydrate (Cohen et al. 1995).  In another study of eight noninsulin dependent
diabetics administered capsules containing 16 mg vanadium as vanadyl sulfate as capsules 2 times/day for
4 weeks, diarrhea and abdominal cramps were reported during the first week of treatment, but not
reported thereafter (in one subject, the effects persisted for 11 days) (Boden et al. 1996).  In noninsulin-
dependent diabetics administered via capsules containing 42 mg vanadium as sodium metavanadate (no 
additional dosing information was provided) for 6 weeks, vomiting was reported by 8/20 subjects
(2 withdrew from the study due to the vomiting) and nausea during the first 3 weeks of the study was
reported in 17/20 subjects (Afkhami-Ardekani et al. 2008).  Similarly, 4/11 noninsulin-dependent
diabetics reported gastrointestinal effects (4 reported diarrhea and 2 reported abdominal discomfort)
during exposure to vanadyl sulfate; effects were only reported during the first 2 weeks of exposure in 3 of
the 4 affected subjects (Cusi et al. 2001).  Initially, the subjects were administered capsules containing
8 mg vanadium 2 times/day; the amount of vanadium in the capsule and frequency of ingestion was
increased every 2–3 days and reached 16 mg vanadium/capsule administered 3 times per day by week 2.
In a study examining the effect of vanadium on serum cholesterol levels in patients with ischemic heart
disease (Somerville and Davies 1962), upper abdominal pain, anorexia, and nausea were reported in 
5/12 patients administered 75 mg/day diammonium vanado-tartrate via capsule for 2 weeks and
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125 mg/day for the next 5 months; doses were administered in three divided daily doses.  Similarly, 
abdominal pain, nausea, vomiting, and multiple daily diarrhea were observed in a woman ingesting an 
unknown fatal dose of ammonium vanadate (Boulassel et al. 2011).  Several animal studies have reported
diarrhea in rats exposed to ≥8.35 mg vanadium/kg/day as sodium metavanadate or ammonium
metavanadate (Ścibior 2005; Zaporowska and Wasilewski 1989, 1990, 1992a); the diarrhea was often 
observed at doses associated with marked decreases in food intake and water consumption.  
Hematological Effects. No alterations in reticulocyte or platelet counts (Dimond et al. 1963) or
erythrocyte, hemoglobin, hematocrit, or platelet levels (Fawcett et al. 1997) were observed in adults 
exposed to 0.19 mg vanadium/kg/day as ammonium vanadyl tartrate for 6–10 weeks or 0.12 mg
vanadium/kg/day as vanadyl sulfate for 12 weeks, respectively.
A series of studies conducted by Zaporowska and associates examined the hematotoxicity of ammonium
metavanadate administered in drinking water to rats for acute or intermediate durations.  A 2-week
exposure to 27.72 mg vanadium/kg/day resulted in significant increases in reticulocyte levels and
increases in the percentage of polychromatophilic erythroblasts in the bone marrow in male rats 
(Zaporowska and Wasilewski 1989); a nonsignificant increase in erythrocytes was also observed at this 
dose level.  Exposures to 12.99–24.47 mg vanadium/kg/day for 4 weeks resulted in decreases in 
erythrocyte levels and hemoglobin levels and increases in reticulocyte levels (Zaporowska and
Wasilewski 1989, 1990, 1991, 1992a, 1992b).  However, death and decreases in body weight gain, food
intake, and water consumption were also observed at these dose levels.  Similar effects were observed in
rats exposed to 8.35 or 10.69 mg vanadium/kg/day as sodium metavanadate for 6 weeks (Ścibior 2005;
Ścibior et al. 2006).  One study in this series tested lower concentrations which did not result in frank
toxicity.  Significant decreases in erythrocyte and hematocrit levels were observed in rats exposed to
1.18 or 4.93 mg vanadium/kg/day as ammonium metavanadate for 4 weeks (Zaporowska et al. 1993);
significant increases in reticulocyte levels were observed at 4.93 mg vanadium/kg/day.  The decreases in
erythrocyte levels were small (approximately 11% less than controls) and not dose-related.  Decreases in
hemoglobin and hematocrit and increases in reticulocytes were observed in rats exposed to 2.1 mg
vanadium/kg/day as sodium metavanadate for 10 weeks (Adachi et al. 2000a) and decreases in
erythrocyte counts were observed in rabbits exposed to 1.8 mg vanadium/kg/day of an unknown 
metavanadate compound for 24 days (Kasbhatla and Rai 1993).  However, other investigators have not
found hematological alterations in rats exposed to 19 mg vanadium/kg/day as vanadyl sulfate for 1 year
(Dai and McNeill 1994), 9.7 mg vanadium/kg/day as ammonium metavanadate for 12 weeks (Dai et al.
1995), 7.6 mg vanadium/kg/day as vanadyl sulfate for 12 weeks (Dai et al. 1995), or 6.6 mg
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vanadium/kg/day as vanadium pentoxide for 10–15 weeks (Mountain et al. 1953).  As suggested by
Ścibior et al. (2006), the differences may be due to the duration of exposure, compound administered, or
age of the animals.
Hepatic Effects. No significant alterations in serum AST, cholesterol, triglyceride, phospholipid, 
and/or bilirubin levels were observed in humans administered, via capsules, 0.19 mg vanadium/kg as
ammonium vanadyl tartrate for 45–68 days (Dimond et al. 1963), 0.12 mg vanadium/kg/day as vanadyl
sulfate for 12 weeks (Fawcett et al. 1997), or 125 mg/day as diammonium oxy-tartratovanadate for
6 weeks (Curran et al. 1959).
Several studies in laboratory animals examining cholesterol and triglyceride levels (Adachi et al. 2000a;
Dai et al. 1994a) or serum enzyme levels (ALT or AST) (Adachi et al. 2000a; Dai et al. 1994b; Yao et al. 
1997) have not found biologically relevant alterations.  The highest NOAEL values for these effects are 
13 mg vanadium/kg/day (Yao et al. 1997) following intermediate-duration exposure and 19 mg
vanadium/kg/day following chronic-duration exposure (Dai et al. 1994a, 1994b).  No histological
alterations were observed in the livers of rats exposed to 3.5 mg vanadium/kg/day as sodium
metavanadate in drinking water for 3 months (Domingo et al. 1985), 4.7 mg vanadium/kg/day as sodium
metavanadate in drinking water for 210 days (Boscolo et al. 1994), or 19 mg vanadium/kg/day as vandyl
sulfate in drinking water for 1 year (Dai et al. 1994b).
Renal Effects. Humans given 0.19 mg vanadium/kg as ammonium vanadyl tartrate capsules for 45– 
68 days did not show any changes in urinalysis for albumin, hemoglobin, or formed elements.  Blood urea
nitrogen levels were also unchanged (Dimond et al. 1963).  Similarly, no alterations in blood urea
nitrogen levels were observed following a 6-week exposure to 125 mg/day as diammonium oxy-
tartratovanadate administered in three divided daily doses (Curran et al. 1959)
There are limited data on the renal toxicity of vanadium compounds.  Narrowing of the lumen of the
proximal tubules was observed in rats exposed to 4.7 or 12 mg vanadium/kg/day as sodium metavanadate 
in drinking water for 7 months (Boscolo et al. 1994; Carmagnani et al. 1991); however, neither study
reported the incidence of the lesion or statistical significance.  Similarly, corticomedullar micro-
hemorrhagic foci were observed in the kidneys of rats exposed to sodium metavanadate in drinking water
for 3 months (Domingo et al. 1985); the investigators noted that the effect was more evident at the highest
dose (3.5 mg vanadium/kg/day), but incidence data or statistical analyses were not included in the paper. 
This study also found significant increases in serum total protein, urea, and uric acid levels in rats
   
 








    
   
 
     
   
 
 




      
 
  
   
    
   
   
  
    
   




     
     
  
    
   





exposed to 3.5 mg vanadium/kg/day. No statistically significant increases in the incidence of histological
alterations were observed in rats exposed to 19 mg vanadium/kg/day as vanadyl sulfate in drinking water
for 1 year (Dai et al. 1994b).  No histological alterations were observed in the kidneys of rats exposed to 
0.7 mg vanadium/kg/day (Schroeder et al. 1970) as vanadyl sulfate in drinking water for 2.5 years or in
mice exposed to 4.1 mg vanadium/kg/day as vanadyl sulfate in the diet for 2 years (Schroeder and Balassa
1967).  
Body Weight Effects. No significant alterations in body weight were observed in adults exposed to
0.12 mg vanadium/kg/day as vanadyl sulfate administered via capsules for 12 weeks (Fawcett et al.
1997).  Numerous studies have reported significant decreases in body weight gain in rats or mice exposed 
to vanadium compounds.  In general, intermediate-duration exposure to <10 mg vanadium/kg/day did not
result in >10% decreases in body weight gain (Adachi et al. 2000a; Dai et al. 1995; Sanchez et al. 1998;
Ścibior 2005; Zaporwska et al. 1993).  At higher concentrations, a considerable amount of variability in
the magnitude of decreases in body weight gain was observed.  Decreases of 12–15% were observed in
rats or mice exposed to 10.69, 13, 20.93, 22.06, or 33 mg vanadium/kg/day as vanadyl sulfate, 
ammonium metavanadate, or sodium metavanadate in drinking water (Llobet et al. 1993; Ścibior et al. 
2006; Yao et al. 1997; Zaporowski and Wasilewski 1989, 1990).  However, decreases of ≥37% were
observed in rats exposed to 12.99 or 19.73 mg vanadium/kg/day as ammonium vanadate in drinking water
(Zaporowski and Wasilewski 1991, 1992a, 1992b); these decreases in body weight gain were
accompanied by marked decreases in food intake and water consumption.  A severe decrease in body
weight gain (54%) and weight loss were observed in rats exposed to 30 or 55 mg vanadium/kg/day,
respectively, as vanadium pentoxide for 75 days (Mountain et al. 1953).  In contrast, no alterations in 
body weight gain were observed in rats exposed to 22 mg vanadium/kg/day as sodium metavanadate in 
drinking water (Bursztyn and Mekler 1993) or administered via gavage at 31 mg vanadium/kg/day as 
vanadyl sulfate (Akgün-Dar et al. 2007; Jain et al. 2007).  Significant decreases in maternal weight gain 
have been observed in rats exposed to 6 mg vanadium/kg/day as sodium metavanadate (Elfant and Keen
1997) and mice administered 7.5 mg vanadium/kg/day as vanadyl sulfate (Paternain et al. 1990). 
Following chronic exposure, a 20% decrease in body weight gain was observed in rats exposed to vanadyl
sulfate in drinking water for 1 year (Dai et al. 1994a).  No alterations in body weight gain were observed
in mice exposed to 4.1 or 0.54 mg vanadium/kg/day as vanadyl sulfate (Schroeder and Balassa 1967;
Schroeder and Mitchener 1975) or rats exposed to 0.7 mg vanadium/kg/day as vanadyl sulfate (Schroeder
et al. 1970).
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It is likely that the decreases in body weight in a number of these studies are secondary to decreases in
water consumption (possibly due to palatability).  Decreases in food intake and body weight gain have
been observed in rats placed on a water restricted diet (Crampton and Lloyd 1954); young rats were
particularly sensitive to the effect (2-month-old rats were used in the Zaporowski and Wasilewski
studies).  Thus, LOAELs for decreases in body weight gain in drinking water studies reporting decreases 
in water consumption (possibly due to palatability) are not presented in Table 3-3 or Figure 3-2; similarly,
LOAELs were not listed for studies that did not report whether there was an effect on drinking water
consumption.
Metabolic Effects. No studies were located regarding metabolic effects in healthy humans after oral
exposure to vanadium.  No significant alterations in blood glucose or insulin levels were observed in rats
exposed to 22 mg vanadium/kg/day as sodium metavanadate in drinking water for 4 weeks (Bursztyn and 
Mekler 1993), rats administered 31 mg vanadium/kg/day as vanadyl sulfate for 60 days (Akgün-Dar et al.
2007), or rats exposed to 19 mg vanadium/kg/day as vanadyl sulfate in drinking water for 1 year (Dai et
al. 1994a).  Additionally, no alterations in the response to an oral glucose tolerance test were observed in 
rats exposed to 13 mg vanadium/kg/day as vanadyl sulfate in drinking water for 7.4 weeks (Yao et al. 
1997).
3.2.2.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans after oral exposure to vanadium.  
Minimal information on immunological effects in animals was located.  Mice exposed to 0.13, 1.3, or
6.5 mg vanadium/kg/day as sodium orthovanadate in the drinking water for 6 weeks showed a dose-
related, but nonsignificant, decrease in the antibody-forming cells in the spleen when challenged with 
sheep erythrocytes (Sharma et al. 1981).  The number of plaques formed was 46, 69, and 78%, 
respectively, lower than the response in the controls; the investigators noted that statistical significance 
was not achieved due to the large variation in the control group.  Decreases in B-cell levels and IgG and
IgM levels were observed in rats exposed to 2.1 mg vanadium/kg/day as sodium metavanadate in the diet
for 10 weeks (Adachi et al. 2000a).  Mild spleen hypertrophy and hyperplasia were seen in rats exposed to
sodium metavanadate in the drinking water for 3 months (Domingo et al. 1985); the investigators noted
that the effects were more evident at the highest dose (3.5 mg vanadium/kg/day), but incidence data were
not reported.  Increases in the responsiveness to the phytohemagglutinin and Con A mitogens was
observed in rats exposed to 0.13 mg vanadium/kg/day as vanadium pentoxide in drinking water for
6 months; this was not observed in rats similar exposed to 13 mg vanadium/kg/day (Mravcová et al. 
   
 








    
    
     
 
  
   
    
     





   
  
   
   
   
      
  
       
 
   
 
  
   
      
   
   
    
   
   




1993).  At the 13 mg vanadium/kg/day dose level, there was an increase in spleen weight and a decrease 
in pokeweed mitogen responsiveness.  Mravcová et al. (1993) also reported increases in spleen weight,
decreases in spleen cellularity, increases in peripheral blood leukocytes, increases in responsiveness to
phytohemagglutinin and Con A mitogens, and an increased response to sheep red blood cells in mice 
administered via gavage 6 mg vanadium/kg as vanadium pentoxide in deionized water 5 days/week for
6 weeks.  The significance of these findings in the rat and mouse studies is difficult to evaluate because 
the investigators only reported the statistically significance of increase in peripheral blood leukocytes in 
mice. The highest NOAEL values and all reliable LOAEL values for immunological effects in each
species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.
3.2.2.4  Neurological Effects 
No studies were located regarding neurological effects in humans after oral exposure to vanadium.  Data 
on the neurotoxicity of vanadium are limited to two studies in rats.  In one study, decreases in travelling
distance and horizontal movement in an open field test and poorer avoidance performance and higher
latency period in an active avoidance test were observed in rats administered 1.72 mg vanadium/kg/day as
sodium metavanadate for 8 weeks (Sanchez et al. 1998).  In the second study, no alterations in travelling
distance or vertical movements were observed in an open field test in rats administered 6.84 mg
vanadium/kg/day as sodium metavanadate for 8 weeks (Sanchez et al. 1999).  A decrease in the number
of avoidance responses to conditioned stimuli and increases in the latency period were also observed in 
these rats. These LOAEL values are recorded in Table 3-3 and Figure 3-2.
3.2.2.5  Reproductive Effects
No studies were located regarding reproductive effects in humans after oral exposure to vanadium.  
Decreases in fertility have been observed in female rats mated to unexposed males (Ganguli et al. 1994b;
Morgan and El-Tawil 2003) and in male rats or mice mated with unexposed females (Jain et al. 2007;
Llobet et al. 1993; Morgan and El-Tawil 2003). The lowest LOAEL values for decreased fertility are 
12 and 10 mg vanadium/kg/day for females and males, respectively (Morgan and El-Tawil 2003).  No 
alterations in fertility were observed in male and female rats administered 8.4 mg vanadium/kg/day as
sodium metavanadate (Domingo et al. 1986).  Decreases in sperm count and motility have also been 
observed in rats administered 31 mg vanadium/kg/day as vanadyl sulfate for 60 days (Jain et al. 2007).  
This NOAEL value and reliable LOAEL values are recorded in Table 3-3 and plotted in Figure 3-2.  
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3.2.2.6  Developmental Effects 
No studies were located regarding developmental effects in humans after oral exposure to vanadium.  A
variety of fetal malformations/anomalies have been observed in animals following gestational exposure to 
vanadium.  Exposure on gestation days 6–14 or 6–15 resulted in increases in facial hemorrhages 
(Paternain et al. 1987), hematomas in facial, neck, and dorsal areas (Paternain et al. 1990), and delayed
ossification (Paternain et al. 1990; Sanchez et al. 1991); the rat and mouse dams were administered 7.5– 
8.3 mg vanadium/kg/day as vanadyl sulfate, sodium metavanadate, or sodium orthovanadate.  One study
also reported increases in early resorptions and decreases in fetal growth in the offspring of mice
administered 7.5 mg vanadium/kg/day as vanadyl sulfate (Paternain et al. 1990); marked decreases in
maternal body weight were also observed at this dose level.  Vanadium exposure throughout gestation and
lactation resulted in decreases in pup body weight and length at ≥2.1 mg vanadium/kg/day (Domingo et
al. 1986; Elfant and Keen 1987; Morgan and El-Tawil 2003).  Increases in stillbirths and decreases in pup
survival were observed at 6 mg vanadium/kg/day (Elfant and Keen 1987); this dose level was associated 
with decreases in maternal food intake and body weight.  Increases in gross, skeletal, and visceral
anomalies were observed in the offspring of rats exposed to 12 mg vanadium/kg/day as ammonium
metavanadate (Morgan and El-Tawil 2003); similar effects were observed in unexposed dams mated with
males exposed to 10 mg vanadium/kg/day (Morgan and El-Tawil 2003).  In rats exposed to 10 mg 
vanadium/kg/day as vanadyl sulfate in drinking water during gestation and lactation and exposed until
postnatal day 100, significant decreases in survival were observed (Poggioli et al. 2001).  This study also 
found significant decreases in the number of rearings in an open field test and no alterations in locomotor
activity or working memory.  A two-generation, one-dose study in rats showed altered lung collagen 
metabolism in fetuses of adults with lifetime exposure (Kowalska 1988).  The toxicological significance
of this finding is also not known.  Reliable LOAEL values from these studies are recorded in Table 3-3 
and plotted in Figure 3-2.
3.2.2.7  Cancer
No studies were located that specifically studied cancer in humans or animals after oral exposure to
vanadium.  However, some studies designed to test other end points noted no increase in tumor frequency
in rats and mice chronically exposed to 0.5–4.1 mg vanadium/kg as vanadyl sulfate in drinking water
(Schroeder and Balassa 1967; Schroeder and Mitchener 1975; Schroeder et al. 1970).  Although results of
these oral studies were negative for carcinogenicity, they were inadequate for evaluating carcinogenic 
effects because insufficient numbers of animals were used, it was not determined whether or not a 
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maximum tolerated dose was achieved, a complete histological examination was not performed, and only
one exposure dose per study was evaluated.
3.2.3 Dermal Exposure 
No studies were located regarding the following health effects in humans or animals after dermal
exposure to vanadium:
3.2.3.1  Death 
3.2.3.2  Systemic Effects
3.2.3.3 Immunological and Lymphoreticular Effects 
3.2.3.4  Neurological Effects 
3.2.3.5  Reproductive Effects
3.2.3.6  Developmental Effects 
3.2.3.7  Cancer
3.3  GENOTOXICITY
The in vitro and in vivo data on the genotoxicity of vanadium compounds are summarized in Tables 3-4 
and 3-5, respectively.  In workers exposed to vanadium pentoxide, no alterations in the occurrence of
sister chromatid exchange (Ivancsits et al. 2002) or deoxyribonucleic acid (DNA) strand breaks (Ehrlich
et al. 2008; Ivancsits et al. 2002) were observed; however, an increase in micronuclei formation was 
observed in lymphocytes (Ehrlich et al. 2008).  Similarly, increases in the micronuclei formation were
observed in mouse bone marrow cells following oral exposure to vanadyl sulfate (Ciranni et al. 1995; 
Villani et al. 2007), sodium orthovanadate (Ciranni et al. 1995), or ammonium metavanadate (Ciranni et
al. 1995); however no increases in micronuclei formation were observed in mouse erythrocytes following
intermediate duration inhalation exposure to vanadium pentoxide (NTP 2002).  Increases in chromosomal
aberrations were also observed in mouse bone marrow following a single gavage exposure to vanadyl
sulfate, sodium orthovanadate, or ammonium metavanadate (Ciranni et al. 1995).  As with the vanadium
workers, DNA damage was not observed in mouse bone marrow or testis cells following intermediate 
duration exposure to vanadyl sulfate in drinking water.
Conflicting results have been found for genotoxicity tests in prokaryote assays.  Impaired recombination
repair were found in Bacillus subtilis following exposure to vanadium pentoxide, vanadyl dichloride, or
   
 









   
 





   
    
 
 
   
 
 




















      
 
 












    
 
 











    
 
 
   
 
     
  
 
     
   
 
   
 
 
      
 
 























Table 3-4.  Genotoxicity of Vanadium and Compounds In Vitro
Results
With Without
Species (test system) End point activation activation Reference Form
Bacillus subtilis Recombination repair No data	 + Kada et al. 1980 V2O5 
+	 VOCl2 
+	 NH4VO3 
B. subtilis Recombination repair No data	 + Kanematsu et al. V2O5 
+ 1980 VOCl2 
+ NH4VO3 
Escherichia coli Gene mutation No data C Kanematsu et al. V2O5 
C 1980 NH4VO3 
Salmonella typhimurium	 Gene mutation No data C Kanematsu et al. V2O5 
C 1980 NH4VO
S. typhimurium Gene mutation C	 C NTP 2002 V2O5 
Saccharomyces cerevisiae	 Induction of diploid No data + Sora et al. 1986 VOSO4 
spores
S. cerevisiae	 Reverse point + + Bronzetti et al. NH4VO3 
mutation 1990
S. cerevisiae Mitotic gene +	 + Bronzetti et al. NH4VO3 
conversion 1990
Mouse erythroleukemia DNA repair No data + Foresti et al. NaVO3 
cells 2001
Mouse 3T3 and 3T6 cells DNA synthesis No data	 + Smith 1983 Na3VO4 
VOSO4 
Chinese hamster ovary DNA protein crosslinks No data + Cohen et al. NH4VO3 
cells 1992
Hamster V79 fetal lung hprt mutation No data + Cohen et al. NH4VO3 
fibroblasts frequency 1992
Chinese hamster V79 cells hprt mutation No data + Klein et al. 1994 NH4VO3 
frequency
Chinese hamster V79 cells gpt mutation No data C Klein et al. 1994 NH4VO3 
frequency
Chinese hamster V79 cells hprt mutation No data C Zhong et al. V2O5 
frequency 1994
Syrian hamster ovary cells Micronuclei formation No data C Gibson et al. V2O5 
1997
Chinese hamster V79 cells Micronuclei formation No data + Zhong et al. V2O5 
1994
Chinese hamster ovary Sister chromatid + + Owusu-Yaw et VOSO4 
cells exchange + + al. 1990 V2O3 
+ + NH4VO3 
Chinese hamster V79 cells Sister chromatid No data C Zhong et al. V2O5 
exchange 1994
   
 








   
 





   
  
 


















     
 
 
     
 
 
      










    
 
 
     
 
 





   
 
 
       













    
 
   
    
 


















Table 3-4.  Genotoxicity of Vanadium and Compounds In Vitro
Results
With Without
Species (test system) End point activation activation Reference Form
Chinese hamster V79 cells Chromosomal
aberrations


















Human tumor cells Colony formation No data + Hanauske et al.
1987
<0.1 pM V
Human tumor cells Colony formation No data C Hanauske et al.
1987
>0.1 pM V
Human leukocytes DNA strand break No data + Birnboim 1988 Na3VO4 










DNA strand break No data C Kleinsasser et al.
2003
V2O5 
Human lymphocytes DNA strand break No data + Kleinsasser et al.
2003
V2O5 





DNA strand break No data + Wozniak and 
Blasiak 2004
VOSO4 
Human lymphocytes DNA strand break No data ± Rojas et al. 1996 V2O5 
Human leukocytes DNA strand break No data + Rojas et al. 1996 V2O5 
Human leukocytes DNA double strand 
breaks




Human leukocytes DNA double strand 
breaks



































   
 








   
 






































    
     
     





Table 3-4.  Genotoxicity of Vanadium and Compounds In Vitro
Results
With Without
Species (test system) End point activation activation Reference Form
Human lymphocytes	 Numerical No data + Roldán and V2O5 
chromosomal Altamirano 1990
aberrations





Roldán and V2O5 
exchange	 Altamirano 1990
Human lymphocytes Sister chromatid No data 
exchange




Human lymphocytes Micronuclei formation No data + Migliore et al. Na3VO4, 
+ 1995 VOSO4 
Human lymphocytes Micronuclei formation No data + Migliore et al. NH4VO3, 
+ 1993 NaVO3, 
+	 Na3VO4,
+	 VOSO4 
C = negative result; + = positive result; ± = weakly positive; DNA = deoxyribonucleic acid; hprt = hypoxanthine 
phosphoribosyltransferase; NaVO3= sodium metavanadate; Na3VO4 = sodium orthovanadate; NH4VO3 = ammonium
metavanadate; V2O5 = vanadium pentoxide; V2O3 = vanadium trioxide; V2O4 = vanadium tetraoxide;
VOSO4 = vanadyl sulfate; VOCl2 = vanadyl dichloride
   
 









     
 



































       
 
      




















       
       
 
         





Table 3-5. Genotoxicity of Vanadium and Compounds In Vivo
Exposure 
Species (test system) End point Route Result Reference Form
Human leukocytes Sister chromatid Inhalation C Ivancsits et al. V2O5 
exchange (occupational) 2002
Human lymphocytes Sister chromatid Inhalation C Ivancsits et al. V2O5 
exchange (occupational) 2002
Human lymphocytes Micronuclei formation Inhalation + Ehrlich et al. V2O5 
(occupational) 2008
Human leukocytes DNA strand breaks Inhalation C Ivancsits et al. V2O5 
(occupational) 2002
Human lymphocytes DNA strand breaks Inhalation C Ivancsits et al. V2O5 
(occupational) 2002
Human lymphocytes DNA strand breaks Inhalation C Ehrlich et al. V2O5 
(occupational) 2008
CD-1 mouse bone marrow Micronuclei formation Drinking water C Villani et al. 2007 VOSO4 
CD-1 mouse blood Micronuclei formation Drinking water ± Villani et al. 2007 VOSO4 
reticulocytes
CD-1 mouse bone marrow Micronuclei formation Gavage + Ciranni et al. VOSO4
+ 1995 Na3VO4 
+ NH4VO3
B6C3F1 mouse Micronuclei formation Inhalation C NTP 2002 V2O5 
erythrocytes
CD-1 mouse bone marrow Chromosome Gavage + Ciranni et al. VOSO4
aberrations + 1995 Na3VO4 
+ NH4VO3
CD-1 mouse bone marrow DNA damage Drinking water C Villani et al. 2007 VOSO4 
CD-1 mouse testis cells DNA damage Drinking water C Villani et al. 2007 VOSO4 
C = negative result; + = positive result; ± = weakly positive; DNA = deoxyribonucleic acid; V2O5 = vanadium pentoxide;
VOSO4 = vanadyl sulfate; Na3VO4 = sodium orthovanadate; NH4VO3 = ammonium metavanadate
   
 









     
   
     
 
   
  
   
       
  
   
   
      
 
    
  
   
  
   
   
   
     
    
  
    
   
  
   
  
  




ammonium metavanadate (Kada et al. 1980; Kanematsu et al. 1980).  No alterations in gene mutation
frequency were found in Escherichia coli or Salmonella typhimurium for vanadium pentoxide
(Kanematsu et al. 1980; NTP 2002) or ammonium metavanadate (Kanematsu et al. 1980). In
nonmammalian eukaryotes, increases in reverse point mutations and mitotic gene conversion were found 
in Saccharomyces cerevisiae (Bronzetti et al. 1990).  In general, alterations in DNA repair, synthesis, 
formation of cross links or strand breaks, and gene mutation frequency were observed in mammalian cells 
for vanadium trioxide, vanadium tetraoxide, vanadium pentoxide, ammonium metavanadate, vanadyl
sulfate, and sodium orthovanadate (Birnboim 1988; Cohen et al. 1992; Foresti et al. 2001; Ivancsits et al.
2002; Klein et al. 1994; Kleinsasser et al. 2003; Rodríguez-Mercado et al. 2011; Rojas et al. 1996; Smith
1983; Wozniak and Blasiak 2004; Zhong et al. 1994).  In vitro human data suggest cell-specific 
differences in the ability of vanadium compounds to induce DNA strand breaks. DNA strand breaks were 
found in fibroblasts and lymphocytes (Ivancsits et al. 2002; Kleinsasser et al. 2003; Wozniak and Blasiak
2004) but not in erythrocytes or nasal epithelial cells (Ivancsits et al. 2002; Kleinsasser et al. 2003).  In a
study comparing the ability of several vanadium compounds to induce double DNA strand breaks, 
significant increases in DNA double strand breaks were found in human leukocytes exposed to vanadium
tetraoxide, but no alterations were found for vanadium trioxide and vanadium pentaoxide (Rodríguez-
Mercado et al. 2011).  Increases in the occurrence of chromosomal aberrations were observed in Chinese 
hamster V79 cells exposed to vanadium pentoxide (Zhong et al. 1994), Chinese hamster ovary cells
exposed to vanadyl sulfate, vanadium trioxide, or ammonium metavanadate (Owusu-Yaw et al. 1990), 
and human lymphocytes exposed to ammonium metavanadate, sodium metavanadate, sodium
orthovanadate, vanadium pentoxide, or vanadyl sulfate (Migliore et al. 1993; Roldán and Altamirano 
1990).  An increase in sister chromatid exchange was found in Chinese hamster ovary cells exposed to 
vanadyl sulfate, vanadium trioxide, or ammonium metavanadate (Owusu-Yaw et al. 1990), but not in 
Chinese hamster V79 cells exposed to vanadium pentoxide (Zhong et al. 1994) or human lymphocytes
exposed to vanadium pentoxide, ammonium metavanadate, sodium metavanadate, sodium orthovanadate, 
or vanadyl sulfate (Migliore et al. 1993; Roldán and Altamirano 1990).  Increases in micronuclei
formation were also found in Chinese hamster V79 cells exposed to vanadium pentoxide (Zhong et al.
1994) and in human lymphocytes exposed to sodium orthovanadate, vanadyl sulfate, ammonium
metavanadate, or sodium metavanadate (Migliore et al. 1993, 1995), but not in Syrian hamster ovary cells 
exposed to vanadium pentoxide (Gibson et al. 1997).  Thus, the available data provide evidence that
vanadium compounds are genotoxic, both clastogenic effects and DNA damage have been observed in in 
vitro and in vivo studies.
   
 








   
 







   
 
 
     
   
   
  
  
     




   
   
   
 





    





3.4.1.1  Inhalation Exposure 
Several occupational studies indicate that absorption can occur in humans following inhalation exposure.  
An increase in urinary vanadium levels was found in workers exposed to <1 ppm of vanadium (Gylseth et
al. 1979; Kiviluoto et al. 1981b; Lewis 1959; NIOSH 1983).  The vanadium concentration in serum was
also reported to be higher than the nonoccupationally exposed controls following exposure to vanadium
pentoxide dust (Kiviluoto et al. 1981b).  
Indirect evidence of absorption after inhalation of vanadium in animals is indicated in studies involving
inhalation exposure or intratracheal administration.  In rats and mice exposed to 0.28–2.2 mg
vanadium/m3 as vanadium pentoxide for 14 days or 2 years (6 hours/day, 5 days/week), marginal
increases in blood vanadium levels were observed, suggesting that vanadium pentoxide was poorly
absorbed or rapidly cleared from the blood (NTP 2002); in the 2-year studies, the increase in blood
vanadium levels were somewhat concentration-related.  Intratracheal studies suggest that soluble 
vanadium compounds are readily absorbed through the lungs.  Initial pulmonary clearance is rapid in rats.
There was rapid 100% absorption of vanadium in rats receiving radiolabeled vanadyl chloride (Conklin et 
al. 1982).  The greatest absorption of a radioactive dose, 48V, was found to occur 5 minutes after
administration (Roshchin et al. 1980).  Most of the vanadium, 80 and 85% of the tetravalent (V4+) and 
pentavalent (V5+) forms of vanadium, respectively, cleared from the lungs 3 hours after intratracheal
exposure (Edel and Sabbioni 1988).  After 24 hours, >50% of vanadyl oxychloride was cleared from the
lungs of male rats (Oberg et al. 1978), and at 3 days, 90% of vanadium pentoxide was eliminated from the
lungs of female rats (Conklin et al. 1982).  In another study 50% was cleared in 18 minutes, and the rest
within a few days (Rhoads and Sanders 1985).
3.4.1.2  Oral Exposure
No studies were located regarding the rate and extent of absorption in humans after oral exposure to 
vanadium.
The absorption of vanadium through the gastrointestinal tract of animals is low.  Less than 0.1% of an 
intragastric dose was detectable in the blood of rats at 15 minutes postexposure, and less than 1% at
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1 hour (Roshchin et al. 1980).  Similarly, only 2.6% of an orally administered radiolabeled dose of
vanadium pentoxide was absorbed 3 days after exposure in rats (Conklin et al. 1982).  In contrast, 16.5%
of vanadium was absorbed in rats exposed to sodium metavanadate in the diet for 7 days (Adachi et al.
2000b).  Vanadium was reported in tissues and urine within hours after a single (Edel and Sabbioni 1988)
and repeated oral exposure in rats (Bogden et al. 1982; Parker and Sharma 1978), suggesting that it is
rapidly absorbed.  Young rats that consumed vanadium in the drinking water and feed were found to have
higher tissue vanadium levels 21 days after birth than they did 115 days after birth (Edel et al. 1984).  The
data suggest that there is a higher absorption of vanadium in these young animals due to a greater
nonselective permeability of the undeveloped gastrointestinal barrier.
3.4.1.3  Dermal Exposure 
No specific studies were located regarding absorption in humans or animals after dermal exposure to
vanadium, although absorption by this route is generally considered to be very low (WHO 1988).  
Absorption through the skin is thought to be quite minimal due to its low lipid/water solubility.
3.4.2 Distribution 
Vanadium has been detected in the lungs (in 52% of the cases) and intestines (in 16% of the cases) of
humans with no known occupational exposure, collected from autopsy data (Schroeder et al. 1963).  In 
the gastrointestinal tract, it was primarily found in the ileum (37%), cecum (45.1%), sigmoid colon 
(15.9%), and rectum (26.2%).  The heart, aorta, brain, kidney, muscle, ovary, and testes were found to 
have no detectable vanadium concentrations.  Bone was not tested.  
3.4.2.1  Inhalation Exposure 
There are limited data on the distribution of vanadium in workers; serum vanadium levels in workers
were highest within a day after exposure followed by a rapid decline in levels upon cessation of exposure 
(Gylseth et al. 1979; Kiviluoto et al. 1981b).  Analytical studies have shown low levels of vanadium in 
human kidneys and liver, with even less in brain, heart, and milk.  Higher levels were detected in hair, 
bone, and teeth (Byrne and Kosta 1978). 
Inhalation exposure and intratracheal administration studies in laboratory animals have examined the 
distribution of vanadium.  Following nose-only exposure of rats to ammonium metavanadate (2 mg
vanadium/m3, 8 hours/day), lung vanadium levels increased by 44% after 2 days of exposure and rapidly
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decreased by 39% after exposure termination on day 4 (Cohen et al. 1996). In rats chronically exposed to 
0.56 or 1.1 mg vanadium/m3 as vanadium pentoxide (6 hours/day, 5 days/week), vanadium lung burdens
peaked after 173 days of exposure and declined for the remainder of the study (day 542); lung burden 
levels never reached steady state (NTP 2002).  In contrast, lung burdens appeared to reach steady state by
exposure day 173 in rats exposed to 0.28 mg vanadium/m3 (NTP 2002).  Similarly, lung burdens did not
reach steady state in mice exposed to 1.1 or 2.2 mg vanadium/m3 as vanadium pentoxide, 6 hours/day, 
5 days/week for 542 days (NTP 2002).  Rather, lung burdens peaked near day 54 and declined through 
day 535.  Steady state was achieved in mice exposed to 0.56 mg vanadium/m3 during the first 26 days of
exposure. These data suggest that vanadium is cleared more rapidly from the lungs of mice compared to
rats.
Vanadium is rapidly distributed in tissues of rats after acute intratracheal administration. Within
15 minutes after exposure to 0.36 mg/kg vanadium oxychloride, radiolabeled vanadium was detectable in 
all organs except the brain.  The highest concentration was in the lungs, followed by the heart and kidney.  
The other organs had low levels.  Maximum concentrations were reached in most tissues between 4 and
24 hours (Oberg et al. 1978).  Vanadium is found to have a two-phase lung clearance after a single acute 
exposure (Oberg et al. 1978; Rhoads and Sanders 1985).  The initial phase is rapid with a large percentage
of the absorbed dose distributed to most organs and blood 24 hours postexposure, followed by a slower
clearance phase.  Vanadium is transported mainly in the plasma.  It is found in appreciable amounts in the 
blood initially and only at trace levels 2 days after exposure (Roshchin et al. 1980).  The pentavalent and
tetravalent forms of vanadium compounds were found to have similar distribution patterns (Edel and 
Sabbioni 1988).  Three hours after intratracheal exposure to the pentavalent or tetravalent form, 15–17%
of the absorbed dose was found in the lung, 2.8% in the liver, and 2% in the kidney (Edel and Sabbioni
1988).  Although levels in the kidney are high after exposure, the bone had greater retention of vanadium.
Skeletal levels of vanadium peaked 1–3 days postexposure (Conklin et al. 1982; Rhoads and Sanders
1985; Roshchin et al. 1980) and have been reported to persist after 63 days (Oberg et al. 1978).  
3.4.2.2  Oral Exposure
No studies were located regarding distribution in humans after oral exposure to vanadium.
Acute studies with rats showed the highest vanadium concentration to be located in the skeleton.  Male
rats had approximately 0.05% of the administered 48V in bones, 0.01% in the liver, and <0.01% in the
   
 








     
 
     
    
       
   
   
 




   
    
    
    
  
   




    
  
 
   








kidney, blood, testis, or spleen after 24 hours (Edel and Sabbioni 1988).  Similar findings were noted by
other authors who found that the bone had the greatest concentration of radiolabeled vanadium, followed 
by the kidney (Roshchin et al. 1980).  Conklin et al. (1982) reported that after 3 days, 25% of the
absorbed vanadium pentoxide was detectable in the skeleton and blood of female rats.  In female rats
exposed to sodium metavanadate in the diet for 7 days, the highest concentrations of vanadium were
found in bone, followed by the spleen and kidney (Adachi et al. 2000b); the lowest concentration was
found in the brain.  As summarized in Table 3-6, vanadium elimination half-times in various tissues were 
3.57–15.95 or 3.18–13.50 days following a 1-week exposure to 8.2 mg vanadium/kg/day as sodium
metavanadate or vanadyl sulfate, respectively, administered in a liquid diet (Hamel and Duckworth 1995).  
Although the elimination half-times were longer in rats administered sodium metavanadate compared to
vanadyl sulfate, no statistical comparisons were made.
Oral exposure for an intermediate duration produced the highest accumulation of vanadium in the kidney.  
Adult rats exposed to 5 or 50 ppm vanadium in the drinking water for 3 months had the highest vanadium
levels in the kidney, followed by bone, liver, and muscle (Parker and Sharma 1978).  The retention in 
bone may have been due to phosphate displacement.  All tissue levels plateaued at the third week of
exposure.  A possible explanation for the initially higher levels in the kidney during intermediate-duration 
exposure is the daily excretion of vanadium in the urine.  When the treatment is stopped, levels decrease 
in the kidney.  At the cessation of treatment, vanadium mobilized rapidly from the liver and slowly from
the bones.  Other tissue levels decreased rapidly after oral exposure was discontinued. Thus, retention of
vanadium was much longer in the bones (Edel et al. 1984; Parker and Sharma 1978).
In rats exposed to approximately 100 mg/L vanadium in drinking water as vanadyl sulfate or ammonium
metavanadate for 12 weeks, significant increases, as compared to controls, in bone, kidney, and liver
vanadium levels were observed; no alterations in vanadium muscle levels were found (Thompson et al. 
2002).  The highest concentration of vanadium was found in the bone, followed by the kidney and liver.  
Tissue vanadium concentrations were significantly higher in rats exposed to ammonium metavanadate as 
compared to animals exposed to vanadyl sulfate.  
3.4.2.3  Dermal Exposure 
No studies were located regarding distribution in humans and animals after dermal exposure to vanadium.
   
 















   
   
   
   
   
   
   
   






Table 3-6.  Vanadium Elimination Half-Times in Various Organs in Rats Exposed 
to 8.2 mg Vanadium/kg/day for 1 Week
Half-time (days)










Source:  Hamel and Duckworth 1995
   
 




























   
 
  






     







3.4.2.4  Other Routes of Exposure 
After intraperitoneal administration to rats, vanadium is distributed to all organs.  After 24 hours, the
highest concentrations were found in the bones and kidney, although initial levels were highest in the
kidney (Roshchin et al. 1980; Sharma et al. 1980).  This is similar to the distribution seen following
inhalation and oral exposure.
3.4.3 Metabolism
Vanadium is an element, and as such, is not metabolized.  In the oxygenated blood, it circulates as a 
polyvanadate (isopolyanions containing pentavalent vanadium) but in tissues, it is retained mainly as the 
vanadyl cation (cationic form of tetravalent vanadium).  Depending on the availability of reducing
equivalents (such as reduced glutathione-SH, NADPH, NADH) and oxygen, vanadium may be reduced, 
reoxidized, and/or undergo redox cycling (Byczkowski and Kulkarni 1998).  
3.4.4 Elimination and Excretion 
3.4.4.1  Inhalation Exposure 
Occupational studies showed that urinary vanadium levels significantly increased in exposed workers
(Gylseth et al. 1979; Kiviluoto et al. 1981b; Lewis 1959; NIOSH 1983; Zenz et al. 1962).  Male and 
female workers exposed to 0.1–0.19 mg/m3 vanadium in a manufacturing company, had significantly
higher urinary levels (20.6 μg/L) than the nonoccupationally exposed control subjects (2.7 μg/L) (NIOSH 
1983).  The correlation between ambient vanadium levels and urinary levels of vanadium is difficult to
determine from these epidemiological studies (Kiviluoto et al. 1981b).  In most instances, no other
excretion routes were monitored.  Analytical studies have shown very low levels in human milk (Byrne
and Kosta 1978).  Evidence from animal studies supports the occupational findings. Vanadium
administered intratracheally to rats was reported to be excreted predominantly in the urine (Oberg et al.
1978) at levels twice that found in the feces (Rhoads and Sanders 1985).  Three days after exposure to 
vanadium pentoxide, 40% of the 48V dose was excreted, mostly in the urine while 30% remained in the
skeleton (5 days after exposure) (Conklin et al. 1982).
In female rats exposed to 0.56 or 1.1 mg vanadium/m3 as vanadium pentoxide for 16 days (6 hours/day, 
5 days/week), lung clearance half-times during an 8-day recovery period were 4.42 and 4.96 days, 
   
 









   
  
  








   
     
    
   
    
 








    
 
  
      
    
   




respectively (NTP 2002).  In mice similarly exposed to 1.1 or 2.2 mg vanadium/m3, lung clearance half-
times were 2.55 and 2.40 days, respectively (NTP 2002).  In contrast to the 16-day exposure data, the
lung clearance half-times in female rats exposed to 0.28, 0.56, or 1.1 mg vanadium/m3 for 2 years 
(6 hours/day, 5 days/week) were 37.3, 58.6, and 61.4 days, respectively (NTP 2002).  In mice, the half-
times were 6.26, 10.7, and 13.9 days at 0.56, 1.1, and 2.2 mg vanadium/m3 exposure levels (NTP 2002). 
These data suggest that vanadium is more rapidly cleared from the lungs following a short exposure
period compared to longer periods.
3.4.4.2  Oral Exposure
No studies were located regarding excretion in humans after oral exposure to vanadium.
Since vanadium is poorly absorbed in the gastrointestinal tract, a large percentage of vanadium is excreted
unabsorbed in the feces in rats following oral exposure. More than 80% of the administered dose of
ammonium metavanadate or sodium metavanadate accumulated in the feces after 6 or 7 days (Adachi et
al. 2000b; Patterson et al. 1986).  After 2 weeks of exposure, 59.1±18.8% of sodium metavanadate was
found in the feces (Bogden et al. 1982).  However, the principal route of excretion of absorbed vanadium
is through the kidney in animals.  Approximately 0.9% of ingested vanadium was excreted in the urine of
rats exposed to sodium metavanadate in the diet for 7 days (Adachi et al. 2000b).  An elimination half-
time of 11.7 days was estimated in rats exposed to vanadyl sulfate in drinking water for 3 weeks 
(Ramanadham et al. 1991).
3.4.4.3  Dermal Exposure 
No studies were located regarding excretion in humans or animals after dermal exposure to vanadium.
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
   
 









     
 
  
    
   
   
     
  
   
   
 
       
  










    
 




   
  




pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
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sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-3 shows a conceptualized representation of a PBPK model.
If PBPK models for vanadium exist, the overall results and individual models are discussed in this section
in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.
No PBPK models for vanadium were located.
3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
In the body, there is an interconversion of two oxidation states of vanadium, the tetravalent form, vanadyl
(V+4), and the pentavalent form, vanadate (V+5).  Vanadium can reversibly bind to transferrin protein in
the blood and then be taken up into erythrocytes.  Vanadate is considered more toxic than vanadyl
because vanadate is reactive with a number of enzymes and is a potent inhibitor of the Na+K+-ATPase of
plasma membranes (Harris et al. 1984; Patterson et al. 1986).  There is a slower uptake of vanadyl into 
erythrocytes compared to the vanadate form.  Five minutes after an intravenous administration of
radiolabeled vanadate or vanadyl in dogs, 30% of the vanadate dose and 12% of the vanadyl dose is found 
in erythrocytes (Harris et al. 1984).  It is suggested that this difference in uptake is due to the time
required for the vanadyl form to be oxidized to vanadate.  When V+4 or V+5 is administered intravenously, 
a balance is reached in which vanadium moves in and out of the cells at a rate that is comparable to the 
rate of vanadium removal from the blood (Harris et al. 1984).  Initially, vanadyl leaves the blood more
rapidly than vanadate, possibly due to the slower uptake of vanadyl into cells (Harris et al. 1984).  Five
hours after administration, blood clearance is essentially identical for the two forms. A decrease in
glutathione-SH, NADPH, and NADH occurs within an hour after intraperitoneal injection of sodium
vanadate in mice (Bruech et al. 1984).  It is believed that the redox cycling of vanadium V+5/V+4, 
depending on the local availability of oxygen in tissues, depletes reducing equivalents that are necessary
for activity of cytochrome P-450.  
Vanadium in the plasma can exist in a bound or unbound form (Bruech et al. 1984).  Vanadium as
vanadyl (Patterson et al. 1986) or vanadate (Harris and Carrano 1984) reversibly binds to human serum
transferrin at two metal-binding sites on the protein.  With intravenous administration of vanadate or
   
 























Figure 3-3.  Conceptual Representation of a Physiologically Based  
Pharmacokinetic (PBPK) Model for a 
Hypothetical Chemical Substance  













































Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  adapted from Krishnan and Andersen 1994
   
 









   
   
   
    
   
 
     
 
   
    
   
  
   
 
    
 





   
     
   
  
      
  
    
   
   
    




vanadyl, there is a short lag time for vanadate binding to transferrin, but at 30 hours, the association is
identical for the two vanadium forms (Harris et al. 1984).  The vanadium-transferrin binding is most
likely to occur with the vanadyl form as this complex is more stable (Harris et al. 1984). The transferrin-
bound vanadium is cleared from the blood at a slower rate than unbound vanadium in rats, which explains
a biphasic clearance pattern (Sabbioni and Marafante 1978). The metabolic pathway appears to be 
independent of route of exposure (Edel and Sabbioni 1988).
3.5.2 Mechanisms of Toxicity
In vitro studies (as reviewed by Barceloux 1999; Etcheverry and Cortizo 1998; Harland and Harden-
Williams 1994; Léonard and Gerber 1994; Mukherjee et al. 2004) have shown that vanadium acts as a
phosphate analog and, as such, interferes with various ATPases, phosphatases, and phosphate-transfer
enzymes.  Vanadium has been shown to inhibit Na+K+ATPase, Ca2+ATPase, H+K+ATPase,
K+ATPase, Ca+Mg+ATPase, dynein ATPase, actomyosin ATPase, acid and alkaline phosphatases,
glucose-6-phosphatase, ribonuclease, phosphodiesterase, and phosphotryosyl-phosphatase.  It has also
been shown to stimulate tyrosine kinase phosphorylase, NADPH oxidase, and adenylate cyclase.
Additionally, vanadium has been shown to have insulin-mimetic properties, particularly the ability to
stimulate glucose uptake and oxidation and glycogen synthesis, and the ability to induce cell proliferation.  
The effect of vanadium on various enzymes may be responsible for the diverse effects observed in
animals exposed to vanadium.  However, little information is available regarding the mechanism of
vanadium toxicity in vivo.
Although the respiratory tract is a sensitive target following inhalation exposure to vanadium, little
information is available on the mode of action.  Yu et al. (2011) showed that vanadium pentoxide induced 
mucin production in mouse airway epithelial cells; however, the mucin production was induced via
EGFR- and MAPK-independent pathways.  Vanadium pentoxide-induced mucin production did appear to 
be dependent on a RAF1-1KK-NF-κB pathway. Results of studies by Turpin et al. (2010) found that the
vanadium pentoxide-induced airway fibrosis was associated with increased collagen and/or fibroblasts 
around the airways. Vanadium increased mRNA levels encoding several pro-fibrogenic growth factors
(e.g., TGF-β1, CTGF, and PDGF-C) and chemokines (e.g., IFN-α, IFN-β, CXCL9, and CXCL10); 
collagen mRNA levels were also increased in the vanadium-exposed mice. Wang et al. (2003) showed 
that aspiration of sodium metavanadate resulted in inflammation and an increase in apoptosis, with a
minimal amount of lung cell necrosis. The inflammatory cell influx and lung cell apoptosis were likely
due to the generation of reactive oxygen species, particularly hydrogen peroxide.
   
 













   
 
    
 
   
  
   
   
  
 
   
 
  
   
      
  
   
 
   
    
  
   
  







3.5.3 Animal-to-Human Extrapolations 
There are little data available to evaluate potential toxicokinetic differences between humans and 
laboratory animals.  Similar effects have been reported in humans and animals following inhalation or
oral exposure to vanadium; however, this conclusion is based on the limited human toxicity data.  In 
absence of data to the contrary, rats or mice appear to be valid models for extrapolation to humans.
3.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial. The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997b).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
   
 








     
  
 
      
 
 
   
 
  
        
 
   
    
 
     
   
  
 
   
    
   
  
   
   
 
   
   
   
   
  
    




to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
No in vivo or in vitro studies were located regarding endocrine disruption in humans and/or animals after
exposure to vanadium.
3.7  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are
critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage
may not be evident until a later stage of development.  There are often differences in pharmacokinetics
and metabolism between children and adults.  For example, absorption may be different in neonates
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth
   
 








   
   
      
    
  
 
   
    






   
  
 
      
    
 
  
     
   
 
 
   
  
   
  







and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
There are limited data on the toxicity of vanadium in children. A study in rats examined the influence of
age on the renal toxicity of vanadium.  Male rats were administered 10 mg/kg/day sodium orthovanadate
via intraperitoneal injection for 8 days.  Similar morphological effects were observed in the kidneys of
22-day-old rats and 62-day-old rats; however, the effects were more severe in the older rats (de la Torre et
al. 1999).  The difference in lesion severity is likely due to the significantly lower renal vanadium
concentration in the young rats.
Edel et al. (1984) examined age-related changes in the distribution of vanadium in rats exposed to 
background levels of vanadium.  At 21 days of age, the highest concentrations of vanadium (ng
vanadium/g wet weight) were found in the kidney, heart, lung, brain, and liver.  By 115 days of age, the
highest concentration was in the femur; levels in the heart, lung, brain, spleen, and muscle were
approximately 3–4 times lower.  The concentrations of vanadium in the kidney, liver, and lungs
significantly decreased with increasing age of the rat. The investigators suggested several mechanisms 
that may be responsible for the age-related changes in vanadium tissue concentration, including higher
gastrointestinal absorption of vanadium in young rats, which may be due to increased bioavailability of
vanadium in breast milk compared to the diet, or a higher vanadium retention capacity in undeveloped 
tissue due to a greater affinity or lower elimination rate.
   
 











   
     
 
   
 
   
   
 
 
     




    
    
   
  
   
     
  
   
 
  
   
 
  
     




As discussed in Section 3.2, a number of developmental effects including decreases in growth, increases
in malformation and anomalies, and death have been observed in developmental toxicity studies
(Domingo et al. 1986; Elfant and Keen 1987; Morgan and El-Tawil 2003; Paternain et al. 1990); however
most of these effects occurred at doses associated with significant maternal toxicity.
3.8  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment
of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  However, several
factors can confound the use and interpretation of biomarkers of exposure.  The body burden of a
substance may be the result of exposures from more than one source. The substance being measured may
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from
exposure to several different aromatic compounds).  Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken.  It may be difficult to
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids
(e.g., essential mineral nutrients such as copper, zinc, and selenium).  Biomarkers of exposure to 
vanadium are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by vanadium are discussed in Section 3.8.2.
   
 









   
   
  
    
   
 
      
 
 
     
     
   
    
   
 
 
    
      
   
   
  
   
    
    
    
     
   
 
 
    
 
   




A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Vanadium
Several biomarkers of exposure have been identified for vanadium but none of them can be used to 
quantitatively determine exposure levels.  Elevated levels of vanadium have been found in the serum
(Gylseth et al. 1979; Kiviluoto et al. 1981b), blood (Kučera et al. 1998), and urine (Gylseth et al. 1979;
Kiviluoto et al. 1981b; Kučera et al. 1998; Lewis 1959; NIOSH 1983; Zenz et al. 1962) of exposed 
workers.  Elevated levels of vanadium have also been detected in children accidentally exposed to high
levels of vanadium in drinking water (Kučera et al. 1992).  Although elevated vanadium levels have been 
detected in vanadium-exposed individuals and a significant correlation between serum vanadium levels
and urinary vanadium levels have been found (Kiviluoto et al. 1981b), relationships between exposure
levels and blood/serum or urine vanadium levels have not been established.  Some vanadium workers
develop a characteristic green tongue, as a result of direct accumulation of the vanadium dusts on the
tongue (Lewis 1959).  One report from the 1950s states that vanadium exposure was associated with 
decreased cystine content in the fingernails of vanadium workers (Mountain et al. 1955).  However,
alterations in cystine levels can also be associated with dietary changes and with other disease states, so
this is not specific for vanadium exposure.  Another occupational exposure study did not find significant
alterations in cysteine levels in fingernails (Kučera et al. 1998). Analytical methods have been developed 
to measure vanadium levels in hair (Fernandes et al. 2007; Kučera et al. 1992, 1998); however, a 
relationship between exposure levels and hair levels has not been established. Kučera et al. (1992) did 
not find a significant increase in hair vanadium levels in children exposed to elevated vanadium drinking
water levels; however, significant increases in blood vanadium levels were found in this group. In an 
occupational exposure study, elevated hair vanadium levels were found (Kučera et al. 1998).
3.8.2 Biomarkers Used to Characterize Effects Caused by Vanadium
The primary effects of inhalation exposure to vanadium dusts are coughing, wheezing, and other
respiratory difficulties. These effects, however, are not specific to vanadium and can be found following
inhalation of many types of dusts.  
   
 













    
    
 
  
    
  
   
 




   
  
    
















3.9  INTERACTIONS WITH OTHER CHEMICALS
Vanadium in the drinking water of mice had no influence on tumor induction by the known carcinogen 
1,2-dimethylhydrazine given by subcutaneous injection (Kingsnorth et al. 1986), but dietary vanadium
did decrease mammary tumors in mice caused by 1-methyl-1-nitrosourea administered concurrently
(Thompson et al. 1984).  The latter effect may have been due to interaction with DNA.
The combination of manganese and vanadium or of nickel and vanadium administered to pregnant mice
caused some alterations in behavioral development of the pups as compared to either element
administered alone (Hoshishima et al. 1983).  Oral administration of vanadium in rats interfered with 
copper metabolism, probably by inhibiting the intestinal absorption of copper (Witkowska et al. 1988).
3.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to vanadium than will most persons
exposed to the same level of vanadium in the environment.  Reasons may include genetic makeup, age, 
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These
parameters result in reduced detoxification or excretion of vanadium, or compromised function of organs
affected by vanadium.  Populations who are at greater risk due to their unusually high exposure to 
vanadium are discussed in Section 6.7, Populations with Potentially High Exposures.
No unusually susceptible populations have been identified, but persons with pre-existing respiratory
disorders such as asthma or chronic obstructive pulmonary disease (COPD) may be expected to have 
increased adverse effects from breathing vanadium dusts.  Due to the insulin-mimetic effects of
vanadium, individuals with hypoglycemia may be unusually susceptible to exposure to high levels of
vanadium.
3.11  METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to vanadium.  However, because some of the treatments discussed may be experimental and
unproven, this section should not be used as a guide for treatment of exposures to vanadium.  When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
   
 








    
   
 
 





    
 
      
   
    
 
 






   
     





    
   
    




for medical advice.  The following texts provide specific information about treatment following exposures
to vanadium:
Haddad LM, Winchester JF.  1990. Clinical management of poisoning and drug overdose.  2nd ed.  
Philadelphia, PA: W.B. Saunders Company, 1033.
Stutz DR, Janusz SJ.  1988.  Hazardous materials injuries:  A handbook for pre-hospital care.  2nd ed.  
Beltsville, MD:  Bradford Communications Corporation, 406-407.
3.11.1 Reducing Peak Absorption Following Exposure 
There is no known treatment to decrease absorption after inhaling or ingesting vanadium and/or its
compounds.  If vanadium gets onto the skin, washing the contaminated area with soapy water has been 
advised.  For ocular exposure, it is suggested that the eyes be flushed with large amounts of saline or
water (Stutz and Janusz 1988).
3.11.2 Reducing Body Burden
Several studies have evaluated the effectiveness of chelating agents in reducing vanadium body burden. 
Significant increases in urinary excretion of vanadium were observed in rodents treated with ascorbic acid
(Domingo et al. 1990), tiron (sodium 4,5-dihydroxybenzene-1,3-disulfonate) (Domingo et al. 1990;
Gomez et al. 1991), deferoxamine mesylate (Gomez et al. 1988, 1991), 2-mercaptosuccinic (Domingo et
al. 1990), deferrioxamine (Tubafard et al. 2010), or deferiprone (Tubafard et al. 2010) following
intramuscular injection of vanadyl sulfate (Domingo et al. 1990), 6-week oral exposure to sodium
metavanadate or vanadyl sulfate (Gomez et al. 1991), or 60-day exposure to vanadium (specific 
compound and route of exposure not reported (Tubafard et al. 2010).  Administration of ethylene diamine
tetraacetate (EDTA), 2-mercaptosuccinic or tiron also significantly reduced kidney vanadium levels 
(Domingo et al. 1990) and tiron reduced spleen and kidney vanadium levels (Gomez et al. 1991).  
Administration of calcium disodium EDTA resulted in increases in urinary excretion of vanadium in 
calves exposed to high levels of dietary vanadium (Gummow et al. 2006); however, no difference in 
vanadium excretion was observed after vanadium exposure was terminated.  Other studies have examined
the potential of chelating agents to reduce toxicity.  Humans or animals with vanadium poisoning have
not been helped by the chelating agent dimercaprol (BAL), which is often effective in lessening the 
toxicity of other metals (Lusky et al. 1949).  Intraperitoneal injections of ascorbic acid and EDTA reduced
vanadium-induced morbidity in mice and rats (Jones and Basinger 1983; Mitchell and Floyd 1954).  
Decreased mortality was also observed in mice following intraperitoneal injection of D-pencillamine, 
   
 








    
   
    
  
   
   
     
 
       
 
    
 
   
    
   
    
  
 
    
    





   
 
   
   
    
  
  




tiron, and deferoxamine mesylate (Jones and Basinger 1983).  Administration of tiron 0, 24, 48, or
72 hours after pregnant mice received a 25 mg/kg sodium metavanadate intraperitoneal injection on
gestation day 12 resulted in significant reductions in vanadium-induced abortions, early deliveries, fetal
deaths, and incidence of reduced ossification (Domingo et al. 1993a).  Administration of tiron after a
6-week exposure to sodium metavanadate reverted the vanadium-induced impairment in performance on 
neurobehavioral tests (Sanchez et al. 1999).  Co-exposure to calcium disodium EDTA did not
significantly alter the toxicity of ingested vanadium in calves (Gummow et al. 2006).  
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
There are limited data on treatments which interfere with the mechanism of action for vanadium toxicity.
Moderate to severe morphological alterations (average severity score of 3.0) were observed in the kidneys 
25 days after rats were administered 1 mg vanadium/kg/day as ammonium metavanadate via 
subcutaneous injection (Al-Bayati et al. 2002).  Administration of the antifibrotic agent, pirfenidone, for
41 days after exposure termination resulted in a decrease in the severity of the kidney lesions; the lesions 
were scored as very mild with a severity score of 1.42.  Although the mechanism associated with the 
reduction in toxicity was not determined, it is possible that the pirfenidone-induced reduction in collagen-
deposition in the kidney may have contributed to the diminished toxicity.  Chandra et al. (2007a)
demonstrated a reduction in testes toxicity in rats administered 0.4 mg vanadium/kg/day as sodium
metavanadate via intraperitoneal injection for 26 days and 50 or 100 mg/kg vitamin E acetate
simultaneously in the diet compared to rats administered vanadium only.  The likely mechanism is that
vitamin E interrupts the chain reactions of lipid peroxidation and scavenges ROS generated during the
univalent reduction of molecular oxygen and normal activity of oxidative enzymes; thus its prevents the
detrimental effect of vanadium on testis by inhibiting the oxidative stress.
3.12  ADEQUACY OF THE DATABASE
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of vanadium is available. Where adequate information is not
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of vanadium.
   
 












   
 
    
 
  
     
  
     





   
   
     
    
 
  
     
    
 
   
 
 
   




The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Vanadium
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
vanadium are summarized in Figure 3-4.  The purpose of this figure is to illustrate the existing
information concerning the health effects of vanadium.  Each dot in the figure indicates that one or more
studies provide information associated with that particular effect. The dot does not necessarily imply
anything about the quality of the study or studies, nor should missing information in this figure be
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature.
Data are available from humans regarding acute, intermediate, and chronic inhalation exposure to
vanadium pentoxide and on immunologic and neurologic effects, primarily from case studies of factory
workers.  Data regarding acute effects are available from volunteers who ingested ammonium vanadyl
tartrate in capsules for intermediate periods.  No human dermal data were located.
Data are available regarding the effects of inhalation of vanadium pentoxide in rats, mice, and monkeys
following acute, intermediate, and chronic exposures. Data are available in humans orally exposed to
vanadyl sulfate or ammonium metavanadate.  Data are available following acute, intermediate, and
chronic oral exposures in animals, including information on death (from ammonium metavanadate, 
sodium metavanadate, or vanadyl sulfate), systemic toxicity (from vanadyl sulfate, sodium metavanadate,
sodium orthovanadate, or ammonium metavanadate), immunological (from sodium orthovanadate), 
neurological (from vanadium pentoxide), developmental (from vandyl sulfate, sodium orthovanadate, 
ammonium metavanadate, or sodium metavanadate), and reproductive effects (from sodium
metavanadate, ammonium metavanadate, or vanadyl sulfate).  No animal dermal data were located.
   
 




















































































































   
 








    
 
      
    
   
   
    
   
  
  






   
   
     
   
  
    
    
 
  
    
      
    
       
 





3.12.2 Identification of Data Needs 
Acute-Duration Exposure. Information on the acute toxicity of inhaled vanadium in humans is
limited to the finding of symptoms of respiratory irritation (persistent coughing) in a small number of
subjects exposed to vanadium pentoxide dust for 8 hours (Zenz and Berg 1967).  Several animal studies
confirm that the respiratory tract is the most sensitive target of vanadium toxicity (Knecht et al. 1985, 
1992; NTP 2002). These studies only examined the respiratory tract; however, longer duration studies
have confirmed the respiratory tract as the most sensitive target following inhalation exposure.  At lower
concentrations, the observed effects included lung inflammation and alveolar and bronchiolar epithelial
hyperplasia in rats and mice exposed to vanadium pentoxide for 6 or 13 days (NTP 2002); the severity of
the lung effects increased with increasing vanadium concentrations.  Impaired lung function was reported 
in monkeys exposed to fairly low concentrations of vanadium pentoxide for 6 hours (Knecht et al. 1985, 
1992).  The animal data were sufficient to derive an acute-duration inhalation MRL for vanadium based
on lung inflammation in rats (NTP 2002).  
There are limited data on human toxicity following ingestion of vanadium; gastrointestinal effects
(diarrhea, cramps, nausea, vomiting) have been reported in patients given vanadium supplement as part of
a diabetes treatment plan (Boden et al. 1996; Cusi et al. 2001; Goldfine et al. 1995).  However, these
studies are limited by the small number of subjects and the lack of control groups.  A small number of
studies in laboratory animals have examined the acute toxicity of vanadium following oral exposure.  At
the lowest doses tested, marked developmental toxicity (decreases in fetal growth, increases in resorptions 
and gross, visceral, and skeletal malformations and anomalies) was observed in rat and mouse offspring
(Paternain et al. 1987, 1990; Sanchez et al. 1991).  In adult rats, hematological effects (including
increases in reticulocyte levels and polychromatophilic erythroblasts in bone marrow) were observed at
higher doses than the developmental effects (Zaporowska and Wasilewski 1989).  The database was 
considered inadequate for derivation of an acute-duration oral MRL due to the limitations in the human 
studies and the serious effects observed at the lowest animal dose tested. At the lowest adverse effect
level, a 46% decrease in weight gain (considered a serious health effect) was observed in the rat dams
(Paternain et al. 1990); it is ATSDR policy to not use serious LOAELs as the basis of an MRL.
Additional studies which examine a variety of end points are needed to identify the most sensitive effect
following acute oral exposure. These additional studies might provide a suitable basis for an acute-
duration oral MRL.
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No dermal exposure studies were identified in humans or animals.  Studies are needed to establish the 
potential toxicity of vanadium compounds applied to the skin.
Intermediate-Duration Exposure. No human studies examined the toxicity of vanadium following
intermediate-duration inhalation exposure.  Animal data come from 16-day and 13-week exposure studies 
in rats and mice (NTP 2002). These studies clearly identify the respiratory tract as the most sensitive 
target of toxicity.  At low concentrations of vanadium pentoxide, alveolar and bronchiolar epithelial
hyperplasia were observed in both species.  At higher concentrations, nasal effects were also observed.
Although the NTP (2002) study is a high quality study which identified NOAEL and LOAEL values for a
sensitive end point, an intermediate-duration inhalation MRL was not derived because the NOAEL value 
was the same as the LOAEL for lung inflammation in rats exposed to vanadium pentoxide for 13 days 
(NTP 2002).  An explanation for the inconsistent findings is not apparent from the available data.  An 
additional study designed to examine respiratory effects after various exposure durations may provide
insight into the inconsistent findings of the NTP study and may be useful for derivation of an MRL.
Data on the toxicity of vanadium following intermediate-duration oral exposure come from two human 
studies and a number of animal studies.  The human studies examined a number of potential end points in 
subjects exposed to relatively low doses of vanadium for 6–12 weeks; no adverse effects were observed
(Dimond et al. 1963; Fawcett et al. 1997).  Animal studies have identified several sensitive effects 
including hematological alterations (decreased erythrocyte levels and increased reticulocyte levels)
(Ścibior 2005; Ścibior et al. 2006; Zaporowska and Wasilewski 1990, 1991, 1992a, 1992b; Zaporowska
et al. 1993), increased blood pressure (Boscolo et al. 1994; Carmagnani et al. 1991, 1992), alterations in 
neurobehavioral performance tests (Sanchez et al. 1998), and developmental toxicity (Domingo et al. 
1986; Elfant and Keen 1987; Morgan and El-Tawil 2003; Poggioli et al. 2001).  However, the findings
are inconsistent and a cause of the conflicting results has not been identified.  Additional animal studies 
examining hematological, blood pressure, and neurological end points are needed to support the findings
of the animal studies.  An intermediate-duration oral MRL based on the NOAEL identified in one of the
human studies (Fawcett et al. 1997) was derived.
No dermal exposure studies were identified in humans or animals.  Studies utilizing several vanadium
compounds would be useful for assessing the potential dermal toxicity of vanadium.
Chronic-Duration Exposure and Cancer. Sufficient information is available in occupationally
exposed humans to identify the respiratory system as a target organ following chronic inhalation exposure
   
 








   
 
    
  
     
   
 
    
  
     










    
     
    
    
     
    
    









(Lewis 1959; NIOSH 1983; Sjöberg 1956; Vintinner et al. 1955; Wyers 1946). Two-year rat and mouse 
studies (NTP 2002) confirm the identification of the respiratory tract as the most sensitive target of
inhaled vanadium pentoxide.  At the lowest concentrations tested, histological alterations in the lungs
(alveolar and bronchiolar epithelial hyperplasia), larynx (degeneration and hyperplasia of epiglottis
epithelium), and nasal cavity (goblet cell hyperplasia) were observed.  The NTP (2002) rat study was used
as the basis of a chronic-duration inhalation MRL for vanadium.
No studies examining the chronic oral toxicity of vanadium in humans were identified.  Several studies
have examined chronic oral toxicity in rats and mice (Dai and McNeill 1994; Dai et al. 1994a, 1994b;
Schroeder and Balassa 1967; Schroeder et al. 1970); however, the doses tested did not result in adverse
effects, with the exception of a decrease in body weight gain, and the most sensitive targets of vanadium
toxicity following chronic exposure have not been identified.  Additional studies examining a variety of
end points, including potential hematological and cardiovascular effects (sensitive targets following
intermediate-duration exposure), are needed to identify sensitive targets and establish dose-response 
relationships.
Data are not available to determine target organs in humans from chronic dermal exposure.  Dermal
exposure studies which could be used to identify targets of toxicity and dose-response relationships are 
needed.  
No studies were located regarding the carcinogenicity in humans after inhalation, oral, or dermal exposure
to vanadium.  Significant increases in the incidence of lung tumors (alveolar/bronchiolar adenoma and/or
carcinoma) were observed in mice exposed to airborne vanadium pentoxide for 2 years (NTP 2002).  
Suggestive evidence of lung carcinogenicity was also observed in male rats chronically exposed to
vanadium pentoxide (NTP 2002).  Although several oral studies did not find increases in tumor frequency
in rats or mice exposed to vanadyl sulfate in drinking water (Schroeder and Balassa 1967; Schroeder and 
Mitchener 1975; Schroeder et al. 1970), these studies were considered inadequate for carcinogenicity
assessment due to the small number of animals tested, low doses (maximum tolerated dose was not
achieved), incomplete histological examination, and the use of one exposure dose per study.  No studies
examined the potential carcinogenicity of vanadium following dermal exposure.  Additional studies are
needed to evaluate the potential carcinogenicity of vanadium following oral and dermal exposure.
Genotoxicity. In vivo genotoxicity assays have been conducted in vanadium pentoxide workers
(Ehrlich et al. 2008; Ivancsits et al. 2002), in mice exposed to airborne vanadium pentoxide (NTP 2002), 
   
 








   
 
    
    
 
     
 
     
    
   
 




    
   
     
   
 
    
   
   
     
  









in mice exposed to vanadyl sulfate in drinking water (Villani et al. 2007), and in mice administered a
gavage dose of vanadyl sulfate, ammonium metavanadate, or sodium orthovanadate (Ciranni et al. 1995).  
Most of the in vitro genotoxicity assays have been conducted in mammalian systems, although there are 
also mutagenicity assays in cultured bacteria (Kada et al. 1980; Kanematsu et al. 1980; NTP 2002) and
yeast (Bronzetti et al. 1990; Sora et al. 1986).  In mammalian systems, mutagenicity (Cohen et al. 1992), 
DNA damage (Birnboim 1988; Foresti et al. 2001; Ivancsits et al. 2002; Kleinsasser et al. 2003; Rojas et
al. 1996; Smith 1983; Wozniak and Blasiak 2004), and clastogenicity (Gibson et al. 1997; Migliore et al. 
1993, 1995; Owusu-Yaw et al. 1990; Roldán and Altamirano 1990; Zhong et al. 1994) have been 
observed.  In general these studies provide evidence that vanadium compounds damage DNA and induce
clastogenic alterations.  However, there are a number of inconsistencies in the results and additional
studies are needed.
Reproductive Toxicity. No studies were located regarding the reproductive effects in humans after
inhalation, oral, or dermal exposure to vanadium.  Following inhalation exposure, alterations in estrous
cycle were observed in female rats exposed to vanadium pentoxide for 3 months (NTP 2002); no 
alterations in sperm characteristics were observed.  Studies examining reproductive function are needed to
evaluate whether the alterations observed in female rats would result in impaired fertility.  Decreases in
male and/or female fertility were observed in rats and mice orally exposed to vanadium (Ganguli et al.
1994b; Jain et al. 2007; Llobet et al. 1993; Morgan and El-Tawil 2003).  Dermal exposure studies are
needed to evaluate whether the reproductive system is also a target of toxicity for this route.
Developmental Toxicity. The potential developmental toxicity of vanadium has not been assessed in 
humans.  Oral exposure studies in animals provide evidence that developmental toxicity is a sensitive end
point.  The observed effects include decreases in fetal/pup growth, increased mortality, and increases in
gross, skeletal, and visceral malformations and anomalies (Domingo et al. 1986; Elfant and Keen 1987;
Morgan and El-Tawil 2003; Paternain et al. 1987, 1990; Poggioli et al. 2001).  Most of these effects
occurred at doses associated with decreases in maternal food intake and body weight.  Additional studies
utilizing doses not associated with maternal toxicity would be useful in determining whether the observed 
effects are secondary to maternal toxicity or whether the developing organism is a primary target.  No
studies were located regarding the developmental effects in animals after inhalation or dermal exposure to
vanadium.  Studies are needed to determine whether developmental toxicity would also be a sensitive
target following inhalation or dermal exposure.
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Immunotoxicity. Data regarding the immunotoxicity of vanadium in humans are limited to a study of
vanadium workers which did not find signs of allergic reactions on the skin or in the respiratory tract
(Sjöberg 1950).  No alterations in immune response to bacteria and/or viruses were observed in mice
exposed to airborne vanadium pentoxide for 16 days (NTP 2002); an altered response was observed in 
rats.  An altered response to sheep red blood cells in mice exposed to sodium orthovanadate in drinking
water for 6 weeks (Sharma et al. 1981) and decreases in B-cell, IgG, and IgM levels in rats exposed to
sodium metavanadate in the diet for 10 weeks (Adachi et al. 2000a) were observed.  No dermal exposure 
studies examining immunological end points were identified.  Although the animal data provide some
suggestive evidence of immunotoxicity, additional inhalation and oral exposure studies testing a full
immunology battery are needed to establish the potential of vanadium to induce immunotoxicity.
Neurotoxicity. Some workers exposed to vanadium dust complained of dizziness, depression, 
headache, or tremors of the fingers and arms (Levy et al. 1984; Vintinner et al. 1955); however, these
effects may not have been specifically due to vanadium exposure.  Neurotoxicity was not evaluated in
humans following oral or dermal exposure.  In animals, alterations in performance on neurobehavioral
tests were observed in rats orally exposed to sodium metavanadate (Sanchez et al. 1998, 1999).  No 
histological alterations in the nervous system were observed in rats or mice exposed to airborne vanadium
pentoxide (NTP 2002).  Neurotoxicity potential was not assessed in animals following dermal exposure.
Additional studies performing a complete neurological battery of tests are needed to fully evaluate the
potential of vanadium to induce neurotoxicity, particularly since the Sanchez et al. (1998) study provides
suggestive evidence that this may be a sensitive target following oral exposure.
Epidemiological and Human Dosimetry Studies. Studies of health effects on people who have
inhaled vanadium in the workplace clearly show that the target organ is the respiratory system (Domingo
et al. 1985; Levy et al. 1984; Lewis 1959; Musk and Tees 1982; NIOSH 1983; Sjöberg 1950, 1956;
Thomas and Stiebris 1956; Vintinner et al. 1955; Wyers 1946; Zenz and Berg 1967; Zenz et al. 1962).  
The dose-response relationship is not known, because exposure levels are not well quantified.  Further
information on exposure levels associated with respiratory effects would be useful.  However, people 
living near hazardous waste sites are unlikely to come in contact with amounts of vanadium dusts large 
enough to cause adverse health effects.  Further epidemiological studies may be useful in revealing
adverse health effects in people living near boiler ash dumps.  Additional information on potentially
susceptible populations, such as those people with asthma or other respiratory problems, would be useful.  
There are limited data regarding the oral toxicity of vanadium in humans.  Studies in diabetics have
shown that bolus administration can result in symptoms of gastrointestinal irritation (Boden et al. 1996;
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Cusi et al. 2001; Goldfine et al. 1995).  Two studies in healthy individuals (Dimond et al. 1963; Fawcett
et al. 1997) examined a wide variety of potential targets of vanadium toxicity.  However, both studies
used a small number of subjects and additional studies are needed to evaluate the long-term toxicity of
vanadium in humans, particularly since vanadium is present in a number of nutritional supplements and
there is a potential for human exposure. An intermediate-duration oral study (Fawcett et al. 1997) which 
found no adverse effects in subjects administered vanadyl sulfate via capsules was used as the basis of an
MRL.
Biomarkers of Exposure and Effect.
Exposure.  Biomarkers specific for exposure to vanadium include the presence of vanadium in the urine
(Gylseth et al. 1979; Kiviluoto et al. 1981b; Lewis 1959; NIOSH 1983; Zenz et al. 1962) and serum
(Gylseth et al. 1979) and a green discoloration of the tongue (Lewis 1959), the latter resulting from the
direct accumulation of vanadium pentoxide.  Further studies would be helpful in correlating urinary or
serum vanadium levels with exposure levels. Vanadium can also be measured in the hair (Stokinger et al.
1953), and studies could be performed to determine if a correlation exists between levels of vanadium in 
hair and exposure levels.  In the 1950s, decreased cystine content of the hair or fingernails was described 
as a possible biomarker of exposure (Mountain et al. 1955). However, this is not specific for vanadium
since other factors, such as diet or disease, can also affect cystine content.
Effect. There are no specific biomarkers of effects.  It is possible that further biochemical studies might
show specific effects.  For example, it is possible that specific effects may be seen on lung cells, which
can be examined by lavage.
Absorption, Distribution, Metabolism, and Excretion. Data are available from human and 
animal studies regarding the kinetics of vanadium following inhalation and oral exposure.  Specific data
from dermal exposure are lacking; although significant absorption of vanadium by this route in humans is
unlikely (WHO 1988), data are needed to confirm this hypothesis.  No animal studies were located that 
evaluated absorption efficiency following inhalation exposure, although NTP (2002) reported marginal, 
but concentration-related, increases in blood vanadium in rats exposed to vanadium pentoxide for 14 days
or 2 years.  Additionally, information is available from intratracheal exposures (Conklin et al. 1982; Edel
and Sabbioni 1988; Oberg et al. 1978; Rhoads and Sanders 1985).  Oral exposure studies suggest that
approximately 3–17% of ingested vanadium is absorbed and that absorption efficiency may vary among 
vanadium compounds (Adachi et al. 2000b; Conklin et al. 1982).  Intratracheal administration and oral
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exposure suggest similar patterns of distribution and excretion (Adachi et al. 2000b; Conklin et al. 1982;
Ramanadham et al. 1991; Rhoads and Sanders 1985) for the two routes of exposure.  Additional studies
are needed to provide information on the toxicokinetic properties of vanadium following inhalation and 
dermal exposure.  Additionally, there are limited data comparing the absorption and distribution of
various vanadium compounds; inhalation, oral, and dermal exposure studies are needed to evaluate
whether there are compound-specific differences.
Comparative Toxicokinetics. Animal data (Conklin et al. 1982; Oberg et al. 1978; Rhoads and 
Sanders 1985; Roshchin et al. 1980) and limited human (Dimond et al. 1963; Gylseth et al. 1979;
Schroeder et al. 1963) data are available on the kinetics of vanadium.  There is little reason to believe that
vanadium toxicokinetics would differ between animals and humans.  The data indicate that the kinetics
are similar in both.  However, as with any particulate substance, extrapolations on inhalation absorption
rates from animals to humans would be difficult.  Studies are available in humans, rats, mice, and dogs.  
Methods for Reducing Toxic Effects. No vanadium-specific information on reducing the
absorption of vanadium following inhalation, oral, or dermal exposure were identified; such information 
would be useful in the treatment of persons who may have been exposed to vanadium and/or its 
compounds near hazardous waste sites.  Several animal studies have explored the use of chelating agents 
for reducing the vanadium body burden.  Administration of ascorbic acid, tiron, deferoxamine mesylate,
or 2-mercaptosuccinic have been shown to increase urinary excretion of vanadium or reduce kidney levels
(Domingo et al. 1990; Gomez et al. 1988, 1991), and EDTA and tiron have been shown to reduce toxicity
(Domingo et al. 1993a; Jones and Basinger 1983; Mitchell and Floyd 1954; Sanchez et al. 1999), 
presumably by reducing the body burden.  There is some evidence that pirfenidone (an antifibrotic agent)
(Al-Bayati et al. 2002) and vitamin E (Chandra et al. 2007a) may interfere with the mechanism of
vanadium toxicity.  Additional data are needed, particularly studies examining methods for reducing the
toxicity of inhaled vanadium.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
There are limited data on the susceptibility of children to vanadium toxicity.  No human or animal studies
examined possible age-related differences in toxicity following inhalation, oral, or dermal exposure.  An 



















3.  HEALTH EFFECTS 
compared to older rats (62 days of age) (de la Torre et al. 1999).  Additional studies are needed to 
evaluate if there are age-related differences in vanadium toxicity or toxicokinetic properties.   
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:  
Exposures of Children.
3.12.3 Ongoing Studies 
The National Institute of Environmental Health Sciences is sponsoring research studies by James Bonner 
and Daniel Morgan to examine the mechanisms through which vanadium pentoxide induces lung fibrosis 
(FEDRIP 2012). 
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
Vanadium is a naturally occurring element that appears in group 5(B5) of the periodic table (Lide 2008).  
Vanadium is widely distributed in the earth’s crust at an average concentration of 100 ppm
(approximately 100 mg/kg), similar to that of zinc and nickel (Byerrum 1991).  Vanadium is the 22nd most
abundant element in the earth’s crust (Baroch 2006). Vanadium is found in about 65 different minerals;
carnotite, roscoelite, vanadinite, and patronite are important sources of this metal along with bravoite and
davidite (Baroch 2006, Lide 2008). It is also found in phosphate rock and certain ores and is present in 
some crude oils as organic complexes (Lide 2008). Table 4-1 lists common synonyms and other pertinent
identification information for vanadium and representative vanadium compounds.
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
Vanadium is a gray metal with a body-centered cubic crystal system.  It is a member of the first transition
series.  Because of its high melting point, it is referred to as a refractory metal (Baroch 2006).  When
highly pure, it is a bright white metal that is soft and ductile.  It has good structural strength and a low-
fission neutron cross section.  Vanadium has good corrosion resistance to alkalis, sulfuric and 
hydrochloric acid, and salt water; however, the metal oxidizes readily above 660 °C (Lide 2008).  The
chemistry of vanadium compounds is related to the oxidation state of the vanadium (Woolery 2005).  
Vanadium has oxidation states of +2, +3, +4, and +5.  When heated in air at different temperatures, it
oxidizes to a brownish black trioxide, a blue black tetraoxide, or a reddish orange pentoxide.  It reacts
with chlorine at fairly low temperatures (180 °C) forming vanadium tetrachloride and with carbon and 
nitrogen at high temperatures forming VC and VN, respectively.  The pure metal in massive form is 
relatively inert toward oxygen, nitrogen, and hydrogen at room temperature (HSDB 2009).  Vanadium
pentoxide is an industrially important vanadium compound (Lide 2008).  Table 4-2 lists important 
physical and chemical properties of vanadium and vanadium compounds.
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Table 4-1.  Chemical Identity of Vanadium and Compoundsa 
Characteristic Vanadium Vanadium pentoxide Vanadyl sulfate
Synonym(s) Vanadium, elemental Vanadium oxide; Vanadic sulfate;
vanadium(V) oxide; vanadium oxide 
vanadic anhydride; sulfate 
divanadium pentoxide
Registered trade name(s)
Chemical formula V V2O5 VOSO4 
Identification numbers:
CAS registry 7440-62-2 1314-62-1 27774-13-6
EINECS 231-171-1 215-239-8 248-652-7
RTECSb YW1355000 YW2450000 YW1925000
EPA hazardous waste No data P120 No data
OHM/TADS No data No data No data
DOT/UN/NA/IMDG shipping No data UN2862 UN2931
HSDB 1022 1024 1026
NCI No data No data No data


































    
    
    
    
     
     
     
      
     
     
     
     
 









4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Vanadium and Compoundsa 
Sodium Ammonium
Characteristic metavanadate Sodium orthovanadate metavanadate
Synonym(s) Sodium vanadate(V); Sodium o-vanadate; Ammonium
vanadic acid, sodium pervanadate; vanadate(V);
monosodium sodium vanadium oxide; ammonium







Chemical formula NaVO3 Na3VO4 NH4VO3 
Identification numbers:
CAS registry 13718-26-8 13721-39-6 7803-55-6
EINECS 237-272-7 237-287-9 232-261-3
RTECSb YW1050000 YW1120000 YW0875000
EPA hazardous waste No data No data P119
OHM/TADS No data No data No data
DOT/UN/NA/IMDG shipping No data No data UN2859
HSDB No data No data 6310
NCI No data No data No data
aAll information obtained from ChemIDPlus 2009 and HSDB 2009, except where noted.
bRTECS 2009
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System;
RTECS = Registry of Toxic Effects of Chemical Substances













   
 
 












    
     
     
     
    
    
      
     
    
   
 
 








    
     
     
   
 
  
     
    
    
    
    
    
VANADIUM 110
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Vanadium and Compoundsa 
Vanadyl sulfate
Property Vanadium Vanadium pentoxide dihydrate
Molecular weight 50.9415 181.88 199.035c 
Color Light gray or white 
lustrous powder, fused 




hard lumps or body- Yellow-orange powder or
centered cubic crystals. dark-gray flakes dispersed
Pure vanadium is bright in air. Yellow to red
white, soft and ductile. crystalline powder.
Physical state Solidb Solidb Solid
Melting point 1,910 °C 690 °C
Boiling point 3,407 °C 1,750 °C (decomposes)
Density at 18.7 °C 6.11 3.357 No data
Odor No data Odorless No data
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water Insoluble 1 g dissolves in Soluble in waterc 
approximately 125 mL 
water
Other solvents Soluble in nitric, Soluble in concentrated No data






Log Kow No data No data No data
Log Koc No data No data No data
Vapor pressure 2.34x10-2 mm Hg at No data No data
1,916 °C (extrapolated)
Henry's law constant No data No data No data
Autoignition temperature No data No data No data
Flashpoint No data No data No data
Flammability limits No data No data No data
Conversion factors No data No data No data
Explosive limits No data No data No data

























    
    
    
    
    
    
     
     
    




     
 
 
    
     
     
    
     
    
    
    
    
    
 







4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Vanadium and Compoundsa 
Sodium Ammonium
Property metavanadate Sodium orthovanadate metavanadate










Physical state Solid Solid Solid
Melting point 630°Cb 850–866 °Cb 200 °C
Boiling point No data No data No data
Density No data No data 2.326 g/cm3 
Odor No data No data No data
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water 21 g/100 g water at
25 °Cc 
Soluble in waterc Slightly soluble in cold 
water




Log Kow No data No data No data
Log Koc No data No data No data
Vapor pressure No data No data No data
Henry's law constant No data No data No data
Autoignition temperature No data No data No data
Flashpoint No data No data No data
Flammability limits Noncombustibleb No data Nonflammableb 
Conversion factors No data No data No data
Explosive limits No data No data No data
aAll information obtained from HSDB 2009, except where noted.
bLewis 2007
cLide 2008
dVanadyl sulfate pentahydrate - Ethereal blue solid; readily soluble in water
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
TRI information is available in the TRI database on facilities that manufacture or process vanadium
(except when contained in an alloy) and vanadium compounds for Release Year 2009, in accordance with 
Section 313 of the Emergency Planning and Community Right-to-Know Act (Title III of the Superfund
Amendments and Reauthorization Act of 1986) (TRI09 2011).
Seven U.S. firms produced ferrovanadium, vanadium pentoxide, vanadium metal, and vanadium-bearing
chemicals or specialty alloys by processing materials such as petroleum residues, spent catalysts, utility
ash, and vanadium-bearing pig iron slag (USGS 2012).
Vanadium occurs in uranium-bearing minerals of Colorado, in the copper, lead, and zinc vanadates of
Africa, and with certain phosphatic shales and phosphate rocks in the western United States.  Commercial
production from petroleum ash holds promise as an important source of vanadium.  It is a constituent of
titaniferous magnetites that are widely distributed in Russia, South Africa, Finland, People’s Republic of
China, eastern and western United States, and Australia.  The vanadium deposits from sulfide and 
vanadate ores in the Peruvian Andes have been depleted.  Most reserves are in deposits where vanadium
would be a by-product or co-product with other minerals, including phosphate, titanium, iron, and 
petroleum (Baroch 2006). High-purity ductile vanadium can be obtained by reduction of vanadium
chloride with magnesium or with magnesium-sodium mixtures.  Much of the vanadium metal now being
produced is made by calcium reduction of V2O5 in a pressure vessel (Lide 2008).
World mine production reported for 2011 (in metric tons) was: China, 23,000; Russia, 15,000; South 
Africa, 19,000; and other countries, 1,500, or about 60,000 metric tons for the world (USGS 2012).
Table 5-1 lists the facilities in each state that manufacture or process vanadium (except when contained in 
an alloy), the intended use, and the range of maximum amounts of this material that are stored on site.  
Table 5-2 lists the facilities in each state that manufacture or process vanadium compounds, the intended 
use, and the range of maximum amounts of this material that are stored on site. The data listed in
Tables 5-1 and 5-2 are derived from the Toxics Release Inventory (TRI09 2011).  Only certain types of
facilities were required to report (EPA 2005b). Therefore, this is not an exhaustive list.
Current U.S. manufacturers of vanadium and selected vanadium compounds are given in Table 5-3.
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Table 5-1.  Facilities that Produce, Process, or Use Vanadium (Except When  
Contained in an Alloy)  
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AL 7 100 49,999,999 1, 2, 3, 5, 7, 12, 13, 14
AR 6 0 99,999 1, 2, 3, 5, 8, 12, 13, 14
AZ 6 10,000 9,999,999 1, 2, 3, 4, 5, 6, 12, 13, 14
CA 12 0 999,999 1, 2, 3, 5, 6, 8, 9, 10, 12, 13, 14
CT 2 10,000 999,999 1, 4, 5, 9, 12
FL 8 0 999,999 1, 4, 5, 9, 10, 12, 13, 14
GA 1 1,000,000 9,999,999 1, 11, 13
ID 5 10,000 999,999 1, 2, 3, 5, 10, 12
IL 11 0 999,999 1, 5, 7, 9, 12, 13, 14
IN 4 0 999,999 8, 10, 12, 14
KS 5 100 49,999,999 1, 5, 11, 12, 14
KY 6 0 99,999 1, 5, 7, 8, 11, 12
LA 8 0 999,999 1, 2, 3, 6, 7, 10, 12, 13, 14
MD 3 0 99,999 1, 5
MI 3 1,000 99,999 2, 5, 7, 8, 11, 14
MO 1 1,000 9,999 12
MS 7 10,000 999,999 1, 2, 3, 4, 7, 8, 10, 11, 12
NC 2 1,000 999,999 8
ND 1 100,000 999,999 1, 5, 12
NE 3 10,000 99,999 1, 3, 4, 5, 9, 12, 13
NH 1 0 0 0
NJ 1 10,000 99,999 2, 13
NM 2 10,000 9,999,999 12
NV 1 10,000 99,999 2, 3, 12
NY 3 100 999,999 1, 5, 6
OH 16 0 9,999,999 1, 3, 4, 5, 7, 8, 11, 12, 13, 14
OK 2 10,000 99,999 1, 5, 11, 14
OR 1 10,000 99,999 12
PA 11 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 12, 13, 14
PR 3 0 99,999 1, 5, 11
SC 10 0 999,999 1, 3, 4, 5, 6, 9, 12, 13
TN 7 100 99,999 1, 2, 3, 5, 8, 9, 13, 14
TX 32 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT 1 10,000 99,999 12
VA 3 0 99,999 1, 2, 5, 12, 13, 14
WA 1 0 0 0
WI 1 1,000 9,999 7, 8
   
 















     
     
     
 
  





















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1.  Facilities that Produce, Process, or Use Vanadium (Except When  
Contained in an Alloy)  
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
WV 2 1,000 99,999 10, 12
WY 3 10,000 99,999 1, 10, 12, 13
aPost office state abbreviations used.  
bAmounts on site reported by facilities in each state.  
cActivities/Uses:  
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI09 2011 (Data are from 2009)
   
 
















     
      
       
        
       
          
      
      
        
        
       
     
        
        
          
           
       
          
        
       
       
      
        
          
      
       
      
        
      
        
      
          
        
       
          
           
        
       
        
VANADIUM 116
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-2.  Facilities that Produce, Process, or Use Vanadium Compounds
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AK 1 10,000 99,999 1, 5, 12, 13, 14
AL 29 0 999,999 1, 3, 4, 5, 7, 8, 9, 12, 13, 14
AR 17 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
AZ 23 100 99,999,999 1, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14
CA 36 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14
CO 26 100 999,999 1, 4, 5, 9, 12, 13, 14
CT 5 100 9,999 1, 4, 5, 9, 12, 13
DE 13 0 999,999 1, 2, 3, 5, 9, 10, 12, 13, 14
FL 58 0 9,999,999 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 13, 14
GA 32 0 49,999,999 1, 3, 4, 5, 7, 9, 10, 12, 13, 14
HI 1 100 999 1, 5
IA 15 0 999,999 1, 3, 4, 5, 9, 12, 13, 14
ID 13 0 49,999,999 1, 2, 3, 5, 6, 10, 12, 14
IL 53 0 999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
IN 61 0 9,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14
KS 23 0 999,999 1, 3, 4, 5, 8, 9, 10, 12, 13, 14
KY 30 0 9,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14
LA 61 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MA 12 1,000 99,999 1, 2, 5, 9, 11, 12, 13, 14
MD 19 0 999,999 1, 3, 4, 5, 6, 7, 9, 12, 13, 14
ME 7 0 99,999 1, 5, 12, 13
MI 40 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14
MN 12 100 999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14
MO 23 0 999,999 1, 3, 5, 9, 10, 12, 13, 14
MS 17 0 9,999,999 1, 2, 3, 4, 5, 8, 9, 10, 13, 14
MT 6 100 999,999 1, 5, 9, 10, 12, 14
NC 39 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14
ND 7 10,000 999,999 1, 5, 9, 12, 13, 14
NE 11 1,000 999,999 1, 3, 4, 5, 9, 12, 13
NH 7 0 999,999 1, 5, 9, 12
NJ 24 100 999,999 1, 2, 3, 4, 5, 6, 7, 9, 10, 12, 13, 14
NM 9 1,000 999,999 1, 3, 4, 5, 9, 12, 13, 14
NV 23 0 499,999,999 1, 2, 3, 5, 6, 9, 10, 12, 13, 14
NY 23 0 999,999 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 14
OH 53 0 9,999,999 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OK 18 0 99,999 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 13, 14
OR 3 1,000 99,999 1, 3, 4, 5, 9, 14
PA 66 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
   
 















     
      
       
      
        
          
        
       
     
        
       
          
      
 
 





















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-2.  Facilities that Produce, Process, or Use Vanadium Compounds
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
PR 10 0 99,999 1, 2, 5, 10, 13
SC 24 0 9,999,999 1, 3, 4, 5, 7, 8, 9, 12, 13, 14
SD 2 10,000 99,999 1, 5, 9, 13, 14
TN 32 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
TX 85 0 499,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14
UT 27 100 49,999,999 1, 2, 3, 4, 5, 7, 9, 10, 11, 12, 13, 14
VA 22 0 999,999 1, 3, 4, 5, 8, 9, 10, 12, 13, 14
VI 1 100,000 999,999 10, 14
WA 7 1,000 999,999 1, 3, 4, 5, 9, 12, 13, 14
WI 18 0 999,999 1, 3, 4, 5, 7, 9, 12, 13, 14
WV 28 0 999,999 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14
WY 22 0 999,999 1, 4, 5, 9, 11, 12, 13, 14
aPost office state abbreviations used.  
bAmounts on site reported by facilities in each state.  
cActivities/Uses:  
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI09 2011 (Data are from 2009)
   
 














    
  
   




    
  
  
   
    
  
    
  
   









5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL




International Specialty Alloys New Castle, Pennsylvania
Vanadium pentoxide
Denison Mines (USA) Corp. Blanding, Utah
Gulf Chemical & Metallurgical Corp. Freeport, Texas
Stratcor, Inc. Hot Springs, Arizona
Vanadyl sulfate
The Shepherd Chemical Co. Cincinnati, Ohio
Shieldalloy Metallurgical Corp.; Specialty Products Division Cambridge, Ohio
Stratcor, Inc. Hot Springs, Arizona
Sodium metavanadate
Denison Mines (USA) Corp. Blanding, Utah
Shieldalloy Metallurgical Corp.; Specialty Products Division Cambridge, Ohio
Sodium orthovanadate
Shieldalloy Metallurgical Corp.; Specialty Products Division Cambridge, Ohio
Ammonium metavanadate
Denison Mines (USA) Corp. Blanding, Utah
Shieldalloy Metallurgical Corp.; Specialty Products Division Cambridge, Ohio
Stratcor, Inc. Hot Springs, Arizona
aStanford Research Institute (SRI 2008), except where otherwise noted.  SRI reports production of chemicals
produced in commercial quantities (defined as exceeding 5,000 pounds or $10,000 in value annually) by the 
companies listed.
bUSGS 2009b
   
 









   
 
     
     
   





     
       
    
   
  
 
   
    
   
  
 







   
 
   
   
  
VANADIUM 119
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.2  IMPORT/EXPORT
Import sources of ferrovanadium from 2007 to 2010 were 45% from the Republic of Korea, 26% from
Canada, 15% from Austria, 12% from Czech Republic, and 2% from other sources.  Vanadium pentoxide
import sources in this same time period were 46% from Russia, 33% from South Africa, 20% from China, 
and 1% from other sources (USGS 2012).
5.3  USE 
Vanadium is used in producing rust-resistant, spring, and high-speed tool steels.  It is an important
carbide stabilizer in making steels.  About 80% of the vanadium produced is used as ferrovanadium as a
steel additive. Vanadium foil is used as a bonding agent in cladding titanium to steel. Vanadium
pentoxide is used in ceramics and as a catalyst as well as in producing a superconductive magnet with a 
field of 175,000 gauss (Lide 2008).  Metallurgical use as an alloying agent for iron and steel accounted
for approximately 95% of domestic vanadium consumption in 2008 (USGS 2012).
Vanadium, as elemental vanadium or vanadyl sulfate, also may be found in various commercial
nutritional supplements and multivitamins (NLM 2009). Vanadyl sulfate and sodium metavanadate have 
been used in supplements for individuals with diabetes, as well by weight training athletes (Barceloux
1999; IOM 2001; Smith et al. 2008).  
5.4  DISPOSAL
Waste material contaminated with vanadium should be disposed of in a manner not hazardous to 
employees.  The disposal method must conform to applicable local, state, and federal regulations and 
must not constitute a hazard to the surrounding population or environment.  Chemical precipitation has
been investigated as a possible wastewater treatment technology for vanadium (EPA 1982). 
Approximately 1.5x106 and 3.3x107 pounds of vanadium (except when contained in an alloy) and 
vanadium compounds, respectively, were reported for on-site disposal and other releases in 2009.  On-site 
disposal or other releases include emissions to the air, discharges to bodies of water, disposal at the
facility to land, and disposal in underground injection wells.  Approximately 6.2x105 and 6.6x106 pounds
of vanadium (except when contained in an alloy) and vanadium compounds, respectively, were reported 
for off-site disposal and other releases in 2009.  An off-site disposal or other release is a discharge of a 
   
 


















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
toxic chemical to the environment that occurs as a result of a facility’s transferring a waste containing a 
TRI chemical off-site for disposal or other release (TRI09 20011).  The TRI data should be used with 
caution because only certain types of facilities are required to report (EPA 2005b).  This is not an
exhaustive list.
Some tool steel scrap was recycled mainly for its vanadium content, and vanadium was recycled from
spent chemical process catalysts; however, these two sources together accounted for only a small
percentage (USGS 2012).












   
 
    
   




    
       
    
    
   
 
   
    
     
      
     
     
    
  
    
    
     
     
   
   




6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
Vanadium has been identified in at least 319 of the 1,699 hazardous waste sites that have been proposed 
for inclusion on the EPA National Priorities List (NPL) (HazDat 2007).  However, the number of sites
evaluated for vanadium is not known.  The frequency of these sites can be seen in Figure 6-1.  All of
these sites are located within the United States.
Vanadium is widely distributed in the earth’s crust at an average concentration of 100 ppm
(approximately 100 mg/kg), similar to that of zinc and nickel (Byerrum 1991).  Vanadium is the 22nd most
abundant element in the earth’s crust (Baroch 2006). There are about 65 different vanadium-containing
minerals; carnotite, roscoelite, vanadinite, and patronite are important sources of this metal along with
bravoite and davidite (Baroch 2006; Lide 2008).  It is also found in phosphate rock and certain ores and is
present in some crude oils as organic complexes (Lide 2008).  
Vanadium is released naturally to the atmosphere by the formation of continental dust, marine aerosols,
and volcanic emissions. Vanadium is a constituent of nearly all coal and petroleum crude oils.  Eastern 
U.S. coal has an average vanadium content of approximately 30 ppm, while coal from western states has
average content of 15 ppm, and coal from the interior portion of the United States contains an average
vanadium concentration of 34 ppm (Byerrum et al. 1974).  The average vanadium content of bituminous
and anthracite coal is 30 and 125 ppm, respectively (Byerrum et al. 1974). The most important
anthropogenic sources of vanadium include the combustion of fossil fuels, particularly residual fuel oils, 
which constitute the single largest overall release of vanadium to the atmosphere. While the levels of
vanadium in residual fuel oil vary by source, levels of 1–1,400 ppm have been reported (Byerrum et al. 
1974).  Natural gas and distillate fuel oils contain very low or undetectable levels (<0.05 ppm) of
vanadium and are not considered a significant source of vanadium to the environment, except in the case
of large accidental spills. The natural release of vanadium to water and soils occurs primarily as a result
of weathering of rocks and soil erosion.  This process usually involves the conversion of the less-soluble
trivalent form to the more soluble pentavalent form.  Deposition of atmospheric vanadium is also an 
important source both near and far from industrial plants burning residual fuel oils rich in vanadium.  
Other anthropogenic sources include leachates from mining tailings, vanadium-enriched slag heaps,
municipal sewage sludge, and certain fertilizers.  Natural releases to water and soil are far greater overall








6. POTENTIAL FOR HUMAN EXPOSURE
Figure 6-1. Frequency of NPL Sites with Vanadium Contamination 










   
   
  
    
 
     
   
  
 
   
  
    




     
  
   
   
  
 




   
    
  
   




6.  POTENTIAL FOR HUMAN EXPOSURE
Ambient atmospheric levels of vanadium are generally low (parts per trillion range) in rural and remote 
areas and greater in urban locations; however, vanadium levels in both rural and urban locations in the
eastern United States tend to be significantly higher than in other areas throughout the country, 
particularly during winter months.  A high density of oil fired power plants that consume vanadium-rich 
residual fuel oil stretching from southern New York to North Carolina are likely to be the greatest 
potential source of the high vanadium levels observed in the eastern United States (Polissar et al. 2001). 
In 2007, the Department of Energy reported that nearly 80% of the residual fuel oil consumed for power
generation was purchased in the East Coast districts (DOE 2008).
The general population is exposed to background levels of vanadium primarily through ingestion of food.
Vanadium in food is mainly ingested as VO2+ (vanadyl, V4+) or HVO42- (vanadate) (Sepe et al. 2003).  
Vanadium, as elemental vanadium or vanadyl sulfate, is also found in some dietary supplements and
multivitamins; consumption of some vanadium-containing supplements may result in intakes of vanadium
that would exceed those from food.  Workers in industries processing or using vanadium compounds are
commonly exposed to higher than background levels of vanadium as vanadium oxides via the inhalation
pathway.  Exposure to vanadium oxides through inhalation may also be of importance in urban areas, 
particularly in the northeastern United States where large amounts of residual fuel oil are burned.  Other
populations possibly exposed to higher-than-background levels, include those ingesting foodstuffs
contaminated by vanadium-enriched soil, fertilizers, or sludge.  Populations in the vicinity of vanadium-
containing hazardous waste sites may also be exposed to higher than background levels.  Individuals
exposed to cigarette smoke may also be exposed to higher-than-background levels of vanadium.  
6.2  RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005b).  This is not an exhaustive list.  Manufacturing and 
processing facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities










    
   
  
 
     
 
    
  
    
     
  
    
  
 
   
    
 






   
   
  







6.  POTENTIAL FOR HUMAN EXPOSURE
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces,
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005b).
6.2.1 Air
Estimated releases of 5.8x104 pounds (~26 metric tons) of vanadium (except when contained in an alloy)
to the atmosphere from 39 domestic manufacturing and processing facilities in 2009, accounted for about
2.8% of the estimated total environmental releases from facilities required to report to the TRI (TRI09 
2011).  Estimated releases of 4.8x105 pounds (~218 metric tons) of vanadium compounds to the
atmosphere from 510 domestic manufacturing and processing facilities in 2009, accounted for about 1.2%
of the estimated total environmental releases from facilities required to report to the TRI (TRI09 2011).
These releases are summarized in Tables 6-1 and 6-2.
Natural sources of atmospheric vanadium include continental dust, marine aerosol, and volcanic
emissions (Byerrum et al. 1974; Van Zinderen Bakker and Jaworski 1980; Zoller et al. 1973).  The
quantities entering the atmosphere from each of these sources are uncertain; however, continental dust is 
believed to account for the largest portion of naturally emitted atmospheric vanadium followed by marine
aerosols.  Contributions from volcanic emissions are believed to be negligible when compared with the 
other two sources (Zoller et al. 1973).
Combustion of heavy fuels, especially in oil-fired power plants, refineries, and industrial boilers, and coal
are the major source of anthropogenic emissions of vanadium into the atmosphere (Mamane and Pirrone 
1998; Sepe et al. 2003).  Global anthropogenic atmospheric emission of vanadium as been estimated to be
2.1x105 metric tons (MT)/year, 3 times higher than vanadium releases due to natural sources.  However,
other estimates indicated that anthropogenic releases of particulate-bound vanadium (9x104 MT/year)
were more similar to releases due natural sources, such as continental or volcanic dusts, which have 
releases of 7x104 and 1x104 MT/year, respectively) (Mamane and Pirrone 1998).  
Fuel oils may contain vanadium in concentrations ranging from 1 to 1,400 ppm, depending on their origin 
(Byerrum et al. 1974).  During the combustion of residual oils organovanadium compounds found in fuel
oils are oxidized and transformed into various compounds (e.g., vanadium pentoxide, vanadium tetroxide,
vanadium trioxide, and vanadium dioxide).  These compounds are emitted as fly ash into the atmosphere
(Mamane and Pirrone 1998).  














   
       
 
    
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
 










   










6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or  
Use Vanadium (Except When Contained in an Alloy)a  
Reported amounts released in pounds per yearb 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej 
Total release
Off-sitek On- and off-site
AL 1 0 0 0 3,674 0 3,674 0 3,674
AR 1 2 0 0 0 100 2 100 102
AZ 2 173 0 0 127,031 0 127,204 0 127,204
CA 3 467 0 0 418,028 0 418,494 8 418,503
ID 1 0 0 0 672,592 0 669,256 3,336 672,592
IL 1 250 0 0 0 1,924 250 1,924 2,174
KS 3 5,742 0 0 12,279 26,292 17,021 392,292 409,313
KY 1 8 0 0 0 80 8 80 88
LA 3 106 4,880 0 49,465 3 4,986 49,468 54,454
MI 1 7 0 0 4,784 0 4,791 0 4,791
MS 1 0 0 0 0 0 0 0 0
ND 1 50,253 11 0 89,062 0 91,196 48,130 139,326
NH 1 0 0 0 0 0 0 0 0
OH 3 516 20 0 51,000 0 536 51,000 51,536
OR 1 0 0 0 15,458 0 15,458 0 15,458
PA 1 10 0 0 5 0 15 43,807 43,822
PR 1 154 0 0 9,911 0 154 9,911 10,065
SC 1 44 1,934 0 3,046 0 5,024 0 5,024
TN 2 26 0 0 5,114 417 26 5,531 5,557
TX 8 544 1,794 0 14,145 0 3,044 13,439 16,483
VA 1 70 19 0 0 0 89 0 89
WY 1 218 0 0 118,374 0 118,592 0 118,592
Total 39 58,590 8,658 0 1,593,968 28,816 1,479,820 619,027 2,098,847
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an  
exhaustive list.  Data are rounded to nearest whole number.  
bData in TRI are maximum amounts released by each facility.  
cPost office state abbreviations are used.  
dNumber of reporting facilities.  
eThe sum of fugitive and point source releases are included in releases to air by a given facility.  
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal  
and metal compounds).  
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface  
impoundments, other land disposal, other landfills.
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for  
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
kTotal amount of chemical transferred off-site, including to POTWs.  
RF = reporting facilities; UI = underground injection
Source:  TRI09 2011 (Data are from 2009)
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6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-2.  Releases to the Environment from Facilities that Produce, Process, or  
Use Vanadium Compoundsa  
Reported amounts released in pounds per yearb 
Total release
On- and off-
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek site
AL 19 4,721 18,841 0 1,111,800 21,000 1,134,113 22,250 1,156,363
AK 1 0 6 0 33,000 0 33,006 0 33,006
AR 9 12,419 151,601 0 1,195,161 1,450 1,358,806 1,824 1,360,630
AZ 7 1,237 5 0 250,677 0 251,913 5 251,918
CA 14 723 1,605 0 27,232 90 1,661 27,990 29,650
CO 10 1,290 107 0 268,477 225 178,174 91,924 270,098
CT 2 0 0 0 31,700 0 0 31,700 31,700
DE 4 753 11,193 0 344,027 20,358 56,479 319,852 376,331
FL 21 19,222 2,473 26,719 1,700,859 235,222 695,760 1,288,735 1,984,494
GA 17 18,478 10,508 0 1,233,511 14,610 1,213,179 63,928 1,277,107
HI 1 45 0 0 30,353 0 45 30,353 30,398
IA 7 1,496 595 0 287,488 16,334 216,579 89,334 305,913
ID 1 896 1,100 0 2,263,589 11 2,265,585 11 2,265,596
IL 19 7,940 10,342 0 424,580 114,035 320,274 236,623 556,897
IN 28 11,060 10,644 0 2,471,511 2,158 2,187,747 307,626 2,495,372
KS 8 9,033 0 0 280,360 0 289,125 268 289,393
KY 18 58,135 23,180 0 4,050,595 18,790 4,131,218 19,482 4,150,700
LA 25 149,968 43,257 23 361,536 39,140 515,936 77,988 593,924
MA 3 725 1,136 0 18,903 0 4,192 16,572 20,764
MD 10 3,372 1,455 0 101,105 263,964 70,700 299,196 369,896
ME 2 882 4,549 0 3,654 0 9,085 0 9,085
MI 18 3,189 7,537 0 727,433 1,695 608,128 131,726 739,854
MN 4 1,773 45 0 277,611 128 248,423 31,134 279,557
MO 12 5,251 28 0 356,710 0 361,984 5 361,989
MS 9 924 129,473 1,321,526 2,640,672 36,000 3,750,004 378,591 4,128,595
MT 4 3,236 190 0 187,827 7,630 191,187 7,696 198,883
NC 17 3,686 9,149 0 1,372,162 1,979 1,053,049 333,927 1,386,976
ND 3 1,114 1 0 143,187 681 139,519 5,464 144,983
NE 4 3,001 0 0 192,186 0 195,187 0 195,187
NH 1 94 0 0 15,950 0 2,594 13,450 16,044
NJ 7 1,241 5,300 0 7,483 4,707 6,541 12,190 18,731
NM 4 1,432 165 0 560,034 0 561,631 0 561,631
NV 4 20 0 0 1,994,350 0 1,994,312 58 1,994,370
NY 7 15,567 1,137 0 113,671 112,819 56,255 186,939 243,194
OH 25 55,568 1,638 2,757 2,016,980 249,860 1,678,230 648,571 2,326,802
OK 11 25,855 10 0 113,108 0 102,343 36,630 138,973













   





          
          
          
          
          
          
          
          
          
          
          
          
          
          
 





















6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-2.  Releases to the Environment from Facilities that Produce, Process, or  
Use Vanadium Compoundsa  
Reported amounts released in pounds per yearb 
Total release
On- and off-
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek site
OR 1 255 0 0 2,200 0 2,455 0 2,455
PA 32 19,104 2,077 0 1,659,005 2,107 995,706 686,587 1,682,294
SC 13 5,675 9,532 0 339,405 46,078 336,669 64,021 400,690
SD 1 114 0 0 23,452 0 21,126 2,440 23,566
TN 12 2,025 24,887 0 1,896,639 145 1,837,999 85,697 1,923,696
TX 42 11,942 67,356 18,329 1,910,956 633 1,874,004 135,212 2,009,216
UT 8 808 1,000 0 282,299 394 282,147 2,354 284,501
VA 1 1,933 8,380 0 539,812 3,323 486,961 66,487 553,448
VI 13 1,550 4,965 0 12,771 352 11,953 7,685 19,638
WA 2 462 126 0 52,693 0 52,963 318 53,281
WI 12 4,165 1,140 0 274,365 87,446 38,993 328,123 367,116
WV 13 3,516 976 0 1,577,671 4,900 1,149,666 437,397 1,587,063
WY 4 1,855 0 0 290,674 0 219,629 72,900 292,529
Total 510 477,749 567,708 1,369,354 36,071,424 1,308,263 33,193,236 6,601,262 39,794,498
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an  
exhaustive list.  Data are rounded to nearest whole number.  
bData in TRI are maximum amounts released by each facility.  
cPost office state abbreviations are used.  
dNumber of reporting facilities.  
eThe sum of fugitive and point source releases are included in releases to air by a given facility.  
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal  
and metal compounds).  
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface  
impoundments, other land disposal, other landfills.  
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for  
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
kTotal amount of chemical transferred off-site, including to POTWs.  
RF = reporting facilities; UI = underground injection
Source:  TRI09 2011 (Data are from 2009)
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Vanadium has not been identified in air collected at current or former NPL hazardous waste sites where 
vanadium was detected in some environmental media (HazDat 2007). 
6.2.2 Water
Estimated releases of 8,658 pounds (~4 metric tons) of vanadium (except when contained in an alloy) to 
surface water from 39 domestic manufacturing and processing facilities in 2009, accounted for about
0.4% of the estimated total environmental releases from facilities required to report to the TRI (TRI09 
2011).  Estimated releases of 5.7x105 pounds (~258 metric tons) of vanadium compounds to surface water
from 510 domestic manufacturing and processing facilities in 2009, accounted for about 1.4% of the
estimated total environmental releases from facilities required to report to the TRI (TRI09 2011). These 
releases are summarized in Tables 6-1 and 6-2.
Natural sources of vanadium release to water include wet and dry deposition, soil erosion, and leaching
from rocks and soils.  The largest amount of vanadium release occurs naturally through water erosion of
land surfaces.  It has been estimated that approximately 32,300 tons of vanadium are dissolved and
transported to the oceans by water, and an additional 308,650 tons are thought to be transported in the
form of particulate and suspended sediment (Van Zinderen Bakker and Jaworski 1980).
Anthropogenic releases to water and sediments are far smaller than natural sources (Van Zinderen Bakker
and Jaworski 1980).  Such sources of vanadium in water may include leaching from the residue of ores 
and clays, vanadium-enriched slags, urban sewage sludge, and certain fertilizers, all of which are
subjected to rain and groundwater drainage, as well as leachate from ash ponds and coal preparation 
wastes (Byerrum et al. 1974; Van Zinderen Bakker and Jaworski 1980).  Leaching may potentially occur
from landfills and from the airborne particulate matter that is deposited in areas with high residual fuel oil 
combustion, although neither of these release sources is documented.
Vanadium has been identified in groundwater and surface water at 224 and 129 sites, respectively, of the 
319 NPL hazardous waste sites where it was detected in some environmental media (HazDat 2007).
6.2.3 Soil 
Estimated releases of 1.6 x 106 pounds (~725 metric tons) of vanadium (except when contained in an 

































6. POTENTIAL FOR HUMAN EXPOSURE
of the estimated total environmental releases from facilities required to report to the TRI (TRI09 2011). 
Estimated releases of 3.6x107 pounds (~1.6x104 metric tons) of vanadium compounds to soils from
510 domestic manufacturing and processing facilities in 2009, accounted for about 91% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI09 2011).  These releases are 
summarized in Tables 6-1 and 6-2.
Natural releases of vanadium to soil result from weathering of rock-bearing vanadium minerals, 
precipitation of vanadium particulate from the atmosphere, deposition of suspended particulate from
water, and plant and animal wastes.  The largest amount of vanadium released to soil occurs through the 
natural weathering of geological formations (Byerrum et al. 1974; Van Zinderen Bakker and Jaworski 
1980).
Anthropogenic releases of vanadium to soil are less widespread than natural releases and occur on a 
smaller scale.  These include the use of certain fertilizers containing materials with a high vanadium
content such as rock phosphate (10–1,000 mg/kg vanadium), superphosphate (50–2,000 mg/kg
vanadium), and basic slag (1,000–5,000 mg/kg vanadium) (Van Zinderen Bakker and Jaworski 1980) as 
well as disposal of industrial wastes such as slag heaps and mine tailings.  Additional release to the 
environment may also result from the disposal of vanadium-containing wastes in landfills, although this 
has not been specifically documented, and from wet and dry deposition of airborne particulate, 
particularly in areas with high levels of residual fuel oil combustion (Byerrum et al. 1974). 
Vanadium has been identified in soil at 172 sites and in sediment at 44 sites collected from 319 NPL 
hazardous waste sites, where vanadium was detected in some environmental media (HazDat 2007).  
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
The global biogeochemical cycling of vanadium is characterized by releases to the atmosphere, water, and 
land by natural and anthropogenic sources, long-range transportation of particles in both air and water, 
wet and dry deposition, adsorption, and complexing.  Vanadium generally enters the atmosphere as an 
aerosol. From natural sources, vanadium is probably in the form of mineral particles; it has been 
suggested that these may frequently be in the less-soluble trivalent form (Byerrum et al. 1974; Zoller et al. 
1973). From human-made sources, almost all of the vanadium released to the atmosphere is in the form
of simple or complex vanadium oxides (Byerrum et al. 1974).
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The size distribution of vanadium-bearing particles in the atmosphere is substantially altered during long-
range transportation (Zoller et al. 1973).  Natural sources of vanadium, as well as man-made sources such
as ore-processing dust, tend to release large particles that are more likely to settle near the source.
Smaller particles, such as those emitted from oil-fueled power plants, have a longer residence time in the 
atmosphere and are more likely to be transported farther away from the site of release (Zoller et al. 1973).
Vanadium transported within the atmosphere is eventually transferred to soil and water on the earth's
surface by wet and dry deposition and dissolution in sea water (Duce and Hoffman 1976; Van Zinderen 
Bakker and Jaworski 1980).  Eventually, in the course of biogeochemical movement between soil and 
water, these particulates are adsorbed to hydroxides or associated with organic compounds and are 
deposited on the sea bed (WHO 1988).
Deposition rates ranging from 20.5 to 84.9 µg/cm2/day of vanadium were reported in urban dust collected 
between March and September 2002 from six locations Adapazarí, Turkey (Dundar 2006).  Vanadium is
considered a marker of air pollution emitted from residual oil and coal combustion (Mamane and Pirrone
1998).
The transport and partitioning of vanadium in water and soil is influenced by pH, redox potential, and the
presence of particulate.  In fresh water, vanadium generally exists in solution as the vanadyl ion (V4+) 
under reducing conditions and the vanadate ion (V5+) under oxidizing conditions, or as an integral part of, 
or adsorbed onto, particulate matter (Wehrli and Stumm 1989).  The chemical formulas of the vanadyl
species most commonly reported in fresh water are VO2+ and VO(OH)+, and the vanadate species are 
-H2VO4 and HVO42- (Wehrli and Stumm 1989).  The partitioning of vanadium between water and 
sediment is strongly influenced by the presence of particulate in the water.  Both vanadate and vanadyl
species are known to bind strongly to mineral or biogenic surfaces by adsorption or complexing (Wehrli
and Stumm 1989).  Thus, vanadium is transported in water in one of two ways:  solution or suspension.  It
has been estimated that only 13% is transported in solution, while the remaining 87% is in suspension 
(WHO 1988).
Upon entering the ocean, vanadium in suspension or adsorbed and/or absorbed onto particulate is
deposited upon the sea bed (WHO 1988).  The fate of the remaining dissolved vanadium is more
complex.  Only about 0.001% of vanadium entering the oceans is estimated to persist in soluble form
(Byerrum et al. 1974).  Adsorption/absorption and biochemical processes are thought to contribute to the
extraction of vanadium from sea water (WHO 1988). Adsorption to organic matter as well as to















   
  
     
 
   
 
   
   
   
    
 
   
  
  
   
     
   
    












6.  POTENTIAL FOR HUMAN EXPOSURE
manganese oxide and ferric hydroxide, demonstrated by the high particle-water partition coefficient of
5.7x105 L/kg for the adsorption of manganese oxide in sea water, results in the precipitation of the
dissolved vanadium (Wehrli and Stumm 1989; WHO 1988).  Biochemical processes are also of
importance in the partitioning from sea water to sediment (WHO 1988).  Some marine organisms, in 
particular the ascidians (sea squirts), bioconcentrate vanadium very efficiently, attaining body
concentrations approximately 10,000 times greater than the ambient sea water (Byerrum et al. 1974).
Upon the death of the organism, the body burden adds to the accumulation of vanadium in silt (WHO
1988).  The extent to which either bioconcentration or adsorption dominates is uncertain (WHO 1988).
In general, marine plants and invertebrates contain higher levels of vanadium than terrestrial plants and
animals.  In the terrestrial environment, bioconcentration is more commonly observed amongst the lower
plant phyla than in the higher, seed-producing phyla.  The vanadium levels in terrestrial plants are 
dependent upon the amount of water-soluble vanadium available in the soil, pH, and growing conditions.  
It has been found that the uptake of vanadium into the above-ground parts of many plants is low, although 
root concentrations have shown some correlation with levels in the soil (Byerrum et al. 1974).  Certain
legumes, such as Astralagus preussi, have been shown to be vanadium accumulators.  Vanadium is
believed to replace molybdenum as a specific catalyst in nitrogen fixation (Cannon 1963), and the root
nodules of these plants may contain vanadium levels three times greater than those of the surrounding soil
(Byerrum et al. 1974).  Of the few plants known to actively accumulate vanadium, Amanita muscaria, a
poisonous mushroom, has been demonstrated to contain levels up to 112 ppm (dry weight).  Vanadium
appears to be present in all terrestrial animals, but, in vertebrates, tissue concentrations are often so low
that detection is difficult. The highest levels of vanadium in terrestrial mammals are generally found in
the liver and skeletal tissues (Van Zinderen Bakker and Jaworski 1980; WHO 1988).  No data are
available regarding biomagnification of vanadium within the food chain, but human studies suggest that it
is unlikely; most of the 1–2% vanadium that appears to be absorbed by humans following ingestion is
rapidly excreted in the urine with no evidence of long-term accumulation (Fox 1987).
The form of vanadium present in the soil is determined largely by the parent rock.  Ferric hydroxides and 
solid bitumens (organic) constitute the main carriers of vanadium in the sedimentation process.  Iron acts 
as a carrier for trivalent vanadium due to the high affinity between trivalent vanadium and trivalent iron, 
and is responsible for its diffusion through molten rocks where it becomes trapped during crystallization.  
The mobility of vanadium in soils is affected by the pH of the soil.  Relative to other metals, vanadium is 
fairly mobile in neutral or alkaline soils, but its mobility decreases in acidic soils (Van Zinderen Bakker
and Jaworski 1980).  Similarly, under oxidizing, unsaturated conditions, some mobility is observed, but














    
 
  
   
   
 
     
 
   
  




   
  
 
   
 
   
 
 
   
   
   
  




6.  POTENTIAL FOR HUMAN EXPOSURE
under reducing, saturated conditions, vanadium is immobile (Van Zinderen Bakker and Jaworski 1980).  
In a 30-month field study to examine the movement of metal ions through a profile of an acidic loamy
sand soil from the Upper Coastal Plain (South Carolina), <3% of the applied vanadium, as dissolved salt
(vanadyl sulfate), was found to move below the surface 7.5 cm region (Martin and Kaplan 1998).  
Buchter et al. (1989) reported log Kd values for various metal ions in 11 soils from 7 states in the U.S. 
(Louisiana, South Carolina, Hawaii, Iowa, New Hampshire, New Mexico, and Florida).  Log Kd values 
for vanadium (applied as ammonium vanadate) ranged from 1.035 in Calciorthid soil from New Mexico 
(pH 8.5, 0.44% total organic carbon [TOC], 70.0% sand, 19.3% silt, 10.7% clay) to 3.347 in Kula soil
from Hawaii (pH 5.9, 6.62% TOC, 73.7% sand, 25.4% silt, 0.9% clay).  
6.3.2 Transformation and Degradation
As an element, vanadium cannot be degraded in the environment, but may undergo various precipitation
or ligand exchange reactions.  Vanadium in compounds may undergo oxidation-reduction reactions under
various environmental conditions.  Vanadium can be complexed by various ligands present in the
environment (e.g., fulvic and humic acids).  Despite forming complexes with organic matter, it is 
generally not incorporated into organic compounds.  Thus, transformation occurs primarily between 
various inorganic compounds during its movement through the environment, and biotransformation is not
considered to be an important environmental fate process.  Vanadium can exist in many different
oxidation states, ranging from -2 to +5; however, under environmental conditions, vanadium can exist in 
the +3, +4, or +5 oxidation states, with the +5 oxidation state being the most prevalent under most
environmental conditions (Crans et al. 1998). 
6.3.2.1  Air
Vanadium-containing particulates emitted to the atmosphere from anthropogenic sources are frequently
simple or complex oxides (Byerrum et al. 1974) or may be associated with sulfates (Zoller et al. 1973).  
Generally, lower oxides formed during combustion of coal and residual fuel oils, such as vanadium
trioxide, undergo further oxidation to the pentoxide form, often before leaving the stacks (EPA 1985a).  
The average residence time for vanadium in the atmosphere is unknown as the particle size varies
considerably.  An estimated residence time of about 1 day has been proposed for the settling of fly ash
vanadium pentoxide when associated with hydrogen sulfate (EPA 1985a).
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6.3.2.2  Water
Vanadium entering water by leaching from vanadium-containing rocks is rapidly oxidized from less-
soluble vanadium(III) to more-soluble vanadium(V), which is the most common oxidation state of
vanadium found in surface waters (Byerrum et al. 1974; Crans et al. 1998).  In water, vanadium can 
undergo hydrolytic reactions, forming oligomeric anionic species.  The equilibrium of vanadium(V) in 
solution is sensitive to vanadium concentration, pH, ionic strength, and oxidation-reduction potential
(Crans et al. 1998). The species of vanadium most likely to be found in sea water are (H2V4O13)4-, 
HVO42-, and VO3- (Van Zinderen Bakker and Jaworski 1980).  Vanadium(III) is only found in very
reducing environments or is complexed to organic ligands (Crans et al. 1998).  Vanadium is continuously
precipitated from sea water by ferric hydroxides and organic matter (WHO 1988) and forms sediments on 
the seabed.
6.3.2.3  Sediment and Soil
There are about 65 different vanadium-containing minerals (Baroch 2006; Lide 2008).  The main 
vanadium-containing minerals include carnotite, cuprodescloizite, descloizite, mottramite, patronite,
roscoelite, and vanadinite (Crans et al. 1998).  Vanadium exists in its +3 to +5 oxidation states in these 
minerals.  Vanadium(V) is more soluble and is easily leached from soils into water. The vanadium
oxides, carnotite, cuprodescloizite, descloizite, mottramite, and vanadinite, are mostly vanadium(V)
minerals and comprise most of the vanadium-containing minerals. Roscoelite contains vanadium(III), 
and the exact chemical composition of patronite is not known (Crans et al. 1998). Weathering of rocks
and minerals during soil formation may extract vanadium in the form of a complex anion that may remain 
in the soil or enter the hydrosphere.  Vanadium remains in the soil after being precipitated from the
weathering solution. This can be brought about by precipitation with polyvalent cations such as divalent
calcium and divalent copper, by binding with organic complexing agents, adsorbing onto anion 
exchangers such as clay particles in the soil, and coprecipitating and adsorbing to hydrous ferric oxide in 
the soil (Van Zinderen Bakker and Jaworski 1980).  In the presence of humic acids, mobile metavanadate 
anions can be converted to the immobile vanadyl cations resulting in local accumulation of vanadium
(Van Zinderen Bakker and Jaworski 1980).
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to vanadium depends in part on the reliability of
supporting analytical data from environmental samples and biological specimens.  Concentrations of










     
  
  
        
   
 
     
 
      




     
     
   
    
         
   
   
  
   
 
   
     
   
   
   
   





6.  POTENTIAL FOR HUMAN EXPOSURE
vanadium in unpolluted atmospheres and in pristine surface waters are often so low as to be near the
limits of current analytical methods.  In reviewing data on vanadium levels monitored or estimated in the
environment, it should also be noted that the amount of chemical identified analytically is not necessarily
equivalent to the amount that is bioavailable. The analytical methods available for monitoring vanadium
in a variety of environmental media are detailed in Chapter 7.
6.4.1 Air
Levels of vanadium measured in ambient air vary widely between rural and urban locations, time of
season, and geographical location.  In general, urban locations often tend to have greater atmospheric
levels of vanadium as compared to rural sites since there is a larger density of combustion sources capable 
of emitting particulate matter containing vanadium to the environment.  Sweet et al. (1993) reported 
average vanadium concentrations of 3.0 and 3.0 ng/m3 (fine particles, <2.5 µm) and 3.7 and 3.0 ng/m3 
(coarse particles, 2.5–10 µm) in samples of inhalable particulate matter collected over a 3-year sampling
period in southeast Chicago and East St. Louis Illinois, respectively. The average vanadium
concentrations in fine particulate matter (<2.5 µm) measured as part of the Harvard Six Cities Studies 
between 1979 and 1988 were 23.2, 2.0, 1.4, 0.1, 10.5, and 0.6 ng/m3 in Watertown, Massachusetts; St.
Louis, Missouri; Kingston-Harriman, Tennessee; Portage, Wisconsin; Steubenville, Ohio; and Topeka,
Kansas, respectively (Laden et al. 2000). Average vanadium concentrations in fine and coarse particulate 
matter collected from a rural site in Bondville, Illinois were 0.8 and 1.2 ng/m3, respectively (Sweet et al.
1993).  Aerosol sampling (PM2.5 fraction) was conducted from 1988 to 1995 at a rural location in 
Underhill, Vermont (Polissar et al. 2001).  A geometric mean concentration of 0.82 ng/m3 was reported 
for vanadium, with seasonal maxima occurring during the winter and spring months and minimum
concentrations observed during the summer months.  A factor analysis method applied to the data
determined that the most likely sources of the vanadium were oil fired power plants predominantly
located in eastern Virginia, Pennsylvania, southern New York, New Jersey, Maryland, and Delaware 
(Polissar et al. 2001).  Measurements obtained at five different rural sites in northwestern Canada were 
found have average vanadium concentrations of 0.72 ng/m3 (range 0.21–1.9 ng/m3) (Zoller et al. 1973).  
Between the years 1965 and 1969, average ambient vanadium concentrations in rural air in the United 
States ranged from <1 to 40 ng/m3 (Byerrum et al. 1974), although some rural areas may have levels as 
high as 64 ng/m3 due to localized burning of fuel oils with a high vanadium content (WHO 1988).  
Vanadium concentrations in air samples collected from a rural forest in Denmark that received heavy
deposition from European cities were 11.5 and 4.4 ng/m3 in samples from 1979 to 1980 and 2002 to 2005, 
respectively (Hovmand et al. 2008).  
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Northeastern locations in the United States typically have higher atmospheric levels of vanadium as 
compared to other regions of the country.  U.S. cities were divided into two groups based on the levels of
vanadium present in the atmosphere and geographic location (Zoller et al. 1973).  The first group of cities
is widely distributed throughout the United States and is characterized by ambient air vanadium
concentrations that range from 3 to 22 ng/m3, with an average concentration of 11 ng/m3 (approximately
20 times that of remote areas).  Cities in the second group, primarily located in the northeastern United 
States, had vanadium concentrations in air that ranged from 150 to 1,400 ng/m3 with an average of
620 ng/m3 (Zoller et al. 1973). The variation is attributed to the use of large quantities of residual fuel oil 
for the generation of heat and electricity, particularly during winter months
Atmospheric levels of vanadium at remote sites tend to be lower since both natural and anthropogenic
emissions are typically negligible. Vanadium concentrations measured over the South Pole ranged from
0.001 to 0.002 ng/m3 (WHO 1988) and are frequently 2 orders of magnitude smaller than those over the
ocean at middle latitudes (WHO 1988).  For example, vanadium concentrations in air measurements taken
at nine rural sites located in the Eastern Pacific averaged 0.1 ng/m3 (range 0.02–0.8 ng/m3).  Atmospheric 
aerosols were collected from Mt. Everest in May–June, 2005; vanadium concentrations ranged from
0.9 to 3.8 ng/m3, with a mean of 1.4 ng/m3 (Cong et al. 2008).  Vanadium concentrations at other remote
locations of 0.044 and 0.0039 ng/m3 were reported for Greenland, 1988–1989 and Terra Nova Bay, 
Antarctica, 2000–2001, respectively (Cong et al. 2008; Mosher et al. 1993).  
Vanadium was detected in exhaust aerosol collected from the Elbtunnel, a major highway tunnel in 
Hamburg, Germany, at an average concentration of 14.8 ng/m3 (range: 7.6–36.9 ng/m3) (Dannecker et al.
1990).  Fine atmospheric particulate PM2.5 (particles with diameters of <2.5 µm) were collected from
November 2000 to September 2001 in Guaynabo, Puerto Rico, an urban industrialized area, and in 
Fajardo, Puerto Rico, a less polluted reference site (Figueroa et al. 2006).  Vanadium concentrations in the
PM2.5 were 40 and 1.4 ng/m3 for Guaynabo and Fajardo, respectively.  Mean urban vanadium
concentrations in winter and summer air (fine and course particulate combined) collected from the 
Birmingham University campus, Edgbaston, United Kingdom in January-February 1992 and July-August
1992 were 11.2 and 3.5 ng/m3, respectively.  Vanadium concentrations were higher in the fine particle
fraction, 7.6 and 2.3 ng/m3 (winter and summer), as compared to the coarse particle samples, 3.6 and
1.2 ng/m3 (winter and summer) (Harrison et al. 1996).  Mean vanadium concentrations in air samples
from a central Copenhagen street (January–March 1992 and February–March 1993) and a city park
(January–March 1992) were reported to be 12 and 10 ng/m3, respectively (Nielsen 1996). Smith et al.










    
   
     
 
   
      
    
 
  
   
  
     
 
 
   




   
    
      
   
     
  
 
     
 
   
 
  
    
  
VANADIUM 136
6.  POTENTIAL FOR HUMAN EXPOSURE
(1996) reported mean vanadium concentrations in air samples collected from a city site, a rural site, and
an industrial site in Lahore, Pakistan in 1992–1993 of 127, 161, and 253 ng/m3, respectively.  Mean
vanadium concentrations in air samples of 10, 180, and 110 ng/m3 were reported in Karachi, Pakistan;
Calcutta, India; and Bombay, India, respectively (Smith et al. 1996).  Schroeder et al. (1987) reported 
concentration ranges of vanadium associated with particulate matter in the atmosphere:  0.001–14 ng/m3 
(remote areas); 2.7–97 ng/m3 (rural); 10–130 ng/m3 (urban Canada); 0.4–1,460 ng/m3 (urban United
States); 11–73 ng/m3 (urban Europe); and 1.7–180 ng/m3 (urban other).
Vanadium and nickel were measured in air particulate samples collected during and after the Kuwait oil
fires (from March 1991 to July 1992) at Dhahran, Saudi Arabia (Sadiq and Mian 1994).  Vanadium
concentrations ranged from not detected to 1,165.8 ng/m3 in the inhalable (PM10, <10 µm) and from not
detected to 160.26 ng/m3 in the total suspended particulate.  The minimum vanadium concentration was
found in samples collected in December 1991 and gradually increased through May 1992.  
Air sampling in homes in two New York counties in the winter of 1986 measured various contaminants in 
the indoor air (Koutrakis et al. 1992).  Mean vanadium concentrations in indoor air of non-source homes
(no kerosene heaters, wood stoves, or cigarette smokers), wood-burning homes, kerosene heater homes, 
and smoking homes were 5, 4, 6, and 6 ng/m3, respectively.  Miguel et al. (1995) reported vanadium
concentrations in samples of indoor air from non-industrial office workplaces and restaurants in the cities 
of Sao Paulo and Rio de Janeiro, Brazil in the summer of 1993 ranging from less than the detection limit
to 0.360 µg/m3. Kinney et al. (2002) reported mean winter and summer vanadium concentrations of
9.49 and 4.17 ng/m3 in indoor air (particle-associated) in 38 homes sampled in 1999 in the West Central
Harlem section of New York City.  A mean vanadium concentration of 0.8 ng/m3 was reported inside 
patrol cars of ten nonsmoking North Carolina State Highway Patrol troopers during 25 work days (3 pm
to midnight shift) during August–October of 2001 (Riediker et al. 2003).
6.4.2 Water
Levels of vanadium in fresh water illustrate geographic variations produced by differences in effluents 
and leachates, from both anthropogenic and natural sources, entering the water table.  Vanadium
concentrations in water can range from approximately 0.2 to >100 µg/L depending on geographical
location (Sepe et al. 2003).  Vanadium was detected in 3,387 of 3,625 surface water samples recorded in
the STORET database for 2007–2008 at concentrations ranging from 0.04 to 104 μg/L in samples where 
vanadium was detected (EPA 2009).  Measurements of vanadium in such natural fresh waters as the

















   
   









   
 
      
  




   





6.  POTENTIAL FOR HUMAN EXPOSURE
Animas, Colorado, Green, Sacramento, San Joaquin, and San Juan Rivers, as well as some fresh water
supplies in Wyoming, range from 0.3 to 200 μg/L (Byerrum et al. 1974; Van Zinderen Bakker and 
Jaworski 1980). The presence of naturally occurring uranium ores resulted in rivers in the Colorado 
Plateau containing vanadium concentrations of up to 70 μg/L, and in Wyoming, vanadium concentrations
in water were found to range from 30 to 220 μg/L (Byerrum et al. 1974).  
Taylor et al. (2001) reported vanadium concentrations of <0.05 µg/L in water collected in June and 
September 1994 from the Alamosa River, Colorado and 6.2 µg/L in water collected in September 1992 
from Big Arsenic Spring, New Mexico.  Saleh and Wilson (1999) reported various metal concentrations
in surface water from the Houston Ship Channel, Texas; vanadium concentrations ranged from 4.062 to 
115.600 µg/L in samples from Buffalo Bayou and the Washburn Tunnel, respectively.  Coal mining
activity in the west-central region of Indiana has resulted in a number of sites where surface waters are 
contaminated with acidic mine drainage.  Surface water samples collected from 12 locations in west-
central Indiana that have been contaminated with acidic mine drainage were reported to contain vanadium
at concentrations ranging from 0.17 to 0.66 mg/L (Allen et al. 1996).  Kennish (1998) reported vanadium
concentrations ranging from 1.0 to 38 nmol/L (0.05–1.9 µg/L) in waters from U.S. estuaries and 
32 nmol/L (1.6 µg/L) in U.S. coastal marine waters. 
Levels in sea water are considerably lower than those in fresh water because much of the vanadium is 
precipitated (Byerrum et al. 1974; Van Zinderen Bakker and Jaworski 1980).  Vanadium concentrations
measured usually average 1–3 μg/L (Sepe et al. 2003; Van Zinderen Bakker and Jaworski 1980), although 
levels as high as 29 μg/L have been reported (Byerrum et al. 1974).  The total content of vanadium in sea 
water has been estimated to be 7.5x1012 kg (7.5x109 metric tons) (Byerrum et al. 1974).  Mean vanadium
concentrations ranging from 2.08 to 2.60 µg/L were reported in seawater samples collected along the
Saudi coast of the Arabian Gulf (Sadiq et al. 1992b).
Fiorentino et al. (2007) measured vanadium concentrations in groundwater collected from the southwest
of the Province of Buenos Aires, Argentina; all samples contained vanadium, and concentrations ranged 
from 0.05 to 2.47 mg/L.  Groundwater samples collected from 104 monitoring wells from shallow
aquifers beneath an industrial city in the Eastern Province of Saudi Arabia contained vanadium
concentrations that ranged from 0.04 to 55.69 µg/L, with a mean concentration of 7.46 µg/L (Sadiq and 
Alam 1997).










   
 
    
 
 
    
  
   
   
       
 
  





    
 











    
 
VANADIUM 138
6.  POTENTIAL FOR HUMAN EXPOSURE
Vanadium is on the EPA Drinking Water Contaminant Candidate List (CCL). The contaminants on this 
list are known or anticipated to occur in public water systems; however, they are currently not regulated 
by existing national primary drinking water regulation.  Research is ongoing to determine whether
regulations are needed (EPA 2008).
Mean vanadium concentrations in tap water collected from homes participating in a dietary study in EPA
Region V (Indiana, Illinois, Michigan, Minnesota, Ohio, and Wisconsin) for the National Human 
Exposure Assessment Survey (NHEXAS) were 1.2 and 1.0 µg/L, respectively, in samples collected after
running the water at high velocity for 3 minutes (flushed tap water) and after there had been no usage of
any tap water or toilet in the home for the previous 4 hours (standing tap water) (Thomas et al. 1999).  
As part of the National Water-Quality Assessment Program of the U.S. Geological Survey (USGS), water
samples were collected during 1991–2004 from domestic wells (private wells used for household drinking
water) for analysis of drinking-water contaminants.  Vanadium was detected in 452 of 662 samples, with 
a median concentration of 1.29 µg/L (USGS 2009a).
Lagerkvist et al. (1986) summarized older reports from the 1960s and 1970s regarding vanadium
concentrations in drinking water.  One report stated that 91% of drinking water samples analyzed from
U.S. sources had vanadium concentrations below 10 µg/L, with an average concentration of 4.3 µg/L.  In 
another report, the typical vanadium concentrations in drinking water were about 1 µg/L.  
6.4.3 Sediment and Soil
Vanadium is widely distributed in the earth’s crust at an average concentration of 100 ppm
(approximately 100 mg/kg) (Byerrum 1991).  The level of vanadium measured in soil is closely related to
the parent rock type (Van Zinderen Bakker and Jaworski 1980; Waters 1977).  A range of 3–310 mg/kg 
has been observed, with tundra podsols and clays exhibiting the highest concentration, 100 and 
300 mg/kg, respectively (Byerrum et al. 1974). The average vanadium content of soils in the United 
States is 200 mg/kg (Byerrum et al. 1974) and seems to be most abundant in the western United States, 
especially the Colorado Plateau (Cannon 1963; Grayson 1983).
Gallagher et al. (2008) measured various metal concentrations in soils collected during the summer of
2005 from a site in Jersey City, New Jersey on the west bank of Upper New York Bay.  This land was
originally an intertidal mud flat and a salt marsh that was filled during 1860–1919 with material 










    
     
   
   
    
  
    
 
   
  
  
     
  
     
 
 
   
  
 
   
   
   
  
   
    
    
  
  
   
 
   
  
 
    
VANADIUM 139
6.  POTENTIAL FOR HUMAN EXPOSURE
consisting of mostly debris from construction projects and refuse from New York City.  It was used as a
railroad yard until 1967. The site was then transferred to the New Jersey Division of Parks and Forestry
in 1970.  Vanadium concentrations in soil collected from this site ranged from below the detection limit 
(<0.01 µg/g) to 317 µg/g, with a median value of 56.4 µg/g (Gallagher et al. 2008).  Metal concentrations
were measured in two alluvial soils from the lower Mississippi River Delta. Median vanadium
concentrations of 3.2 and 3.8 µg/g were reported in freshly deposited alluvium soil from Bonnet Carré
Spillway and in urban soil samples from New Orleans, respectively (Mielke at el. 2000).
Various trace elements were measured in 13 surface soils collected from southwestern Saskatchewan,
Canada (Mermut et al. 1996).  Fertilizers and pesticides are the two major anthropogenic sources of trace 
elements in the Canadian Prairies.  Vanadium concentrations ranged from 31.75 mg/kg in Hatton soil (0– 
13 cm, pH 6.2, 1.32% organic content [OC], 6% clay) to 180.06 mg/kg in Sceptre soil (90–105 cm, pH
8.0, 0.85% OC, 73% clay).  Clay soils were found to contain more vanadium that other soils (Mermut et
al. 1996).  Vanadium concentrations in 16 soil samples collected in May 2000 in the vicinity of a cement
plant in Catalonia, Spain ranged from 5.6 to 12.4 mg/kg dry weight.  These values were generally lower
than vanadium levels found in urban areas (Schuhmacher et al. 2002).  The geometric mean vanadium 
concentrations in 112 samples street dust and 40 samples of urban soil collected in Aviles, Northern Spain 
were 28.1 (range 25.0–34.0) and 34.1 (22.0–67.0) µg/g, respectively (Ordóñez et al. 2003). 
Metal contamination was determined in soil samples collected from 10 locations in the Hafr Al Batin 
Area (Saudi Arabia) near the Saudi/Kuwaiti border following the Gulf War (1990–1991) (Sadiq et al. 
1992a).  Oil burning in Kuwait, atmospheric fallout of particulates form the use of explosives in the Gulf
War, and other war-related ground activities created air pollution problems in the countries neighboring
Kuwait.  Vanadium concentrations in soil ranged from 2 mg/kg collected at the most distant sampling site
from the Kuwaiti border (15–25 cm depth) to 59 mg/kg collected from a sampling site near the border (0– 
5 cm depth).  Vanadium concentrations in soil samples were found to decrease with increasing distance
from the border (Sadiq et al. 1992a).  Various metal concentrations were determined in 25 surface soil 
samples from Surat, India, an industrial area.  Vanadium concentrations ranged from 141.9 to 
380.6 mg/kg with a mean 284.8 mg/kg (Krishna and Govil 2007).
Mean vanadium concentration of 44 and 82 mg/kg were reported in the sediments of Lake Huron and 
Lake Superior.  Vanadium was detected in sediment samples from the Georgian Bay and North Channel
(Lake Huron) at mean concentrations of 67 and 66 mg/kg, respectively (International Joint Commission 
1978).  Heit et al. (1984) reported vanadium concentrations in Rocky Mountain Lake sediments of
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27.3 and 15 mg/kg dry weight in Lake Husted surface (0–2 cm) and subsurface sediments, respectively,
and 35 and 32.8 mg/kg dry weight in Lake Louise surface and subsurface sediments, respectively.
Vanadium concentrations of 55 and 43 mg/kg dry weight were reported in surface sediments from Lake
Haiyaha and The Loch, two other Rocky Mountain lakes.  Total vanadium concentrations of 136 and 
222 mg/kg dry weight were reported in sediment samples from the Texas City channel and Ashtabula 
River, Ohio (Engler 1979). 
Four sediment cores collected January 1996 from Central Park Lake New York City, New York were 
analyzed for various metals including vanadium; average vanadium concentrations ranged from 87 µg/g
at a depth of 44–47 cm to 665 µg/g at a depth of 12–14 cm (Chillrud et al. 1999).  In 1966, approximately
35% of the residual fuel oil used in New York City was from Venezuela. Vanadium is enriched in the 
sulfur-rich petroleum from Venezuela.  Comparison of the approximate year of deposition to vanadium
concentration in the sediment for Central Park Lake showed that vanadium levels in sediments from
Central Park Lake were found to decrease after restrictions on sulfur content of fuel oils used in New
York City were introduced starting in 1966.  The average vanadium concentration peaks at 665 µg/g in 
sediments from 12 to 14 cm depth, which correlates with approximately with the mid 1960s (Chillrud et
al. 1999). Trace metal concentrations were measured in sediment cores collected in February 1992 from
the Gulf of Mexico; the average vanadium concentration was 47.78 µg/g and ranged from 15.6 to
117.5 µg/g (Macias-Zamora et al. 1999).  Metal concentrations were measured in sediment collected
during early and late autumn of 1993 and 1994 from 16 locations in Lake Erie, the Niagara River, and
Lake Ontario; vanadium concentrations ranged from 6.0 to 31.1 µg/kg dry weight in these sediment
samples (Lowe and Day 2002). 
Vanadium concentrations in surface sediments collected during 1988–1991 from the Great Astrolabe
Lagoon, Fiji ranged from 2 to 726 mg/kg dry weight.  This lagoon, which encompasses a number of small
volcanic islands, is considered to be a pristine marine environment with minimal human impact in this
study (Morrison et al. 1997).
A diesel oil spill occurred in April 2002 from a pipeline on the Pacific side of Mexico, in Salina Cruz into 
the San Pedro stream, Xadani estuary, and the Superior Lagoon mouth (Salazar-Coria et al. 2007). 
Vanadium concentrations in sediment collected after the spill during the dry and rainy seasons were
110.5 and 123.0 mg/kg dry weight at the San Pedro site, 95.4 and 148.9 mg/kg dry weight at the Piedra
Estuary, 113.3 and 107.7 mg/kg dry weight at the Xadani estuary, and <5.0 mg/kg dry weight at Superior
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Lagoon, respectively.  Vanadium concentrations in a reference site, upstream from the spill were below
the limit of detection, <5.0 mg/kg dry weight.  
Chemical contamination was measured in sediment from the Shuaiba Industrial Area (SIA), a coastal area 
in Kuwait that receives industrial effluent (Beg et al. 2001). The SIA contains a petrochemical company,
three refineries, two power desalination plants, a melamine company, an industrial gas corporation, a
paper products company, and other smaller industrial plants, as well as a large harbor. Vanadium
concentrations were reported to range from 9.8 to 146.0 mg/kg dry weight in sediment from Shuaiba
coastal area (Beg et al. 2001).
6.4.4 Other Environmental Media 
The majority of foods have naturally occurring low concentrations of vanadium, many of them ≤1 ng/g
(Byrne and Kosta 1978).  Food items containing the highest levels of vanadium include ground parsley
(1,800 ng/g dry weight), freeze-dried spinach (533–840 ng/g), wild mushrooms (50–2,000 ng/g dry 
weight), and oysters (455 ng/g wet weight) (Byrne and Kosta 1978).  Intermediate levels are found in food
types such as certain cereals (ranging from 0.7 ng/g in maize to 30 ng/g in Macedonian rice), fish (ranging
from 3.5 ng/g in mackerel to 28 ng/g in freeze-dried tuna), and liver (ranging from 7.3 ng/g in beef to
38 ng/g in chicken) (Byrne and Kosta 1978).  In general, seafoods have been found to be higher in 
vanadium than terrestrial animal tissues (WHO 1988).  Vanadium concentrations in cow milk ranging 
from about 0.2 to 10 µg/kg also have been reported in older reports from the late 1970s and early 1960s, 
respectively (Lagerkvist et al. 1986).  Pennington and Jones (1987) surveyed 234 foods from a 1984 
collection of the FDA’s Total Diet Study for various trace elements including vanadium.  Sixty-four
percent of the Total Diet Foods had vanadium concentrations of <0.5 µg/100 g and 88% had vanadium
concentrations of <2 µg/100 g.  Foods with the highest vanadium concentrations included breakfast
cereals, canned fruit juices, fish sticks, several vegetables, sweeteners, wine, and beer. The data from this 
survey are summarized in Table 6-3.
Vanadium, as elemental vanadium or vanadyl sulfate, also may be found in various commercial nutritional
supplements and multivitamins; vanadium concentration can range from 0.0004 to 12.5 mg in these
supplements depending on the serving size recommended by the manufacturer (NLM 2009).  Vanadium
has been used in supplements for individuals with diabetes; intakes of 30–150 mg/day for vanadyl sulfate
(9–47 mg V/day) and 125 mg/day for sodium metavanadate (52 mg V/day) have been reported (IOM 
2001; Smith et al. 2008).  

















     
    
    
    
    
    
    
    
    
    
    
    
    
 
    
     
    
    
    
    





6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-3.  Vanadium Levels in Food
Mean Range
Food item (µg/100 g)
Adult foods
Milk, yogurt, and cheese 0.1 0–0.6




Grains and grain products 2.3 0–14.7
Fruits and fruit juices 0.6 0–7.1
Vegetables 0.6 0–7.2
Mixed dishes and soups 0.6 0–2.0
Desserts 0.9 0–2.9
Sweeteners 2.3 0.4–4.7




Meat and poultry 0.5 0–0.8
Cereals 1.6 1.2–2.0
Fruit and juices 1.6 0–13.4
Vegetables 0.4 0–1.1
Mixed dishes 0.2 0–0.6
Custard 0.2 No data
Source:  Pennington and Jones 1987
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Gummow et al. (2005) reported a study that looked at the commonly consumed tissues and milk
concentrations of vanadium in cattle in South Africa that were extensively farmed over a 5-year period 
(1999–2004) in an area adjacent to a vanadium processing plant that was known to have higher-than-
normal background levels of vanadium.  The group of cattle included two groups, one group of 10 cattle
that was farmed adjacent to the mine, with an average exposure of 1,229 mg V/day, and another group of
20 cattle that was farmed 2–3 km from the first group with an exposure about half that of the high 
exposure group (mean=532 mg V/day).  Cattle in the trial were monitored over a 5-year period and six
cohorts of animals were slaughtered over this period.  Concentrations of vanadium in commonly
consumed tissues (liver, kidney, fillet, and triceps) ranged from <0.05 to 11.51 mg/kg (wet-weight) in
triceps and liver, respectively, over both groups.  The median concentration of vanadium in milk was
0.23 mg/kg (range: <0.05–1.92 mg/kg) over both groups.  Concentrations of vanadium in tissues from the
group raised adjacent to the mine and those raised 2–3 km away were not differentiated in the 
presentation of the data.  
Concentrations of various metals, including vanadium, were measured in samples of six fish species 
collected during 1997 and 1998 along the coast of the Adriatic Sea.  Vanadium concentrations (µg/kg
fresh weight) were 45.3–74.4 (anchovy), <4.0–4.8 (angler), <4.0 (hake), 6.7–29.8 (mackerel), 11.8– 
32.4 (red mullet), and <4.0–2.9 (sole) (Sepe et al. 2003).
Vanadium is found in almost all coals used in the United States, with levels ranging from extremely low
to 10 g/kg (Byerrum et al. 1974; WHO 1988).  Eastern U.S. coal has an average content of 30 ppm, 
western coal has an average content of 15 ppm, and coal from the interior contains an average of 34 ppm
(Byerrum et al. 1974).  The average vanadium content of bituminous and anthracite coal is 30 and 
125 ppm, respectively (Byerrum et al. 1974).  
Vanadium is usually the most abundant trace metal found in petroleum samples (Amorim et al. 2007).  
Vanadium concentrations in petroleum may be as high as 1,500 mg/kg, while some crude oils contain 
<0.1 mg/kg.  Vanadium occurs predominantly as the vanadyl ion (VO2+) in the form of organometallic
complexes with porphyrins.  Vanadyl porphyrins originated from the formation of crude oil; the vanadyl
ion was substituted for magnesium ion (Mg2+) in the chlorophylls of plants.  Other vanadium complexes 
in petroleum include non-porphyrin and organic acid complexes (Hovmand et al. 2008).  Mamane and 
Pirrone (1998) reported that residual fuel oils manufactured from U.S. crude oils contain 25–50 ppm of
vanadium.  Venezuelan, Middle Eastern, and North African residual oils have vanadium concentrations of
















    
 
 
   
 
  
   
    
   
    
  
  





   
    
 
 
   
 
   




6.  POTENTIAL FOR HUMAN EXPOSURE
200–300, 10–20, and 50–90 ppm, respectively.  Vanadium is highly enriched relative to other elements in 
heavy fuel oils due to vanadium porphyrins.  Because of this, vanadium is used as a marker for emissions 
from fuel oil combustion (Mamane and Pirrone 1998).
Vanadium concentrations ranging from 0.49 to 5.33 µg/g were measured in 45 different brands of whole
unsmoked cigarettes.  Mean vanadium concentrations of 1.11, 0.67, 0.09, and 0.33 µg/cigarette in whole
unsmoked cigarettes, ash, filter, and smoke of six different brands of cigarettes, respectively (Adachi et al.
1998a).
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Food is the main source of vanadium intake for humans (Lagerkvist et al. 1986).  Higher dietary intake
levels are possible when food is grown in soil contaminated with greater than background levels of
vanadium.  Vanadium in food is mainly ingested as VO2+ (vanadyl, V4+) or HVO42- (vanadate) (Sepe et al.
2003).  Byrne and Kučera (1991) reported a daily intake of vanadium of 10–20 µg.  The dietary intake of
vanadium estimated from the combined total intake of solids and liquids from a dietary study in EPA
Region V (Indiana, Illinois, Michigan, Minnesota, Ohio, and Wisconsin) for the NHEXAS was 
0.34 µg/kg of body weight/day (Thomas et al. 1999).  Pennington and Jones (1987) surveyed 234 foods
from a 1984 collection of the FDA’s Total Diet Study for various trace elements including vanadium.  
Based on this survey, estimated daily intakes of vanadium ranged from 6.2 µg/day for 60–65-year-old 
females to 18.3 µg/day for 25–30-year-old males.  Table 6-4 summarizes the estimated daily intakes of
vanadium for the various age groups in this study.
Various metal concentrations were determined in foods (meat, fish and seafood, pulses [lentil, bean],
cereals, vegetables, fruits, tubers, whole milk, yogurt, eggs, and sugar) purchased from local markets,
supermarkets, and grocery stores in zones of Tarragona County (Catalonia, Spain) near a hazardous waste
incinerator, which has been operating since 1999 (Bocio et al. 2005).  A dietary intake for vanadium of
28.9 µg/day was estimated for an average adult man (70 kg body weight) in Tarragona County (Catalonia, 
Spain).  Fish and seafood (hake, sardine, and mussels) were the only foods that contributed to this value;
vanadium was not detected in any other foods that were surveyed.  The detection limit for vanadium in 
this study was 0.25 µg/g (Bocio et al. 2005).  Sepe et al. (2003) reported an 11–34% contribution to the
daily vanadium ingestion from fish collected during 1997 and 1998 along the coast of the Adriatic Sea for
the population in this area.
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Table 6-4.  Estimated Daily Vanadium Intake
Age group Intake (µg/day)
6–11 Months 6.7
2 Years 6.5
14–16 Years, female 7.1
14–16 Years, male 11.0
25–30 Years, female 8.1
25–30 Years, male 18.3
60–65 Years, female 6.2
60–65 Years, male 10.6
Source:  Pennington and Jones 1987
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Gummow et al. (2005) estimated dietary intakes of vanadium from the consumption of cattle in South 
Africa that were raised over a 5-year period (1999–2004) in an area adjacent to a vanadium processing
plant that was known to have higher-than-normal background levels of vanadium.  The median potential
daily intakes of vanadium in the diet of humans consuming beef from these cattle were estimated to be 
1.9, 1.8, 2.9, and 1.2 µg/kg body weight/day for consuming fillet, triceps, liver, and kidney, respectively.  
The median potential daily intake of vanadium from drinking milk of these cattle was estimated to be 
4.6 µg/kg body weight/day (Gummow et al. 2005).
As compared to food, drinking water is a less important source of vanadium exposure for the general
population. Thomas et al. (1999) reported mean vanadium concentrations of 1.2 and 1.0 µg/L in flushed 
tap water and standing tap water samples from Indiana, Illinois, Michigan, Minnesota, Ohio, and 
Wisconsin, respectively.  Assuming a daily intake of 2 L of water (EPA 1988), a daily intake of
approximately 2 µg of vanadium from tap water can be estimated.  
Vanadium is present in many dietary supplements, including multivitamin and mineral supplement
formulations, as well as products marketed for weight control, bodybuilding, and diabetes control (NTP
2008). The National Library of Medicine’s (NLM’s) Dietary Supplements Label Database lists 
>100 products containing vanadium (NLM 2009).  Many of these products contain <10 µg of vanadium.  
Some of these products contain up to 12.5 mg of vanadium depending on the serving size recommended 
by the manufacturer. Three containing vanadyl sulfate are also listed on the NLM’s Dietary Supplements 
Label Database, containing 0.01–1.66 mg of vanadyl sulfate (0.003–0.52 mg vanadium) depending on the
serving size recommended by the manufacturer (NLM 2009).  According to the Third National Health 
and Nutrition Examination Survey on supplement use of vanadium, the median intake of supplement
vanadium by adults was approximately 9 µg/day (IOM 2001).  Vanadium has been used in supplements
for individuals with diabetes.  Intakes of 30–150 mg/day for vanadyl sulfate (9–47 mg V/day) and 
125 mg/day for sodium metavanadate (52 mg V/day) have been reported (IOM 2001; Smith et al. 2008).  
Vanadyl sulfate supplements have been used as well by weight training athletes at levels up to 60 mg/day
(18.6 mg V/day) (Barceloux 1999).  Consumption of some vanadium-containing supplements may result
in intakes of vanadium that would exceed those from food and water.
The general population may also be exposed to airborne vanadium through inhalation, particularly in 
areas where use of residual fuel oils for energy production is high (Zoller et al. 1973).  Assuming air
concentrations of approximately 50 ng/m3, Byrne and Kosta (1978) estimated a daily intake of 1 μg 
vanadium, assuming an average inhalation rate of 20 m3/day.  In addition, cigarette smoke can contribute
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vanadium exposure.  Koutrakis et al. (1992) estimated an emission rate for vanadium from cigarette 
smoke of 373 ng/cigarette; approximately 0.04 µg of vanadium is released in the smoke of one cigarette.
Lin et al. (2004) reported vanadium concentrations in the blood of 52 Taiwanese college students (19– 
42 years old).  None of these students had occupational exposure to vanadium and five of the students (all
male) were smokers.  The average vanadium concentration in was 0.42 ng/mL in all students, with a
range of 0.01–1.20 ng/mL.  The average vanadium concentration in blood for the female students was 
0.37 ng/L and the average concentration for nonsmoking male students was 0.44 ng/L; the average for the
five smokers was 0.47 ng/mL.  Concentrations of vanadium in human blood reported in the literature
range from 0.032 to 0.095 ng/mL (Kučera et al. 1992; Lin et al. 2004; Sabbioni et al. 1996).  The average
vanadium concentration in blood of individuals that have occupational exposure is 33.2 (3.10–217)
ng/mL (Lin et al. 2004).  Sabbioni et al. (1996) surveyed the literature for reports on vanadium
determination in human blood, serum, and urine and reported that vanadium concentrations in blood 
and/or serum ranged from 0.45–18.4 nmol/L (0.022–0.937 µg/L) and concentrations in urine ranged from
4.16–15.7 nmol/L (0.212–0.800 µg/L).  Normal concentrations of vanadium in blood and serum were
reported to be around 1 nmol/L (0.05 µg/L) and around 10 nmol/L (0.5 µg/L) for urine.  Nixon et al. 
(2002) reported similar values for vanadium concentrations of 0.05 and 0.24 µg/L in serum and urine, 
respectively, in healthy individuals from a literature survey.  Vanadium concentrations ranging from 30 to 
160 µg/kg have been reported in hair (Fernandes et al. 2007; Kučera et al. 1992).  No functional role for
vanadium in higher animals or humans has been identified (IOM 2001).
6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).











      
   
   
   
  
     
  
 
   
 
 
   
    
  








   
  
    
 
  
   
    




6.  POTENTIAL FOR HUMAN EXPOSURE
Similar to adults, dietary intake of vanadium through the ingestion of food is the primary exposure route
for children.  This route of exposure is particularly relevant when the food is contaminated with soil 
because soil contains an average of about 10,000 times as much vanadium as is found in many biological
materials (Byrne and Kosta 1978).  Since young children tend to ingest soil and dust during daily
activities, children may be exposed to vanadium through the ingestion of soil or dust.  Cigarette smoke
can contribute vanadium exposure of children.  Approximately 0.04 µg of vanadium is released in the
smoke of one cigarette (Koutrakis et al. 1992).
Blood and hair samples were collected from 23 children living in the vicinity of a metallurgical plant 
producing vanadium pentoxide (V2O5) approximately 20 km from Prague, Czechoslovakia (Kučera et al. 
1992).  These children may have been exposed to vanadium due to contamination of well water.  A
control group consisted of 17 children from a nonpolluted rural area about 30 km from Prague.  Median
vanadium concentrations in hair samples from the exposed and control groups did not differ significantly, 
and were 98 and 88 µg/kg, respectively.  The median vanadium concentration in the blood of the exposed 
children and the children in the control group were 0.078 and 0.042 µg/L, respectively, and were
considered significantly different (Kučera et al. 1992).
Concentrations of vanadium in human breast milk of 0.46, 0.27, 0.21, 0.11, 0.69, and 0.13 µg/g have been 
reported in samples from Nigeria, Zaire, Guatemala, Hungary, Philippines, and Sweden, respectively
(Nriagu et al. 1992).  Ikem et al. (2002) reported mean vanadium concentrations of 0.001, 0.002, and 
0.003 µg/mL in milk-based liquid formulas from the United Kingdom, milk based powdered formulas 
from the United States, and soy-based powder formulas from the United States, respectively.  Vanadium
was not detected in milk-based powdered formulas from Nigeria and the United Kingdom.  Daily intakes 
of vanadium for infants in the United States were estimated to be 0.05, 3.5, and 2.8 μg/day for milk-based
powder formulas, soy-based powder formulas, and hypoallergenic powder formulas from the United 
States, respectively (Ikem et al. 2002).
Pennington and Jones (1987) reported concentrations in infant foods that ranged from 0.1 µg/100 g in 
formulas to 1.6 µg/100 g in cereals, fruits, and juices. Daily intakes of vanadium of 6.7, 6.5, 7.1, and 
11.6 µg/day for children aged 6–11 months, 2 years, 14–16 years (female), and 14–16 years (male),
respectively, were estimated based on this food survey.  A summary of these data are found in Tables 6-3 
and 6-4.
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6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Populations consuming foods grown in soils supplemented with fertilizers or sludge containing vanadium 
or in soils naturally high in vanadium content may be exposed to concentrations higher than background 
levels. This is due primarily to surface deposition.
Populations in areas with high levels of residual fuel oil consumption may also be exposed to above-
background levels of vanadium, both from increased particulate deposition upon food crops and soil in 
the vicinity of power plants and higher ambient air levels (Zoller et al. 1973).  Cities in the northeastern
United States frequently fall into this category, where ambient air levels often range from 150 to
1,400 ng/m3 (Zoller et al. 1973).  
Personal exposure measurements were conducted on 18 boilermakers and 11 utility workers before and 
during a 3-week overhaul of a large oil-fired power plant (Liu et al. 2005).  Utility workers included 
mechanics, welders, laborers, painters, precipitator operators, work crew supervisors, and laboratory
workers.  During the overhaul, boilermakers worked both inside and outside the boiler and were more
likely to be exposed to ash. Utility workers worked outside the boiler in adjacent areas and had little 
direct contact with the ash. Time-weighted average exposures for the boilermakers and the utility
workers were 1.20 and 1.10 µg/m3, respectively, before the overhaul work and 8.9 and 1.4 µg/m3, 
respectively, during the overhaul work (Liu et al. 2005). Another study of 32 boilermaker workers found 
significant differences between pre- and post-shift urinary vanadium (creatinine adjusted) levels (Kim et
al. 2003). Elevated vanadium levels have also been found in the nasal fluid of boilermakers, as compared
to utility workers (Woodin et al. 1998).
Full-shift, personal breathing sampling was conducted on nine employees working in the finishing and 
cut-off areas (torch cutting, pneumatic hammer, water blast, and the five finishing workstations) of a
titanium investment casting plant in Redmond, Oregon during July 7–10, 2003.  Respirable vanadium
pentoxide concentrations ranged from 0.0005 to 0.0089 mg/m3, with the highest measurement of
0.123 mg/m3 in the torch cutting area (NIOSH 2004).
Vanadium, as elemental vanadium or vanadyl sulfate, may be found in various commercial nutritional
supplements and multivitamins; vanadium concentration can range from 0.0004 to 12.5 mg in these 
supplements depending on the serving size recommended by the manufacturer (NLM 2009).  Vanadium
supplements have be used and studied as supplements for diabetic individuals.  Intakes of 30–150 mg/day
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for vanadyl sulfate (9–47 mg V/day) and 125 mg/day for sodium metavanadate (52 mg V/day) have been 
reported (IOM 2001; Smith et al. 2008).  Vanadyl sulfate supplements have been used as well by weight
training athletes at levels up to 60 mg/day (18.6 mg V/day) (Barceloux 1999).  Consumption of some
vanadium containing supplements may result in intakes of vanadium that would exceed that from food 
and water.  
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of vanadium is available. Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of vanadium.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed.
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical and chemical properties of vanadium and its
compounds are reasonably well documented (see Tables 4-1 and 4-2).  No data needs are indentified.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this
information for 2009, became available in March of 20011.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions.
Companies involved in the vanadium production industry (see Table 5-3), uses of vanadium and various
vanadium compounds (Lide 2008; USGS 2012), and various sources of release are also available (see
Table 6-1).  There is little information available describing the amounts of vanadium consumed in each 










     
   
    
 
        
      
    
      
   
    
 
        
  
   
  
     
 
   
  
 
       
   
     




       
    
 




6.  POTENTIAL FOR HUMAN EXPOSURE
use category or the quantities recycled and disposed of within the United States. Few details were found
regarding the specific disposal methods used (HSDB 2009; USGS 2012). Information in each of these
areas would provide an indication of the potential for human exposure as a result of disposal practices.
Environmental Fate. The relative contributions of natural (Byerrum et al. 1974; Zoller et al. 1973)
and anthropogenic sources (Byerrum et al. 1974; TRI09 2011) of vanadium to the different environmental
media are available.  Partitioning between the various media is described, in particular from soil to water
and from water to sediment (Wehrli and Stumm 1989; WHO 1988), but specific coefficients are not
available in many studies. Information on the transport of vanadium within each media is available (Duce 
and Hoffman 1976; Martin and Kaplan 1998; Wehrli and Stumm 1989; WHO 1988; Zoller et al. 1973).
Bioavailability from Environmental Media. Occupational studies on the uptake of vanadium via
the inhalation route exist; however, data suggesting that this route is relevant with regard to hazardous 
waste sites are lacking.  Dermal absorption data are limited; however, it is likely that absorption via this
route is low since vanadium, like other metals, has low solubility in lipids (WHO 1988).  The daily
intakes of vanadium from air, food, and water are generally small (Bocio et al. 2005; Thomas et al. 1999;
Zoller et al. 1973).  Seafood or milk from cows raised in an area with vanadium contamination can be a
more significant dietary contribution of vanadium (Gummow et al. 2005; Sepe et al. 2003).  No data
needs are identified.
Food Chain Bioaccumulation. The uptake of vanadium in aquatic plants and animals is reasonably
well documented; levels of vanadium present in different species have been established (Byerrum et al.
1974; WHO 1988). Levels present in terrestrial plants (Byerrum et al. 1974; Cannon 1963) and animals
(Van Zinderen Bakker and Jaworski 1980; WHO 1988) have been established for several species.  Uptake 
of vanadium by terrestrial plants grown on sludge-amended, or vanadium-containing fertilized fields has 
been studied.  Vanadium does not appear to concentrate in above-ground portions of terrestrial plants
(Byerrum et al. 1974).  No data needs are identified.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of vanadium
in contaminated media at hazardous waste sites are needed so that the information obtained on levels of
vanadium in the environment can be used in combination with the known body burden of vanadium to 
assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste
sites.










    
 
      
   




      
    
  
  
    
 
    
 
     
  




   
 
 
       
  






6.  POTENTIAL FOR HUMAN EXPOSURE
Estimates of human exposure to vanadium from food (Bocio et al. 2005; Byrne and Kosta 1978; Byrne
and Kučera 1991; Gummow et al. 2005; Pennington and Jones 1987; Sepe et al. 2003; Thomas et al. 
1999; WHO 1988), drinking water (USGS 2009a; Lagerkvist et al. 1986; Thomas et al. 1999), and air
(Byrne and Kosta 1978) are limited.  Current information on emission levels from the combustion of
residual fuel oil would enable a more complete picture of populations potentially exposed to higher than 
background ambient air levels.  A data need is identified regarding vanadium levels found in 
environmental media in the vicinity of hazardous waste sites.
Exposure Levels in Humans. Limited information was located describing levels of vanadium
present in human tissues for the general population (Byrne and Kosta 1978; Fernandes et al. 2007; Kučera
et al. 1992; Lin et al. 2004; Nixon et al. 2002; Sabbioni et al. 1996).  Little information is available on 
tissue levels found in populations near hazardous waste sites.  A data need for vanadium levels in blood 
samples of the general population and those residing near hazardous waste sites is identified.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Measurements of the vanadium in blood and hair of children who have been 
exposed to vanadium, as well as unexposed children, are limited (Kučera et al. 1992).  Additional
information monitoring vanadium concentrations in children are needed.  Specific data on the intake of
vanadium from food eaten by children and from their diet are also limited (Ikem et al. 2002; Pennington 
and Jones 1987).  
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for vanadium were located. This substance is not
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for sub-
registries to be established.  The information that is amassed in the National Exposure Registry facilitates 















6. POTENTIAL FOR HUMAN EXPOSURE
6.8.2 Ongoing Studies 
No long-term research studies on the environmental fate of vanadium were identified.  No ongoing 
studies or long-term research concerning occupational or general population exposures to vanadium were 
identified. 
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The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring vanadium, its metabolites, and other biomarkers of exposure and effect to 
vanadium.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the
analytical methods used for environmental samples are the methods approved by federal agencies and
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other
methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
Vanadium can be determined as the total metal, as well as in its different oxidation states (species). The 
various oxidation states of vanadium can interconvert between the oxidation state depending on 
conditions such as, oxidation-reduction potential, pH, and salinity.  In natural waters, dissolved vanadium
exists as vanadium(IV) or vanadium(V) and these species have different toxic properties; therefore,
determination of the vanadium species present in a sample can be more important than the total vanadium
content of the sample in order to best evaluate human exposure (Pyrzyńska and Wierzbicki 2004). 
Analytical techniques for the determination of species of vanadium include standard atomic spectroscopic 
techniques and separations methods coupled with sensitive detectors.  Separation methods include
capillary electrophoresis (CE) and liquid chromatography (LC).  Atomic spectroscopic methods used for
the determination of vanadium include atomic absorption spectroscopy (AAS) with flame and graphite
tube atomizers, inductively coupled plasma optical emission spectrometry (ICP-OES), inductively
coupled plasma mass spectrometry (ICP-MS), x-ray fluorescence spectrometry (XRF), and 
spectrophotometric methods (Chen and Owens 2008).  
Sample preparation is one of the most important steps in the analysis of vanadium in biological and 
environmental samples.  Direct analysis of vanadium species using atomic spectroscopic or separation
techniques is generally not feasible due to the relatively low concentrations of vanadium found in samples 
as compared to other metals.  In addition, the complexity of the matrices of biological and environmental
samples can interfere with the determination of vanadium species, and it is often necessary to remove the 
matrices prior to vanadium analysis (Pyrzyńska and Wierzbicki 2004; Chen and Owens 2008).  
   
 









   
     









    













   






The main methods for matrix removal are liquid-liquid extraction (LLE) and solid phase extraction (SPE).
LLE is based on the distribution of the analyte between two immiscible solvents and involves the
formation of an uncharged chemical species in the aqueous phase by chelation or ion-association of the 
vanadium ion, followed by extraction into an organic solvent.  Example of complexing reagents (chelates)
used to bind vanadium species include, vanadium(IV) with bis(salicylaldehyde) tetramethylethylene-
diimine in a chloroform/water mixture, vanadium(V) with N-benzoyl-N-phenylhydroxylamine (BPHA) in 
a chloroform/water mixture, and vanadium(V) with 2-(5-bromo-2-pyridylazo)-5-(N-propyl-N-sulfopropy-
lamino)-phenol (5-Br-PAPS) in a xylene/water mixture.  Each of these LLE steps was followed by
separation using liquid chromatography with UV detection.  Other complexing agents that have been 
studied include dibenzo-18-crown-6 and N-phenyl-(1,2-methanofullerene)-formohydroxamic acid 
(PMFFA) (Chen and Owens 2008; Pyrzyńska and Wierzbicki 2004).
SPE is based on the transfer of metal ions from an aqueous phase to the active sites of a solid phase.
Compared to LLE, SPE is simpler and more convenient to automate.  It also uses less solvent and requires 
fewer manipulations.  Several ion-exchange resins, functionalized cellulose sorbents, and chelating resins 
have been studied for the selective preconcentration and separation of vanadium species.  Cellulose 
sorbent with phosphonic acid exchange groups gives excellent enrichment of vanadium(IV) and
vanadium(V) and can be simultaneously eluted using an ethylenediamine tetraacetic acid (EDTA)
solution.  Other solid phases used to separate and preconcentrate vanadium species include Sephadex 
DEAE A-25 with Eriochrome Cyanide R complexation, C18 microcolumn or XAD-7 resin with 
complexation using 2-(5-bromo-2-pyridylazo)-5-diethylaminophenol or dithizone or 8-hydroxyquinoline
(8-HQ), and Chelex 100 (Chen and Owens 2008; Pyrzyńska and Wierzbicki 2004).
Vanadium concentrations in biological and environmental samples are typically very low, and vanadium
analysis requires powerful analytical methods.  Analytical methods with sufficient sensitivity include
neutron activation analysis (NAA), electrothermal atomic absorption spectrometry (ETAAS), inductively
coupled plasma atomic emission spectrometry (ICP-AES), ICP-MS, and some UV-vis spectrophotometric
methods (Pyrzyńska and Wierzbicki 2004).  ETAAS is routinely used for the determination of trace
concentrations of vanadium.  ICP-MS has better sensitivity than ETAAS; however, interference from the 
sample matrix can complicate the analysis.  The species 16O35Cl+ and 34S16OH+ from the sample matrix
can overlap with the most abundant isotope of vanadium at m/z=51 (Nixon et al. 2002; Pyrzyńska and 
Wierzbicki 2004).
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7. ANALYTICAL METHODS
Due to the low levels of vanadium that are typically found in biological and environmental samples, care
must be exercised during sample handling in order to avoid contamination.  Vanadium may be found in 
disposable steel needles, collection vials, storage containers, and chemicals and reagents (Kučera and
Sabbioni 1998).
7.1  BIOLOGICAL MATERIALS
Methods for determination of vanadium in biological samples are summarized in Table 7-1.
NAA has been widely used to measure trace elements (including vanadium) in biological samples (Allen
and Steinnes 1978; Lavi and Alfassi 1988; Martin and Chasteen 1988; Mousty et al. 1984).  In NAA, the
sample is bombarded with neutrons, and the element of interest is made radioactive.  The amount of the
element present in the sample is then determined by measurement of the radioactivity or radioactive 
decay products.  When 51V is bombarded with neutrons, it becomes 52V (half-life 3.75 minutes and 
γ emission of 1.433 MeV).  The resultant γ emission is detected with an efficient detector with high 
spectral resolution such as a well-type germanium detector combined with a multichannel analyzer.  The 
concentration of vanadium is determined through its short-lived half-life of 52V (Seiler 1995).  Detection 
limits of low- to sub-ppb (μg/L) levels of vanadium in blood and urine samples have been obtained (Allen 
and Steinnes 1978; Lavi and Alfassi 1988; Mousty et al. 1984). The advantages of the NAA technique 
are its sensitivity and multi-elemental capability. The disadvantages of this technique include its high
cost and the limited availability of nuclear facilities for NAA analysis (Seiler 1995).
Sabbioni et al. (1996) surveyed the literature for reports on vanadium determination in human blood, 
serum, and urine.  Many analytical methods have been used to determine vanadium concentrations in 
blood, serum, and urine samples, including spectrography, colorimetry, catalytic reactions, XRF, particle
induced x-ray emission (PIXE), ICP-AES, isotope dilution mass spectrometry (ID-MS), graphite furnace
AAS (GF-AAS), and NAA.  Only ID-MS, NAA, and GF-AAS can determine vanadium concentrations at
levels of a few picograms (pg) of vanadium; GF-AAS and NAA are used most frequently (Kučera and
Sabbioni 1998; Nixon et al. 2002; Sabbioni et al. 1996).
Nixon et al. (2002) reported the use of a Dynamic Reaction CellTM ICP-MS (DRC-ICP-MS) for the
analysis of vanadium in serum and urine.  Generally, Zeeman graphite furnace atomic absorption 
spectrometry (ZGFAAS) and NAA are routinely used for the determination of vanadium in urine and 
serum.  While ICP-MS as been routinely used to determine heavy metal concentrations in blood, serum, 
   
 









    
 










   
 
     

















     




   





     
 
 
    













Blood/urine Digest sample and 
evaporate; redissolve 
in acid; extract with 
MIBK; evaporate;
redissolve in acid
NAA ~1 µg/L (blood);
2–4 µg/L (urine)
No data Allen and Steinnes
1978
Urine Wet ashing with HNO3; 
chelation with 






acid, and HCl; extract
with BTA in benzene
ETAAS 0.008 µg/L 90.3%
(serum);
90.8% (urine)
Ishida et al. 1989
Serum Coprecipitate sample 
with lead nitrate or




Blood Microwave digestion 
with HNO3 
ICP-MS 0.0078 µg/L No data Lin et al. 2004
Serum/urine Dilution with 1% HNO3 
and addition of internal
DRC-ICP-
MS
0.028 µg/L No data Nixon et al. 2002
standard
Hair Washing and drying of
hair samples, followed 
by cryogenic grinding;
powdered hair samples
prepared as slurries in 
mixtures of HNO3 and 
a slurry stabilizer
ETAAS 0.28–0.34 µg/L No data Fernandes et al.
2007
BTA = N-benzoyl-N-(o-tolyl)hydroxylamine; DRC-ICP-MS = Dynamic Reaction CellTM inductively coupled mass
spectrometry; MIBK = methyl isobutyl ketone; NAA = neutron activation analysis
   
 








      
  
     




   
   
  









    






     








and urine, and ICP-MS quantitation is at least an order of magnitude better than ZGFAAS for elements
such as arsenic, lead, selenium, and cadmium, interference from 16O35Cl+, which is produced in the argon 
plasma of the instrument, has limited the use of ICP-MS for the determination of vanadium.  In this study
it was found that with proper dynamic reaction cell conditions, OCl+ interference can be eliminated.  The 
detection limit for vanadium (0.028 µg/L) was also found to be superior to that of ZGFAAS (1.9 µg/L)
(Nixon et al. 2002).
Fernandes et al. (2007) reported on a method to analyze hair samples using ETAAS.  Samples were
powdered using cryogenic grinding and hair slurries contained nitric acid, Triton X-100 (a nonionic
surfactant), and water soluble tertiary amines.  Limits of detection of 0.28 and 0.34 µg/L were reported 
using longitudinal heating and transversal heating graphite furnace atomizers, respectively.
7.2  ENVIRONMENTAL SAMPLES 
Standard methods are available to measure vanadium concentrations in air, surfaces, water, soil, sediment,
and plant and animal tissue (EPA 1983a, 1983b, 1983c, 1994a, 1994b, 1997a, 2003a; NIOSH 2003a, 
2003b, 2003c, 2003d; OSHA 2002; USGS 1987, 1993, 1996, 1998, 2006, 2007).  Atomic spectroscopic
methods are generally used in these methods as well as ICP-MS and spectrophotometric methods. 
NIOSH Method 7504 (1994) and OSHA Method ID-185 (1991) can be used to measure vanadium oxides
in air samples using XRF.  Methods for determination of vanadium in environmental samples are
summarized in Table 7-2.
7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of vanadium is available. Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of vanadium.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
   
 



















































   
 
   
 
   
 
 
























Table 7-2. Analytical Methods for Determining Vanadium in Environmental  
Samples  
Sample 
Preparation Analytical detection Percent
Sample matrix method method limit recovery Reference
Vanadium














Wipes	 Wipe surface; ash ICP-AES
wipe with
HNO3/HClO4 
Air, wipe, or bulk	 Digestion of filters ICAP-AES
with HNO3/ 
H2SO4/H2O2 
Water	 Acid solubilization ICP-MS
Water	 Sample is mixed AVICP-AES
with HNO3/HCl 
and heated
Water	 Acidified with FAAS  
HNO3  
Water	 Acidified with GFAAS  
HNO3  
Water	 Filter and ICP-AES
acidified samples













98.3–103.2% NIOSH 2003a  




101.3– NIOSH 2003b  




No data	 NIOSH 2003c
(Method 7303)
No data	 NIOSH 2003d 
(Method 9102)
No data	 OSHA 2002 
(Method ID-125G)
97–109.2%	 EPA 1997a (EPA 
Method 200.10)
93%	 EPA 2003 (EPA 
Method 200.5)
95–100%	 EPA 1983a, 1983b 
(EPA Method 
286.1)
No data	 EPA 1983a, 1983c
(EPA Method 
286.2)
No data	 USGS 1987 (USGS 
Method I-1472-87)
64–105%	 USGS 1998 (USGS 
Method I-2477-92)
   
 






























   
 
 
   
 



















   
 
     
 






Table 7-2. Analytical Methods for Determining Vanadium in Environmental  
Samples  
Sample 
Preparation Analytical detection Percent
Sample matrix method method limit recovery Reference













Water Preserved with 
(unfiltered) HNO3 followed by
digestion
Water/waste Digestion with 
water/solid nitric and 
wastes hydrochloric acid
Water/wastes	 Digestion with 
nitric and 
hydrochloric acid
Water/waste Acid digestion  
water/solid  
wastes  
Soil/sediment	 Air-dried and 
sieved; digestion 





Animal tissue	 Acid digestion






















No data	 USGS 1993 (USGS 
Method I-2880)
98%	 USGS 1998 (USGS 
Method I-4471-97)
No data	 USGS 2006 (USGS 
Method I-2020-05)
No data	 USGS 2006 (USGS 
Method I-4020-05)
84–104%	 EPA 1994a (EPA 
Method 200.7)
74.9–113.4%	 EPA 1994b (EPA 
Method 200.8)
No data	 EPA 2007 (EPA 
Method 6010 C)
No data	 USGS 2006 (USGS 
Method I-5020-05)
101%	 USGS 1996 (USGS 
Method B-9001-95 
[ICP-MS])
96%	 USGS 1996 (USGS 
Method B-9001-95 
[ICP-AES])
   
 













































   
   
  
   
   
















Biota Digestion with 
HNO3 using a 
closed-vessel






Air Collect sample on
PVC filter,
dissolve filter in 
THF; redeposit on 
silver filter
XRD 4–28 µg 
(V2O5), 5– 
62 µg (V2O3), 
7–50.3 µg
(NH4VO3)
No data NIOSH 1994
(Method 7504)
Vanadium pentoxide
Air Collect sample on
PVC filter,
dissolve filter in 
THF; suspension 














AVICP-AES = axially viewed inductively coupled plasma-atomic emission spectrometry; EPA = Environmental
Protection Agency; FAAS = flame atomic absorption spectrometry; GFAAS : graphite furnace atomic absorption 
spectrometry; ICAP-AES = inductively coupled argon plasma-atomic emission spectroscopy; ICP-AES = inductively
coupled plasma-atomic emission spectroscopy; ICP-MS = inductively couples plasma-mass spectrometry;
ICP-OES = inductively coupled plasma-optical emission spectroscopy; MCE = mixed cellulose ester;
NIOSH = National Institute for Occupational Safety and Health; OSHA = Occupational Safety and Health 
Administration; PVC = polyvinyl chloride; THF = tetrahydrofuran; USGS = United States Geological Survey;


























that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.    Sensitive and selective 
methods are available for the detection and quantitative measurement of vanadium after the sample matrix 
in which it is contained as been properly treated.  Atomic spectroscopic methods used for the 
determination of vanadium include AAS with flame and graphite tube atomizers, ICP-OES, ICP-MS, 
XRF, and spectrophotometric methods (Chen and Owens 2008). No data needs are identified. 
Exposure. Methods exist to determine vanadium levels in environmental samples and human tissues.  
While several biomarkers of exposure have been indentified, none of them can be used to quantitatively
determine exposure levels (Rydzynski 2001).  Kučera et al. (1998) reported that blood and urinary
vanadium levels are considered the most reliable indicators of occupational exposure to vanadium.  No 
data needs are identified. 
Effect. No well-documented biomarkers of effect specific for vanadium have been report (Rydzynski 
2001). The primary effects of exposure to vanadium dusts are coughing, wheezing, and other respiratory
difficulties; however, these effects are not specific to vanadium and can be found following inhalation of 
many types of dusts (Rydzynski 2001). No data needs are identified.
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Methods for determining vanadium in water, air, and waste samples with adequate selectivity
and sensitivity are well developed and undergoing constant improvement.  No data needs are identified. 
7.3.2 Ongoing Studies 
No ongoing studies regarding methods for measuring vanadium in biological and environmental samples 
were located. 
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8. REGULATIONS, ADVISORIES, AND GUIDELINES  
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be of concern at hazardous waste sites. 
ATSDR has derived an acute-duration inhalation MRL of 0.0008 mg vanadium/m3 based on a LOAEL of 
0.56 mg vanadium/m3 for lung inflammation in rats exposed to vanadium pentoxide 6 hours/day, 
5 days/week for 13 days (NTP 2002).  The MRL was derived by dividing the human equivalent 
concentration of the LOAEL (0.073 mg vanadium/m3) by an uncertainty factor of 90 (3 for use of a 
minimal LOAEL, 3 for animal to human extrapolation with dosimetric adjustments, and 10 for human 
variability). 
ATSDR has derived a chronic-duration inhalation MRL of 0.0001 mg vanadium/m3 based on a BMCL10 
of 0.04 mg vanadium/m3 for degeneration of epiglottis respiratory epithelium of rats exposed to vanadium
pentoxide 6 hours/day, 5 days/week for 2 years (NTP 2002).  The MRL was derived by dividing the 
human equivalent concentration of the BMCL10 (0.003 mg vanadium/m3) by an uncertainty factor of 30 
(3 for animal to human extrapolation with dosimetric adjustments and 10 for human variability). 
ATSDR has derived an intermediate-duration oral MRL of 0.01 mg vanadium/kg/day based on a NOAEL 
of 0.12 mg vanadium/kg/day for hematological and blood pressure effects in humans exposed to vanadyl 
sulfate for 12 weeks (Fawcett et al. 1997) and an uncertainty factor of 10 for human variability.
IRIS (2012) has derived an oral reference dose (RfD) of 0.009 mg/kg/day for vanadium pentoxide based 
on a NOAEL of 0.89 mg/kg/day for decreased hair cysteine levels in rats exposed to vanadium pentoxide 
for 2.5 years (Stokinger et al. 1953) and an uncertainty factor of 100 (10 for extrapolation from animals to 
humans and 10 to protect against unusually susceptible individuals). 
EPA has not derived an inhalation reference concentration (RfC) for vanadium and vanadium compounds. 
Vanadium pentoxide, vanadyl sulfate dehydrate, and ammonium metavanadate are on the list of 
chemicals appearing in “Toxic Chemicals Subject to Section 313 of the Emergency Planning and 
Community Right-to-Know Act of 1986" and have been assigned a reportable quantity (RQ) limit of 















8. REGULATIONS AND ADVISORIES
substance (EPA 2011c).  The RQ represents the amount of a designated hazardous substance which, when 
released to the environment, must be reported to the appropriate authority.
The international and national regulations, advisories, and guidelines regarding vanadium and compounds 
in air, water, and other media are summarized in Table 8-1.  
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8.  REGULATIONS AND ADVISORIES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Vanadium and  
Compounds  
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification IARC 2009
Vanadium pentoxide Group 2Ba 
WHO Air quality guidelines WHO 2000
Vanadium
TWA based on effects other than 
cancer or odor/annoyance using 
an averaging time of 24 hours
1 µg/m3 





ACGIH TLV (8-hour TWA)b 
Vanadium pentoxide (respirable 
fraction of dust or fume, as V2O5)
0.05 mg/m3 
ACGIH 2008
TLV Basis Irritation and lung
AIHA ERPG values No AIHA 2008
EPA Second AEGL chemical priority list
Vanadium and compounds Yesc 
EPA 2012
Hazardous air pollutant No EPA 2010
42 USC 7412
NIOSH REL (15-minute ceiling)
Vanadium compoundsa 0.05 mg/m3 
NIOSH 2012
REL (TWA)
Vanadium metal and vanadium
carbide
1 mg/m3 
IDLH 35 mg/m3 
Target organ Eyes, skin, and 
respiratory system
OSHA PEL (ceiling limit) for general industry
Vanadium pentoxide



















     
   
   
    
   
 
 







   
   
    
  
   
    
   




    






8. REGULATIONS AND ADVISORIES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to Vanadium and  
Compounds  
Agency Description Information Reference 
NATIONAL (cont.)
b. Water 
EPA Designated as hazardous substances
in accordance with Section 311(b)(2)(A) 
of the Clean Water Act 
 EPA 2011f 
40 CFR 116.4 
Vanadium pentoxide Yes 
Vanadyl sulfate dehydrate Yes 
Drinking water contaminant candidate 
list 
 EPA 1998b 
63 FR 10274
Vanadium Yes 
EPA Drinking water standards and health 
advisories 
No EPA 2006a 
National primary drinking water 
standards
No EPA 2003b 
National recommended water quality 
criteria 
No EPA 2006b 
Reportable quantities of hazardous 
substances designated pursuant to
Section 311 of the Clean Water Act
 EPA 2011a 
40 CFR 117.3 
Vanadium pentoxide 1,000 pounds 
Vanadyl sulfate dehydrate 1,000 pounds 
c. Food
 FDA EAFUSe No FDA 2008 
d. Other 
 ACGIH Carcinogenicity classification A4f ACGIH 2008
Biological exposure indices (end of shift
at end of workweek) 
Vanadium in urine 50 µg/g creatinine
EPA Carcinogenicity classification No IRIS 2012 
RfC No
 RfD
Vanadium pentoxide 9x10-3 mg/kg/day 
Superfund, emergency planning, and 
community right-to-know 
Designated CERCLA hazardous 
substance and their reportable 
quantities 
  Vanadiu m pentoxideg
  Vanadyl sulfateh
  Vanadi c acid, ammonium salti
 1,000 pounds 
 1,000 pounds 
 1,000 pounds 
 EPA 2011b 













     
  
 
   
  
 
    
 
 
   
  
  




















8. REGULATIONS AND ADVISORIES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to Vanadium and  
Compounds  
Agency Description Information Reference 
NATIONAL (cont.)
Effective date of toxic chemical  EPA 2011d 
release reporting 40 CFR 372.65
  Vanadiu m (except when 01/01/2000
contained in an alloy) 
Extremely hazardous substance and  EPA 2011c 
its threshold planning quantity 40 CFR 355,
  Vanadiu m pentoxide 100/10,000 pounds Appendix A
TSCA chemical lists and reporting  EPA 2011e 
periods 40 CFR 712.30
Vanadium, vanadium pentoxide, 
vanadyl sulfate pentahydrate, 
sodium metavanadate, sodium 
orthovanadate, and ammonium 
metavanadate 
  Effective date 07/11/2003
  Rep orting date 09/09/2003
DHHS Carcinogenicity classification No data NTP 2011
IOM Upper Tolerable Limit 1.8 mg/day IOM 2001
aGroup 2B: possibly carcinogenic to humans  
bVanadium peroxide is included in the 2008 Notice of Intended Changes in which the substance and its  
corresponding values and notations for which the withdrawal of the Documentation and adopted TLV are proposed.  
cVanadium and compounds are included on the list of 371 priority chemicals that are acutely toxic and represent the  
selection of chemicals for AEGL development by the NAC/AEGL committee during the next several years.  
dThe REL applies to all vanadium compounds except vanadium metal and vanadium carbide.  
eThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food  
additives or listed or affirmed as GRAS.   
fA4:  not classifiable as a human carcinogen  
gDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) of the Clean Water Act and Section 3001  
of the Resource Conservation and Recovery Act.  
hDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) of the Clean Water Act.  
iDesignated CERCLA hazardous substance pursuant to Section 3001 of the Resource Conservation and Recovery  
Act.  
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;  
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response,  
Compensation, and Liability Act; CFR = Code of Federal Regulations; DHHS = Department of Health and Human  
Services; EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency;  
ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; FR = Federal Register;  
GRAS = Generally Recognized As Safe; IARC = International Agency for Research on Cancer; IDLH = immediately  
dangerous to life or health; IRIS = Integrated Risk Information System; IOM = Institute of Medicine; NAC = National  
Advisory Council; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology  
Program; OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit;  
REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose;  
TLV = threshold limit values; TSCA = Toxic Substances Control Act; TWA = time-weighted average; USC = United  
States Code; WHO = World Health Organization  
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VANADIUM 195
10.  GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response
relationship where biologically observable data are feasible.   
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.













   
 
 
      




   
     
 
   
 
 
   












   
    
      
 
   
 
 
    
   
   
 
    
  
 









Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.













   
 
 
   
 
 




      
 
 
    
 
 
    
  
 
     
 
 
















   
   









Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total
number of individuals in that population who could have developed that condition in a specified time
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study,
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors.  The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
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10.  GLOSSARY
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a










      
  
    
 
 
    
 
 
     
 
   
  
      
  
 





   
    




       
 
     
    
    
 
 
   
 




   
     
 




     
   
    
 
   
VANADIUM 199
10.  GLOSSARY
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.






























    
 
 








     
 
   
 
  
    
    
    
  
   
    






Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or
inherited characteristic that is associated with an increased occurrence of disease or other health-related
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.














    
  
 
    
   
 
  
   
    
   
  
    
    





   
     
   
    
 
   




     
  
VANADIUM A-1
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach. They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently,
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that










    
  
   
  
   
    
  
    
   
 
   
   
  
     
    






are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences (proposed), expert panel peer reviews, and agency-
wide MRL Workgroup reviews, with participation from other federal agencies and comments from the
public. They are subject to change as new information becomes available concomitant with updating the 
toxicological profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously
published levels.  For additional information regarding MRLs, please contact the Division of Toxicology
and Human Health Sciences (proposed), Agency for Toxic Substances and Disease Registry, 1600 Clifton 
Road NE, Mailstop F-62, Atlanta, Georgia 30333.
 














   
   
  











   
   
  




       
      
      
   
     
   




   
  
 
    
 
   
  
  
   
    
     
    
    
      
    
   
VANADIUM A-3
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Vanadium compounds
CAS Numbers: 7440-62-2
Date: July 2012
Profile Status: Post-Public Comment, Third Draft
Route: [X] Inhalation   [ ] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 4
Species: Rat
Minimal Risk Level:  0.0008  [ ] mg/kg/day   [X] mg vanadium/m3 
Reference:  NTP.  2002.  NTP toxicology and carcinogenesis studies of vanadium pentoxide (CAS No. 
1314-62-1) in F344/N rats and B6C3F1 mice (inhalation).  Natl Toxicol Program Tech Rep Ser (507):1-
343.
Experimental design:  Groups of 40–60 female F344 rats were exposed to 0, 1, 2, or 4 mg vanadium
pentoxide/m3 (0, 0.56, 1.1, and 2.2 mg vanadium/m3) 6 hours/day, 5 days/week for 16 days.  On days 6 
and 13, 10 rats/group were killed and a histopathological examination of the lungs was conducted.  Four
animals per group were killed for examination of onset and extent of lung lesions on days 1, 2, 5, 10, and 
16. The remaining animals were used to measure blood and lung concentrations of vanadium, lung
clearance half-times, and cell proliferation rates.
Effect noted in study and corresponding doses:  Hyperplasia of alveolar epithelium and bronchiole
epithelium were observed in 100% of the female rats exposed to 1.1 or 2.2 mg vanadium/m3 for 6 or
13 days.  Significant increases in the incidence of histiocytic infiltrate and inflammation were observed in 
rats exposed to 1.1 or 2.2 mg vanadium/m3 for 6 or 13 days and in rats exposed to 0.56 mg vanadium/m3 
for 13 days.  A significant increase in fibrosis was observed in rats exposed to 2.2 mg vanadium/m3 for 
13 days.  No histopathological alterations were observed in the four female rats killed after 1 day of
exposure; by day 2, inflammation and histiocytic infiltrates (increased number of alveolar macrophages)
were observed in the rats exposed to 2.2 mg vanadium/m3. Hyperplasia of the alveolar and bronchiolar
epidthelium was first observed on day 5 in rats exposed to 1.1 or 2.2 mg vanadium/m3. 
Dose and end point used for MRL derivation:  Increase in the incidence of lung inflammation in rats
exposed to 0.56 mg vanadium/m3 as vanadium pentoxide for 13 days; the human equivalent concentration 
of this LOAEL (LOAELHEC) is 0.073 mg vanadium/m3.
[ ] NOAEL [X] LOAEL
A BMD analysis was considered for determining the point of departure for the inflammation in female 
rats exposed to vanadium pentoxide for 13 days.  All available dichotomous models in the EPA
benchmark dose software ([BMDS] version 2.1) were fit to the incidence data for lung inflammation 
(0/10, 8/10, 10/10, and 10/10 in rats exposed to 0, 0.56, 1.1, or 2.2 mg vanadium/m3) using the extra risk
option. The multistage model was run for all polynomial degrees up to n-1 (where n is the number of
dose groups including control). Adequate model fit is judged by three criteria: goodness-of-fit p-value 
(p>0.1), visual inspection of the dose-response curve, and scaled residual at the data point (except the 
control) closest to the predefined benchmark response (BMR). Among all the models providing adequate
fit to the data, the lowest lower bound on the BMC (BMCL) is selected as the point of departure when the
difference between the BMDLs estimated from these models are more than three-fold; otherwise, the 
BMCL from the model with the lowest AIC is chosen. In accordance with U.S. EPA (2000) guidance, 
























     
     
     
     
     
     
     












benchmark concentrations (BMCs) and BMCLs associated with an extra risk of 10% are calculated for all
models.
Table A-1.  Model Predictions for the Incidence of Inflammation in Female Rats  














Logistic 1.00 14.01 0.46 0.10











Probit 1.00 14.01 0.38 0.09
Weibullb 1.00 14.01 0.25 0.02
Quantal-linear 0.93 12.69 0.03 0.02
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bPower restricted to ≥1 
cBetas restricted to ≥0; 1-degree polynomial
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the concentration associated with the 
selected benchmark response; BMCL = 95% lower confidence limit on the BMC
Source:  NTP 2002 



















     
  
   
     
    
   







    
   
VANADIUM A-5
APPENDIX A
Figure A-1.  Fit of Gamma Model to Data on the Incidence of Inflammation in  
Female Rats Exposed to Vanadium Pentoxide for 13 Days  


















0 0.5 1 1.5 2 
dose 
22:23 05/24 2009 
BMCs and BMCLs indicated are associated with an extra risk of 10%, and are in units of mg vanadium/m3
Source:  NTP 2002
Although the data provide an adequate statistical fit, the estimated BMCL10 of 0.02 mg vanadium/m3 
appears to be an overly conservative estimate of a no-adverse-effect level, which may be a reflection of
the limited amount of information from the study on the shape of the exposure-response relationship 
(incidences of lung inflammation were 0/10 in controls and 8/10 at the lowest vanadium concentration).  
In a chronic-duration study conducted by NTP (2002), no significant alterations in the incidence of lung
inflammation were observed in male and female rats exposed to 0.28 mg vanadium/m3; the LOAEL for
lung inflammation was 0.56 mg vanadium/m3 in males and 1.1 mg vanadium/m3 in females.
Due to the low confidence in the BMCL10, a NOAEL/LOAEL approach was used to determine the point
of departure for the acute MRL.
Uncertainty Factors used in MRL derivation:
[X]  3 for use of a minimal LOAEL
[X]  3 for extrapol











   
 




    
  
 
   
    




     
  
   
  
 
     
  
 
    
      
    
 
      
  
  
     
     
       
   
   
    
   
    
    
   
   
 
   
VANADIUM A-6
APPENDIX A
0.ation from animals to humans with dosimetric adjustment
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
The duration-adjusted LOAEL of 0.1 mg vanadium/m3 was converted to a human equivalent
concentration (LOAELHEC) using the following equation:
LOAELHEC = LOAELADJ x RDDRTH  
LOAELHEC = 0.1 mg vanadium/m3 x 0.732  
LOAELHEC = 0.073 mg vanadium/m3  
where:
The RDDR is a multiplicative factor used to adjust an observed inhalation particulate exposure
concentration of an animal to the predicted inhalation particulate exposure concentration for a human.  
The RDDR program (EPA 1990) was used to calculate a multiplier of 0.732 for the thoracic region was
determined using a default body weight of 0.124 kg (EPA 1994c) and a particle size MMAD of 1.2 µm
with a geometric standard deviation of 1.9
Was a conversion used from intermittent to continuous exposure? The LOAEL was adjusted for
intermittent exposure as follows:
LOAELADJ = LOAEL x 6 hours/day x 5 days/week
LOAELADJ = 0.56 mg vanadium/m3 x 6 hours/24 hours x 5 days/7 days
LOAELADJ = 0.1 mg vanadium/m3 
Other additional studies or pertinent information that lend support to this MRL:  Data on acute toxicity of
vanadium in humans are limited to an experimental study in which a small number of subjects were 
exposed to vanadium pentoxide dust for 8 hours (Zenz and Berg 1967).  A persistent cough lasting for
8 days developed in two subjects exposed to 0.6 mg vanadium/m3; at 0.1 mg vanadium/m3, a productive
cough without any subjective complaints or impact on work or home activities were observed in
5 subjects. The available studies in laboratory animals focused on potential respiratory tract effects.
Impaired lung function characterized as airway obstructive changes (increased resistance and decreased
airflow) were observed in monkeys exposed to 2.5 or 1.7 mg vanadium/m3 as vanadium pentoxide for
6 hours (Knecht et al. 1985, 1992); the highest NOAEL for this effect was 0.34 mg vanadium/m3. 
Alveolar and bronchiolar epithelial hyperplasia and inflammation were observed in the lungs of mice 
exposed to 1.1 mg vanadium/m3 6 hours/day, 5 days/week for 13 days (NTP 2002).  Although the Knecht
et al. (1985, 1992) or NTP (2002) studies did not include examination of potential end points outside of
the respiratory tract, longer-duration studies have identified the respiratory tract as the most sensitive 
target of toxicity (NTP 2002). 
Agency Contacts (Chemical Managers): Jessilynn Taylor, Sam Keith, Larry Cseh
  


































   
 
   
   
 
  
   
    
  
  
    
  
   
  
     
    
  
  
    
    
     
     
 
    
    
VANADIUM A-7
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Vanadium compounds
CAS Numbers: 7440-62-2
Date: July 2012
Profile Status: Post-Public Comment, Third Draft
Route: [X] Inhalation   [ ] Oral
Duration: [ ] Acute   [ ] Intermediate  [X] Chronic
Graph Key: 19
Species: Rat
Minimal Risk Level:  0.0001  [ ] mg/kg/day  [X] mg vanadium/m3 
Reference:  NTP.  2002.  NTP toxicology and carcinogenesis studies of vanadium pentoxide (CAS No. 
1314-62-1) in F344/N rats and B6C3F1 mice (inhalation).  Natl Toxicol Program Tech Rep Ser (507):1-
343.
Experimental design:  Groups of 50 male and 50 female F344 rats were exposed to 0, 0.5, 1, or 2 mg
vanadium pentoxide/m3 (0, 0.28, 0.56, and 1.1 mg vanadium/m3) 6 hours/day, 5 days/week for 104 weeks.  
The following parameters were used to assess toxicity:  clinical observations, body weights (every 
4 weeks from week 5 to 89 and every 2 weeks from week 92 to 104), complete necropsy, and microscopic
examination of major tissues and organs.
Effect noted in study and corresponding doses:  No significant alterations in survival or body weight gain 
were observed in the vanadium-exposed rats.  A summary of selected non-neoplastic respiratory tract 
lesions is presented in Table A-2.  Alveolar histiocytic infiltrates were observed in males and females 
exposed to ≥0.28 mg vanadium/m3.  Significant increases in the incidence of hyperplasia of the alveolar
and bronchiolar epithelium were observed in males exposed to ≥0.28 mg vanadium/m3 and females 
exposed to ≥0.56 mg vanadium/m3.  Squamous metaplasia was observed in alveolar epithelium of males 
and females exposed to 1.1 mg vanadium/m3 and in the bronchiolar epithelium of males exposed to 
1.1 mg vanadium/m3. Chronic inflammation was observed in males exposed to 0.56 or 1.1 mg
vanadium/m3 and females exposed to 1.1 mg vanadium/m3 and interstitial fibrosis was observed in males 
exposed to 1.1 mg vanadium/m3 and females exposed to 0.28 or 1.1 mg vanadium/m3. An increased 
incidence of brownish pigment in alveolar macrophages was observed in males exposed to 1.1 mg
vanadium/m3 and females exposed to 0.56 or 1.1 mg vanadium/m3; this effect was considered to be of
little biological relevance. Chronic inflammation, degeneration, and hyperplasia of the epiglottis were 
observed in the larynx of males and females exposed to ≥0.28 mg vanadium/m3; squamous metaplasia of
the epiglottis respiratory epithelium was also observed in males exposed to ≥0.28 mg vanadium/m3 and in 
females exposed to 1.1 mg vanadium/m3. Goblet cell hyperplasia of the nasal respiratory epithelium was
observed in males exposed to ≥0.28 mg vanadium/m3 and in females exposed to 1.1 mg vanadium/m3.  A 
positive trend for increased incidences of uterine stromal polyp was observed; NTP did not consider it to 
be related to vanadium pentoxide exposure.  An increased incidence of nephropathy was observed in male 
rats exposed to 0.56 or 1.1 mg vanadium/m3; NTP considered the finding to be of marginal biological
significance because there was a lack of increase in severity, as compared to controls, and significant
findings in female rats.  No significant increases in the incidence of lung neoplasms were observed;
however, the incidence of alveolar/bronchiolar adenoma in males exposed to 0.28 mg vanadium/m3 and 
alveolar/bronchiolar carcinoma or combined incidence of adenoma and carcinoma in males exposed to
0.28 or 1.1 mg vanadium/m3 were higher than historical controls. These increases in lung tumors were 
considered to be related to vanadium pentoxide exposure. 













     
     
      
           
          
         
         
          
      
          
   
 
       
   
 
       
    
 
       
      
   
 
       
     
      
          
         
        
        
          
      
          
   
 
       
    
 
       
    
 
     
      
   
 
     
 







Table A-2.  Selected Respiratory Tract Effects Observed in Rats Exposed to  
Vanadium Pentoxide 6 Hours/Day, 5 Days/Week for 2 Years  
Air concentration (mg vanadium/m3) 0 0.28 0.56 1.1
Males
Lungs
Alveolar hyperplasia 7/50 (2.3) 24/49b (2.0) 34/48b (2.0) 49/50b (3.3)
Bronchiole hyperplasia 3/50 (2.3) 17/49b (2.2) 31/48b (1.8) 49/50b (3.3)
Inflammation 5/50 (1.6) 8/49 (1.8) 24/48b (1.3) 42/50b (2.4)
Fibrosis 7/50 (1.4) 7/49 (2.0) 16/48c (1.6) 38/50b (2.1)
Histiocyte infiltration 22/50 (1.3) 40/49b (2.0) 45/48b (2.3) 50/50b (3.3)
Larynx
Chronic inflammation 3/49 (1.0) 20/50b (1.1) 17/50b (1.5) 28/49b (1.6)
Degeneration of epiglottis respiratory 0/49 22/50b (1.1) 23/50b (1.1) 33/50b (1.5)
epithelium
Hyperplasia of epiglottis respiratory 0/49 22/50b (1.1) 23/50b (1.1) 33/49b (1.5)
epithelium
Squamous metaplasia of epiglottis 0/49 18/50b (1.5) 34/50b (1.5) 32/49b (1.9)
respiratory epithelium
Nose




Alveolar hyperplasia 4/49 (1.0) 8/49 (1.8) 21/50b (1.2) 50/50b (3.1)
Bronchiole hyperplasia 6/49 (1.5) 5/49 (1.6) 14/50c (1.3) 48/50b (3.0)
Inflammation 10/49 (1.5) 10/49 (1.1) 14/50 (1.2) 40/50c (1.7)
Fibrosis 19/49 (1.4) 7/49 (1.3) 12/50 (1.6) 32/50b (1.4)
Histiocyte infiltration 26/49 (1.4) 35/49c (1.3) 44/50b (2.0) 50/50b (1.9)
Larynx
Chronic inflammation 8/50 (1.8) 26/49b (1.5) 27/49b (1.3) 37/50b (1.4)
Degeneration of epiglottis respiratory 2/50 (1.0) 33/49b (1.2) 26/49b (1.2) 40/50b (1.5)
epithelium
Hyperplasia of epiglottis respiratory 0/50 25/49b (1.4) 26/49b (1.3) 33/50b (1.5)
epithelium
Squamous metaplasia of epiglottis 2/50 (2.0) 7/49 (1.9) 7/40 (1/7) 16/50b (1.4)
respiratory epithelium
Nose
Hyperplasia of respiratory epithelium 13/50 (2.0) 18/50 (2.0) 16/50 (1.9) 30/50b (2.0)
goblet cell
aAverage severity grade of lesions in affected animals: 1=minimal; 2=mild, 3=moderate; 4=marked
bp≤0.01
cp≤0.05
Source:  NTP 2002











    
    






     
    
    
    
      
    
  
         
     
    
   
  
 
     
 
 










      
      
      
      
      
      
      
      
      
     
      
      
      
      
      
      
      
      
VANADIUM A-9
APPENDIX A
Dose and end point used for MRL derivation: The human equivalent concentration of the BMCL10 for 
degeneration of respiratory epithelium of the epiglottis, 0.003 mg vanadium/m3, was used as the point of
departure for the chronic-duration inhalation MRL.
[ ] NOAEL   [ ] LOAEL   [X] BMCL10 
BMD analysis was used to determine the point of departure for select respiratory tract lesions in rats 
exposed to vanadium pentoxide for 2 years.  A number of lesions were observed in male and female rats 
exposed to 0.28 mg vanadium/m3 including hyperplasia of the alveolar and bronchiolar epithelium, 
chronic inflammation of the larynx, degeneration of the epiglottis, and hyperplasia of respiratory
epithelial goblet cells. The incidence of these lesions in male rats were modeled using all available 
dichotomous models in the EPA BMDS (version 2.1) that were fit to the incidence data for alveolar
hyperplasia, bronchial hyperplasia, using the extra risk option. The multistage model was run for all
polynomial degrees up to n-1 (where n is the number of dose groups including control). Adequate model
fit is judged by three criteria: goodness-of-fit p-value (p>0.1), visual inspection of the dose-response 
curve, and scaled residual at the data point (except the control) closest to the predefined BMR. Among all
the models providing adequate fit to the data, the lowest BMCL is selected as the point of departure when 
the difference between the BMCLs estimated from these models are more three-fold; otherwise, the
BMCL from the model with the lowest AIC is chosen. In accordance with U.S. EPA (2000) guidance, 
BMCs and BMCLs associated with an extra risk of 10% are calculated for all models.
The results of the BMD analyses are presented in Table A-3 and Figures A-2 through A-6.
Table A-3.  Model Predictions for Respiratory Effects in Rats Exposed to  
Vanadium Pentoxide for 2 Years  
Model
χ2 Goodness





Alveolar hyperplasia in male rats
Gammab 0.25 183.50 0.12 0.04
Logistic 0.52 181.44 0.11 0.09
Log-Logistic 0.08 185.40 NA NA
Log-Probit 0.13 184.60 0.15 0.08
Multistagec 0.21 184.00 0.05 0.04
Probit 0.57 181.29 0.10 0.09
Weibullb 0.33 183.11 0.10 0.05
Quantal-Linear 0.21 184.00 0.05 0.04
Bronchiolar hyperplasia in male rats
Gammab 0.28 165.38 0.17 0.10
Logistic 0.60 163.19 0.15 0.12
Log-Logistic 0.08 167.58 NA NA
Log-Probit 0.12 166.67 0.19 0.13
Multistagec 0.56 164.51 0.13 0.07
Probit 0.71 162.87 0.14 0.12
Weibullb 0.45 164.73 0.15 0.09
Quantal-linear 0.03 170.74





















    
      
      
      
      
      
      
      
      
  
      
      
      
      
      
      
      
      
   
      
      
      
      
      
      
      
      
 











Table A-3.  Model Predictions for Respiratory Effects in Rats Exposed to  
Vanadium Pentoxide for 2 Years  
Model
χ2 Goodness





Chronic inflammation in larynx of male rats
Gammab 0.04 230.93 NA NA
Logistic 0.01 235.47 NA NA
Log-Logistic 0.11 229.28 0.10 0.07
Log-Probit 0.00 235.73 NA NA
Multistagec 0.04 230.93 NA NA
Probit 0.01 235.09 NA NA
Weibullb 0.04 230.93 NA NA
Quantal-linear 0.04 230.93 NA NA
Degeneration of epiglottis respiratory epithelium in male rats
Gammab 0.06 210.55 NA NA
Logistic 0.00 230.64 NA NA
Log-Logistic 0.47 206.17 0.06 0.04
Log-Probit 0.01 214.79 NA NA
Multistagec 0.06 210.55 NA NA
Probit 0.00 229.81 NA NA
Weibullb 0.06 210.55 NA NA
Quantal-linear 0.06 210.55 NA NA
Hyperplasia of nasal respiratory epithelial goblet cells in male rats
Gammab 0.12 213.84 0.32 0.20
Logistic 0.07 215.11 NA NA
Log-Logistic 0.15 213.35 0.27 0.16
Log-Probit 0.03 216.79 NA NA
Multistagec 0.12 213.84 0.32 0.20
Probit 0.07 214.97 NA NA
Weibullb 0.12 213.84 0.32 0.20
Quantal-linear 0.12 213.84 0.32 0.20
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bPower restricted to ≥1 
cBetas restricted to ≥0; 1-degree polynomial
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the dose/concentration associated with 
the selected benchmark response; BMDL = 95% lower confidence limit on the BMD; NA = not applicable
Source:  NTP 2002



















Figure A-2.  Fit of Probit Model to Data on the Incidence of Alveolar Hyperplasia in 
Male Rats Exposed to Vanadium Pentoxide for 2 Years
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Figure A-3.  Fit of Probit Model to Data on the Incidence of Bronchiolar  
Hyperplasia in Male Rats Exposed to Vanadium Pentoxide for 2 Years  
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Figure A-4.  Fit of Log-logistic Model to Data on the Incidence  
Chronic Inflammation in Larynx of Male Rats Exposed to
Vanadium Pentoxide for 2 Years  
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Figure A-5.  Fit of Log-logistic Model to Data on the Incidence of Degeneration of  
Epiglottis Respiratory Epithelium in Male Rats Exposed to Vanadium  
Pentoxide for 2 Years  
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VANADIUM A-15
APPENDIX A
Figure A-6.  Fit of Log-logistic Model to Data on the Incidence of Hyperplasia of  
Nasal Respiratory Epithelial Goblet Cells in Male Rats Exposed to Vanadium  
Pentoxide for 2 Years  
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Source:  NTP 2002
In summary, the lowest BMCL10 values for alveolar epithelial hyperplasia, bronchiolar epithelial
hyperplasia, laryngeal chronic inflammation, degeneration of epiglottis epithelium, and hyperplasia of
nasal goblet cells were 0.09, 0.10, 0.07, 0.04, 0.16 mg vanadium/m3, respectively.
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  3 for extrapolation from animals to humans with dosimetric adjustments
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
Human equivalent concentrations were calculated for each BMCL10 using the following equation:
BMCLHEC = BMCLADJ x RDDR 











   
    
 
   















    
 
    
 
 
    
 
 
    
 
 
    
 









       
   
 
     
 
   
     
 
    
    
  
 
    
  
 




The RDDR is a multiplicative factor used to adjust an observed inhalation particulate exposure
concentration of an animal to the predicted inhalation particulate exposure concentration for a human.  
The RDDR program (EPA 1994c) was used to calculate a multiplier for the different regions of the 
respiratory tract was determined using a default body weight of 0.380 kg (EPA 1994c) and a particle size
MMAD of 1.2 µm with a geometric standard deviation of 1.9.  The BMDLHEC values are presented in
Table A-4
Table A-4.  Summary of Human Equivalent Concentrations of BMCL Values for
Rats Exposed to Vanadium Pentoxide for 2 Years
BMCL10 BMCLADJ a BMCLHEC
Effect (mg vanadium/m3) (mg vanadium/m3) RDDR (mg vanadium/m3) 
Alveolar epithelial 0.09 0.016 0.502b 0.008
hyperplasia
Bronchiolar epithelial 0.10 0.018 0.971c 0.017
hyperplasia
Laryngeal chronic 0.07 0.012 0.423d 0.005
inflammation
Degeneration of epiglottis 0.04 0.0071 0.423d 0.003
epithelium
Hyperplasia of nasal 0.16 0.029 0.423d 0.012
goblet cells




BMCL = benchmark concentration, lower confidence limit RDDR = regional deposited dose ratio
Source:  NTP 2002
Was a conversion used from intermittent to continuous exposure? The BMCL10 was adjusted for
intermittent exposure, as noted in Table A-4.
Other additional studies or pertinent information that lend support to this MRL: An increased combined 
incidence of alveolar/bronchiolar adenoma or carcinoma was observed in male rats (NTP 2002).  
Although the incidence was not significantly higher than concurrent controls, it was higher than historical
controls and NTP considered it to be a vanadium-related effect.
In mice exposed to ≥0.56 mg vanadium/m3 for 6 hours/day, 5 days/week for 2 years, significant increases 
in the incidence of alveolar and bronchiolar hyperplasia, chronic lung inflammation, squamous metaplasia
of the respiratory epithelium of the epiglottis, goblet cell hyperplasia in the nasal respiratory epithelium
and nasal olfactory epithelial atrophy, and hyaline degeneration were observed (NTP 2002).  In addition 
to these effects, a significant increase in alveolar/bronchiolar carcinoma incidence was also observed in
mice exposed to ≥0.56 mg vanadium/m3.
Agency Contacts (Chemical Managers): Jessilynn Taylor, Sam Keith, Larry Cseh





















    
 





















   
     
   
 




    
 
      
   
  
  
   
VANADIUM A-17
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Vanadium compounds
CAS Numbers: 7440-62-6
Date: July 2012
Profile Status: Post-Public Comment, Third Draft
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute [X] Intermediate   [ ] Chronic
Graph Key: 12
Species: Human
Minimal Risk Level:  0.01   [X] mg vanadium/kg/day   [ ] mg vanadium/m3 
Reference:  Fawcett JP, Farquhar SJ, Thou T, et al.  1997.  Oral vanadyl sulphate does not affect blood 
cells, viscosity or biochemistry in humans.  Pharmacol Toxicol 80:202-206.
Experimental design:  Groups of men and women enrolled in a weight training program for at least 1 year
were administered capsules containing 0 (11 men and 4 women) or 0.5 mg/kg/day vanadyl sulfate
trihydrate (0.12 mg vanadium/kg/day) (12 men and 4 women) for 12 weeks.  Fasting blood samples were
collected at 0 and 12 weeks and analyzed for hematological (erthyroctye count, hemoglobin, hematocrit, 
mean cell volume, mean cell hemoglobin, platelet count, and total and differential leukocyte count) and 
serum chemistry (cholesterol, high density lipoprotein, triglycerides, albumin, total protein, total and 
direct bilirubin, alkaline phosphatase, ALT) parameters.  Body weight and blood pressure were measured
at weeks 4, 8, and 12.
Effect noted in study and corresponding doses:  No significant alterations in blood pressure, body weight, 
or hematological or clinical chemistry parameters were found.
Dose and end point used for MRL derivation:  NOAEL of 0.12 mg vanadium/kg/day for hematological
alterations and blood pressure.
[X] NOAEL   [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[ ] 10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: Dimond et al. (1963)
also examined healthy adults (one male and five females) administered an average daily dose of 0.19 mg
vanadium/kg/day as ammonium vanadyl tartrate for 45–68 days and found no significant alterations in 
hematological or serum clinical chemistry parameters.  Several studies have reported gastrointestinal
effects in noninsulin-dependent diabetics that persisted for >2 weeks (Afkhami-Ardekani et al. 2008;










        
  
   
 
 
   
   
   
   
   
 
   
   
    
 






   
VANADIUM A-18
APPENDIX A
Goldfine et al. 2000).  The signs of gastrointestinal irritation were likely due to local irritation rather than
a systemic effect and were observed at 31.3 mg vanadium (administered 3 times/day); no effects were 
observed at 7.8 mg vanadium (Goldfine et al. 2000).
Studies in laboratory animals have identified several sensitive effects including alterations in erythrocyte 
and reticulocyte levels, increased blood pressure, neurobehavioral alterations, and developmental toxicity. 
Significant increases in blood pressure have been observed in rats exposed to 0.12 mg vanadium/kg/day
for 210 days (Boscolo et al. 1994); increases in blood pressure have been observed at higher doses in
several other studies by these investigators (Carmagnani et al. 1991, 1992).  In general, other studies have
not found increases in blood pressure in rats exposed to doses as high as 31 mg vanadium/kg/day
(Bursztyn and Mekler 1993; Sušić and Kentera 1986, 1988).  Decreases in erythrocyte levels have been
observed in rats exposed to 1.18 mg vanadium/kg/day as ammonium metavanadate in drinking water for
4 weeks (Zaporowska et al. 1993); at higher concentrations, decreases in hemoglobin and increases in
reticulocyte levels have been observed (Ścibior 2005; Ścibior et al. 2006; Zaporowska and Wasilewski
1990, 1991, 1992a, 1992b; Zaporowska et al. 1993).  Decreases in pup body weight and length have been 
observed in the offspring of rats administered 2.1 mg vanadium/kg/day as sodium metavanadate for
14 days prior to mating and throughout gestation and lactation (Domingo et al. 1986).  At higher doses (6, 
10, or 12 mg vanadium/kg/day), decreases in pup survival, and increases in the occurrence of gross, 
visceral, or skeletal malformations and anomalies were observed (Elfant and Keen 1987; Morgan and El-
Tawil 2003; Poggioli et al. 2001).  
Agency Contacts (Chemical Managers): Jessilynn Taylor, Sam Keith, Larry Cseh
















        
    
   
  
 
      
      






   
 
   
 
    
 
     
 
    
 
 
   
 
  
   
  
 
     
  








   
     
   
    
 
VANADIUM	 B-1
APPENDIX B.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions:
1.	 What effects are known to occur in humans?
2.	 What effects observed in animals are likely to be of concern to humans?
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.










    




    
     
      
 
 
   
    
     
 
 
    
  
  
    
    
    
    
  
 
   
    









   
     
  
   
  
      




   





MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in
conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.














     
    
  
  
   
 
 
       




   
       
   
 
 
   
  
  
   
 






   
  
   
 
    
 
 
    
 




    






See Sample LSE Table 3-1 (page B-6)
(1)	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2)	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3)	 Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4)	 Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5)	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6)	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7)	 System.  This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8)	 NOAEL.  A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").












       
  
    
      
    
 
 
    
 
   













   
 
 
    
  
 
   
      
 
   
   





      
      
     
 
     





(9)	 LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile.
(11)	 CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12)	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15)	 Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.










    
    
   
 
 





(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).
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CHRONIC EXPOSURE




































a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software 
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor










   
   
           





   
  
  



























   
  
   












DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization




Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
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MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances












   












   
  




















   
  
  













OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell





RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization











   
  
  

















≥ greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
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VANADIUM D-1
APPENDIX D.  INDEX  
absorbed dose........................................................................................................................................ 79, 92  
adsorbed ................................................................................................................................................ 3, 130  
adsorption.................................................................................................................................. 129, 130, 131  
alanine aminotransferase (see ALT) ........................................................................................................... 42  
ALT (see alanine aminotransferase) ..................................................................................................... 42, 66  
ambient air ........................................................................................................................ 134, 135, 149, 152  
aspartate aminotransferase (see AST)......................................................................................................... 42  
AST (see aspartate aminotransferase)................................................................................................... 42, 66  
bioavailability ............................................................................................................................................. 90  
biomarker ...................................................................................................................... 91, 92, 103, 155, 163  
body weight effects ............................................................................................................................... 43, 67  
breast milk................................................................................................................................... 90, 147, 148  
cancer ................................................................................................................ 6, 11, 13, 27, 70, 73, 90, 167  
carcinogen........................................................................................................................................... 93, 169  
carcinogenic .................................................................................................................. 6, 13, 27, 44, 70, 169  
carcinogenicity........................................................................................................................ 13, 44, 70, 100  
carcinoma.......................................................................................................................... 13, 19, 45, 46, 100  
cardiovascular ............................................................................................................................... 41, 63, 100  
cardiovascular effects.................................................................................................................... 40, 47, 100  
chromosomal aberrations .......................................................................................................... 71, 73, 74, 76  
clearance ....................................................................................................................... 42, 77, 79, 82, 85, 87  
death................................................................................................................ 27, 28, 45, 47, 65, 91, 96, 131  
deoxyribonucleic acid (see DNA)................................................................................................... 71, 74, 75  
dermal effects.............................................................................................................................................. 43  
developmental effects ....................................................................... 13, 20, 22, 44, 70, 71, 91, 98, 101, 104  
DNA (see deoxyribonucleic acid)............................................................. 71, 72, 73, 74, 75, 76, 91, 93, 101  
elimination half-time............................................................................................................................. 80, 83  
elimination rate ........................................................................................................................................... 90  
endocrine............................................................................................................................................... 88, 89  
fetus............................................................................................................................................................. 89  
gastrointestinal effects ............................................................................................ 12, 20, 23, 24, 41, 63, 98  
general population....................................................................................... 4, 11, 12, 28, 123, 146, 152, 153  
genotoxic............................................................................................................................................... 27, 76  
genotoxicity......................................................................................................................................... 71, 100  
groundwater ...................................................................................................................................... 128, 137  
half-life................................................................................................................................................ 91, 157  
hematological effects ................................................................................................................ 25, 41, 65, 98  
hepatic effects ....................................................................................................................................... 42, 66  
immunological .................................................................................................................. 27, 43, 68, 96, 102  
immunological effects................................................................................................................................. 68  
Kow .................................................................................................................................................... 110, 111  
LD50............................................................................................................................................................. 47  
metabolic effects ......................................................................................................................................... 68  
micronuclei ........................................................................................................................................... 71, 76  
milk ................................................................................................. 11, 78, 82, 141, 143, 144, 146, 148, 151  
musculoskeletal effects ............................................................................................................................... 42  
neurobehavioral................................................................................................................. 23, 88, 95, 99, 102  
neurological effects..................................................................................................................... 6, 44, 69, 71  
nuclear....................................................................................................................................................... 157  










   
   
   
    
   
   
   
   
   
   
   
   





ocular effects......................................................................................................................................... 43, 47  
pharmacodynamic ....................................................................................................................................... 84  
pharmacokinetic........................................................................................................................ 83, 84, 86, 89  
renal effects........................................................................................................................................... 42, 66  
reproductive effects........................................................................................................... 44, 69, 71, 96, 101  
respiratory effects.............................................................................................................. 12, 29, 47, 99, 102  
retention .......................................................................................................................................... 79, 80, 90  
solubility ............................................................................................................................................. 78, 151  
systemic effects............................................................................................................................... 29, 47, 71  
T3.......................................................................................................................................................... 30, 48  
toxicokinetic.................................................................................................................... 11, 27, 88, 104, 105  
tremors ................................................................................................................................................ 44, 102  
tumors ........................................................................................................................................... 45, 93, 100  
 
 
 
 
 
 
 
 
 
 
 
